UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal
year ended December 31,
2009
|
OR
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Commission File Number: 000-52607
Universal Biosensors,
Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
(State or other jurisdiction
of
incorporation or organization)
|
|
98-0424072
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
Universal Biosensors, Inc.
1 Corporate Avenue,
Rowville, 3178, Victoria
Australia
(Address of principal
executive offices)
|
|
Telephone: +61 3 9213 9000
(Registrants telephone
number,
including area code)
|
|
Not Applicable
(Zip
Code)
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
None
|
|
Not applicable
|
Securities registered pursuant to Section 12(g) of the
Act:
Title of each class
Shares of common stock, par value US$0.0001
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes o No þ
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant
was required to submit and post such
files). Yes o No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
is not contained herein, and will not be contained, to the best
of registrants knowledge, in definitive proxy or
information statements incorporated by reference in
Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer o
|
|
Accelerated filer o
|
|
Non-accelerated filer o
(Do not check if a smaller reporting company)
|
|
Smaller Reporting company þ
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange
Act). Yes o No þ
The approximate aggregate market value of voting and non-voting
common equity held by non-affiliates of the registrant was
A$66,649,269 (equivalent to US$54,079,217) as of June 30,
2009.
The number of shares outstanding of each of the
registrants classes of common stock as of March 16,
2010:
|
|
|
Title of Class
|
|
Number of Shares
|
|
Common Stock, US$.0001 par value
|
|
157,292,845
|
DOCUMENTS
INCORPORATED BY REFERENCE:
Certain information contained in the registrants
definitive Proxy Statement for the 2010 annual meetings of
stockholders, to be filed not later than 120 days after the
end of the fiscal year covered by this report, is incorporated
by reference into Part III hereof
1
TABLE OF
CONTENTS
Unless otherwise noted, references on this
Form 10-K
to Universal Biosensors the Company,
Group, we, our or
us means Universal Biosensors, Inc. a Delaware
corporation and, when applicable, its wholly owned Australian
operating subsidiary, Universal Biosensors Pty Ltd. Our
principal place of business is located at 1 Corporate Avenue,
Rowville, Victoria 3178, Australia. Our telephone number is +61
3 9213 9000. Unless otherwise noted, all references in this
Form 10-K
to $, A$ or dollars and
dollar amounts are references to Australian dollars. References
to US$ are references to United States dollars.
2
FORWARD-LOOKING
STATEMENTS
This
Form 10-K
contains forward-looking statements that involve known and
unknown risks, uncertainties and other factors that may cause
our or our industrys actual results, levels of activity,
performance or achievements to be materially different from
those anticipated by the forward-looking statements. All
statements, other than statements of historical facts, are
forward-looking statements. Forward-looking statements include,
but are not limited to, statements about:
|
|
|
|
|
our business and product development strategies;
|
|
|
|
our expectations with respect to the timing and amounts of
revenues from LifeScan, Inc. (LifeScan);
|
|
|
|
our expectations with respect to the services we provide to and,
the development projects we undertake for, LifeScan;
|
|
|
|
our expectations with respect to sales of blood glucose test
strips by LifeScan and the quantities of blood glucose test
strips to be manufactured by us for LifeScan;
|
|
|
|
our expectations with respect to regulatory submissions,
approvals and market launches of the blood glucose test;
|
|
|
|
our expectations with respect to our own research and
development programs;
|
|
|
|
our expectations with respect to corporate collaborations or
strategic alliances with respect to our tests in development,
including revenues expected from such collaborations;
|
|
|
|
our expectations with respect to regulatory submissions and
approvals of our own tests in development;
|
|
|
|
our estimates regarding our research and development expenses;
|
|
|
|
our ability to protect our intellectual property; and
|
|
|
|
our estimates regarding our capital requirements, the
sufficiency of our cash resources and our need for additional
financing.
|
The words anticipates, believes,
continue, estimates,
expects, intends, may,
plans, potential, projects,
should, will, would and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. You should not place undue reliance on
these forward-looking statements, which apply only as of the
date of this
Form 10-K.
The forward-looking statements included in this
Form 10-K
do not guarantee our future performance, and actual results
could differ from those contemplated by these forward-looking
statements. Actual results or events could differ materially
from the plans, intentions and expectations disclosed in the
forward-looking statements that we make. We undertake no
obligation to update any forward-looking statement to reflect
events or circumstances after the date on which the statement is
made or to reflect the occurrence of unanticipated events.
Factors that could cause or contribute to such differences
include, but are not limited to, those discussed in cautionary
statements throughout this
Form 10-K,
particularly those set forth in section
Item 1A Risk Factors. However, new
factors emerge from time to time and it is not possible for us
to predict which factors will arise. In addition, we cannot
assess the impact of each factor on our business or the extent
to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. We do not undertake to update or
revise any forward-looking statements.
3
PART I
The following discussion and analysis should be read in
conjunction with our financial statements and related notes
included elsewhere in this
Form 10-K.
This discussion and analysis contain forward-looking statements
based upon current expectations that involve risks and
uncertainties. Our actual results and the timing of events could
differ materially from those anticipated in these
forward-looking statements as a result of several factors,
including those set forth in the section entitled
Item 1A Risk Factors and elsewhere
in this
Form 10-K.
Business
overview
We are a specialist medical diagnostics company focused on the
research, development and manufacture of in vitro
diagnostic test devices for consumer and professional
point-of-care
use. The blood test devices we are developing comprise a novel
disposable test strip and a reusable meter. These simple to use
portable test devices require a finger prick of blood and are
designed to be used beside the patient (at the
point-of-care)
to provide accurate and quick results to enable a new treatment
to be implemented or an existing treatment to be immediately
reviewed.
Our office, research and development and manufacturing
facilities are located in Melbourne, Australia.
We have rights to an extensive patent portfolio comprising
patent applications owned by our wholly owned Australian
subsidiary, Universal Biosensors Pty Ltd, and a large number of
patents and patent applications licensed to us by LifeScan,
Inc., an affiliate of Johnson & Johnson
(LifeScan). Key inventors for much of this licensed
and owned intellectual property are employees of Universal
Biosensors Pty Ltd.
We use our technology base and our expertise to develop
electrochemical-cell based tests. We have developed a blood
glucose test (used in the management of diabetes) with LifeScan.
We commenced manufacture of the blood glucose test strips for
this test in our facility in Corporate Avenue, Rowville,
Melbourne, in December 2009. This test was launched by LifeScan
in the Netherlands in January 2010. Although we will be the sole
manufacturer of blood glucose test strips during 2010, we
generally act as a non-exclusive manufacturer of the blood
glucose test strips. LifeScan will establish its own
manufacturing capability and, in the future, is likely to
manufacture a large proportion of its own requirements. Subject
to mutually agreed terms, we intend to develop other tests for
LifeScan in the field of diabetes and blood glucose management
generally.
We are also developing other tests using the electrochemical
cell technology. We are developing a C-reactive protein test on
our immunoassay platform to assist in the diagnosis and
management of inflammatory conditions. We are developing a
D-dimer test on our immunoassay platform for the detection and
monitoring of several conditions associated with thrombotic
disease, particularly deep venous thrombosis (clots in the leg)
and pulmonary embolism (clots in the lung). We have undertaken
development work on a prothrombin time test for monitoring the
therapeutic range of the anticoagulant, warfarin, based on
measuring activity of the enzyme thrombin. We do not currently
intend to establish our own sales and marketing force to
commercialize any of the non-blood glucose products which we
develop. Rather, our strategy is focused on establishing
collaborative partnerships for our platform with major
multinationals whose ambition is to lead in key clinical and
market segments. We have commenced business development efforts
to establish partnerships in fields outside the area of blood
glucose and diabetes.
General
development of our business
We were incorporated as a corporation in the State of Delaware
pursuant to the Delaware General Corporation Law on
September 14, 2001. Our wholly owned subsidiary and primary
operating vehicle, Universal Biosensors Pty Ltd ACN 098 234 309,
was incorporated as a proprietary limited company in Australia
under the Corporations Act 2001 (Commonwealth of Australia) on
September 21, 2001. Our research and development and
manufacturing activities are undertaken in Melbourne, Australia,
by Universal Biosensors
4
Pty Ltd. Our shares of common stock in the form of CHESS
Depositary Interests (CDIs) were quoted on the
Australian Securities Exchange (ASX) on
December 13, 2006 and continue to be quoted on that
exchange. Our securities are not currently traded on any other
public market.
Our principal place of business is 1 Corporate Avenue, Rowville,
Victoria 3178, Australia. Our principal telephone number in
Australia is +61 3 9213 9000. Our agent for service in the
United States is Corporation Service Company of 2711 Centerville
Road, Suite 400, Wilmington, County of New Castle,
Delaware, United States. We also maintain a web site at
www.universalbiosensors.com. The information contained in, or
that can be accessed through, our web site is not part of this
Form 10-K.
In April 2002, Universal Biosensors Pty Ltd employed a core
scientific and technical team in Australia which, over the
10 years prior to our incorporation, had been integral to
the development of the suite of novel electrochemical cell
technologies owned by LifeScan and licensed to us.
Also in April 2002, we entered into a license agreement with
LifeScan (License Agreement) pursuant to which
LifeScan granted us a worldwide, royalty free, exclusive
license, with a limited right to
sub-license,
to certain electrochemical cell technologies in all fields of
use excluding the field of diabetes and blood glucose management
generally, the rights to which are retained by LifeScan. In
October 2007, at the time of execution of the Master Services
and Supply Agreement (refer to the details below), the License
Agreement was amended to: a) clarify the fields in which
LifeScan has exclusive rights as the scope of the fields of
diabetes and blood glucose management generally; and b) to
grant us a license to certain new patents outside of
LifeScans field of use.
Also in April 2002, we entered into a development and research
agreement with LifeScan (Development and Research
Agreement) pursuant to which we agreed to undertake
contract research and development for LifeScan in the area of
diabetes management and the development of a blood glucose test
for diabetics. The research and development activities are
supervised by a steering committee comprised of representatives
from both LifeScan and us. The research and development
activities are undertaken by Universal Biosensors Pty Ltd
pursuant to a development subcontract with us. In consideration
of us undertaking the research and development activities,
LifeScan makes quarterly payments to us. Between April 2002 and
December 2009, we have received contract research funding of
A$14,415,089 pursuant to the Development and Research Agreement.
The amount of the quarterly payments over this period has varied
and will continue to vary over time. The initial term of the
Development and Research Agreement was for two years. This term
was subsequently extended by written amendment until
December 31, 2006, at which time, the agreement
automatically renewed for successive one year periods on the
same terms and conditions unless either LifeScan or we give
written notice of termination not less than nine months prior to
the end of the relevant one year period, or the agreement is
otherwise terminated in accordance with its terms. In October
2007, at the time of execution of the Master Services and Supply
Agreement, the Development and Research Agreement was amended to
conform the intellectual property provisions in the Development
and Research Agreement with those in the Master Services and
Supply Agreement such that LifeScan would own all intellectual
property developed by us under the Development and Research
Agreement and we receive a license to such intellectual property
outside of the LifeScan field of diabetes and blood glucose
management generally. In May 2009, the Development and Research
Agreement was further amended to increase the range of
development and research funding that LifeScan may pay us in
2010 and to include a new mechanism for determining research and
development programs whereby we proposes development and
research work, and then the program of development and research
is approved by the joint steering committee.
In June 2003 we acquired certain plant and equipment from Memcor
Australia Pty Ltd (a subsidiary of Water Application and Systems
Corporation). This plant and equipment included some pilot scale
manufacturing equipment designed for research and development as
well as office and laboratory furniture and equipment. We issued
shares to Water Application and Systems Corporation valued at
A$1,753,156 in consideration of this plant and equipment.
In August 2003, we established office, research and development
facilities at 103 Ricketts Road in Melbourne, Australia. We
subsequently relocated to larger office, research and
development and manufacturing
5
facilities at 1 Corporate Avenue, Rowville in Melbourne,
Australia in August 2007. We completed the fit out of the new
facilities in 2008.
From September 2001 to December 2009 we have spent A$27,898,099
relating to the acquisition of manufacturing and research and
development equipment, office furniture and equipment and fit
out of the new facilities.
On October 29, 2007 we entered into a Master Services and
Supply Agreement which contains the terms pursuant to which
Universal Biosensors Pty Ltd would provide certain services in
the field of blood glucose monitoring to LifeScan and would
generally act as a non-exclusive manufacturer of a version of
the blood glucose test strips we developed for LifeScan. On
December 11, 2008, we entered into an additional services
addendum to provide manufacturing process support to assist
LifeScan to establish LifeScans own manufacturing line for
new blood glucose test strips at a location of its choosing. On
December 11, 2008, the Master Services and Supply Agreement
was amended to reflect certain definitional matters in the
document. On May 15, 2009, the Master Services and Supply
Agreement was amended and restated to incorporate the amendments
made in December 2008 and to reflect changes resulting from a
change of blood glucose test strip. The Master Services and
Supply Agreement is structured as an umbrella agreement which
enables LifeScan and us to enter into a series of additional
arrangements for the supply by us of additional services and
products in the field of blood glucose monitoring. LifeScan is
responsible for securing regulatory approvals and is responsible
for sales and marketing of the blood glucose product. In
November 2009, the strip and meter system received its initial
regulatory clearance to sell in Europe and in January 2010,
LifeScan launched the product in the Netherlands under the trade
name One Touch Verio. LifeScan will continue to be
responsible for regulatory strategy and clearances and sales and
marketing for the blood glucose product.
Since 2004, as part of our efforts to create new platforms from
the electrochemical cell, we have carried out our own research
and development activities on a
point-of-care
dry immunoassay blood test for C-reactive protein for use in the
diagnosis and management of inflammatory conditions and since
early 2008, a second
point-of-care
dry immunoassay to measure the amount of D-dimer in the blood.
D-dimer is a well established marker currently being used as a
point-of-care
test for the detection and monitoring of several conditions
associated with thrombotic disease, particularly deep venous
thrombosis (clots in the leg) and pulmonary embolism (clots in
the lung). In another program to extend our technology, since
early 2005, we have carried out research and development
activities on a
point-of-care
prothrombin time blood test. All of these tests are based on our
underlying electrochemical cell technology platform. We continue
to invent and create new intellectual property as we extend the
technology.
For both the C-reactive protein (immunoassay) and prothrombin
time (enzyme activity) tests, we have now developed working
prototypes. Our strategy with each of our non-blood glucose
products is to enter into collaborative arrangements or
strategic alliances with life sciences companies or other
industry participants to complete the development and
commercialization of our products. We have successfully taken
our prothrombin time test to a point where we believe that we
have significantly reduced the risk of technical failure of the
product. We do not currently propose to complete the remaining
development steps for this prothrombin time test until the path
to commercialization for this product is assured and thus we
have elected to deploy our resources away from this project
until our partnering efforts have been successful. In the second
half of 2009 we commenced business development efforts to
establish partnerships in fields outside the area of blood
glucose and diabetes. To date we have not secured a partnership
and cannot predict with any certainty when our efforts might be
successful.
Our total research and development expenses for the fiscal years
ended December 31, 2009 and 2008 was A$26,483,330. Over the
same period we received A$2,507,315 in research and development
payments from LifeScan. We also received over the same period
grant monies of A$300,613 through an Australian Commonwealth
Government R&D Start Grant which is reflected as a
reduction of our research and development costs. In addition to
this, we received a milestone payment from LifeScan of
A$17,722,641 triggered by the first grant to LifeScan of
regulatory clearance to sell the blood glucose product.
Between incorporation and November 2006, we were funded by
private and venture capital investors and raised an aggregate
total of A$19,056,636. On December 5, 2006, we closed our
initial public offering raising
6
A$18 million and our shares were quoted in the form of
CHESS Depositary Interests, or CDIs, on the ASX on
December 13, 2006. Our CDIs continue to be quoted on the
ASX under the trading code UBI. On December 4,
2007, we closed a renounceable rights issue of new ordinary
shares in which we raised A$34,246,043. Between April 2002 to
December 2009, in addition to the funding from LifeScan,
Universal Biosensors Pty Ltd has also received grant monies of
A$2,366,063 through an Australian Commonwealth Government
R&D Start Grant which is reflected as a reduction of our
costs and A$410,000 through a State of Victoria Grant to support
the establishment of a medical diagnostic manufacturing facility
in Victoria, Australia which is reflected as a reduction in
fixed assets.
We made a net profit of A$1,430,463 for the year ended
December 31, 2009. We recognized a net loss of A$11,995,886
and A$8,817,238 in the years ended December 31, 2008 and
2007, respectively. Our accumulated losses from inception to
December 31, 2009 are A$22,922,688. Our ability to generate
future profits is dependent on our ability to generate
sufficient revenues under the Master Services and Supply
Agreement and/ or from the sale of any of our own products.
Our
Strategy
We are a specialist medical diagnostics company focused on the
research, development and manufacture of in vitro
diagnostic test devices for consumer and professional
point-of-care
use. Key aspects of our strategy include:
|
|
|
|
|
manufacturing blood glucose test strips for LifeScan as required;
|
|
|
|
providing post market support services to LifeScan in connection
with the blood glucose test;
|
|
|
|
continuing to undertake contract research and development work
on behalf of LifeScan and seeking to develop additional products
in the field of diabetes and blood glucose monitoring for
LifeScan;
|
|
|
|
extending the electrochemical cell technology by developing new
non-blood glucose tests;
|
|
|
|
seeking to enter into collaborative arrangements or strategic
alliances with other life sciences companies or other industry
participants to complete the development and commercialization
of our non-blood glucose tests.
|
Plan of
Operations for the Remainder of the Fiscal Year Ending December
2010
Our plan of operations over the remainder of the fiscal year
ending December 2010 is to:
|
|
|
|
|
manufacture blood glucose test strips to satisfy LifeScans
demand requirements;
|
|
|
|
provide the necessary post-market support for LifeScan in
connection with the blood glucose test;
|
|
|
|
continuing to undertake contract research and development work
on behalf of LifeScan and seeking to develop additional products
in the field of diabetes and blood glucose monitoring for
LifeScan;
|
|
|
|
advance our research and development activities with respect to
our C-reactive protein test and D-dimer test up to a point where
they provide credible evidence of the value of these tests for
potential partners; and
|
|
|
|
seek to identify and then negotiate collaborative arrangements
or strategic alliances with third parties with respect to one or
more of our non-blood glucose programs.
|
Financial
information about segments
We operate in one segment. Our principal activities are the
research, development and manufacture of in vitro
diagnostic test devices for consumer and professional
point-of-care
use. Although our products are intended for sale worldwide, we
operate predominantly in one geographical area, that being
Australia. For details of our revenues, profit and loss and
total assets for financial years ending December 31, 2009,
2008, 2007, 2006 and 2005, refer to Item 6. Selected
Financial Data.
7
Description
of our business
We are a specialist medical diagnostics company focused on the
research, development and manufacture of in vitro
diagnostic test devices for consumer and professional
point-of-care
use. The blood test devices we are developing comprise a novel
disposable test strip and a reusable meter. These simple to use
pocket portable devices require a finger prick of blood and are
designed to be used at the
point-of-care
to provide accurate and quick results to enable potential or
existing treatments to be immediately reviewed. The first test
we have developed with LifeScan is a test for the
self-monitoring of blood glucose and utilizes an electrochemical
cell at the end of the test strip. The electrical signals
generated when a sample of blood reacts with the chemistry
contained within the cell are then recorded by the meter and
converted into a reading which is displayed on the meter. We are
also seeking to extend the utility of electrochemical cells
beyond their historic domain of the measurement of blood glucose
to the measurement of other blood borne biomarkers using ligand
binding (immunoassay) and other techniques.
Novel
technologies
Electrochemical cells used in
point-of-care
blood tests have electrodes positioned within the
electrochemical cell in a traditional
side-by-side
or co-planar layout. The electrodes in the
electrochemical cell in the test strips which we have developed
and are developing have a parallel, opposing and much more
closely spaced configuration. This novel configuration of the
electrodes in the electrochemical cell is designed to allow for
greater accuracy while retaining other critical features
including the ability to obtain results quickly using only a
small finger prick sample of blood. Data is produced almost
immediately and can be reviewed at the
point-of-care
allowing new treatment to be instigated or existing treatment to
be immediately reviewed and modified if necessary. The
configuration of the electrodes has allowed for increased
miniaturization of the electrochemical cell and is designed to
enable our test strips to be manufactured in a continuous and
considerably simplified process.
Industry
background
The industry in which we operate, the global in vitro
diagnostics (IVD) industry, can be segmented according to
the location where the sample is tested. Historically most
testing has been performed by trained scientists running
sophisticated analyzers and consequently testing has required
the sample taken from the patient be transported to a dedicated
test site. These dedicated, or centralized testing sites include
hospital laboratories and commercial pathology laboratories. In
recent years, and for a variety of reasons, significant interest
has developed in techniques and technologies that allow testing
to be performed proximate (in time and location) to the patient.
It is now estimated by professional market researchers that
nearly 30% of IVD industry derived revenue now comes from
point-of-care
tests and that the growth rate for this sector is nearly double
that for the centralized sector.
Point-of-care
testing can be further segmented to consumer testing, such as
the blood glucose self-monitoring performed by diabetics, or
testing of patients by one of a variety of medical or laboratory
professionals (professional
point-of-care)
in locations such as clinics, physicians office
laboratories and emergency departments.
While not all tests are suited to being performed at the
point-of-care,
it is our belief that a significant number of tests currently
performed in centralized settings are better suited to being
performed at the
point-of-care,
but lack a suitable technology platform to see them adapted for,
and consequently adopted at, the
point-of-care.
We believe our electrochemical cell technology can be a suitable
platform for adapting central laboratory performed tests to a
point-of-care
format.
The key objective of
point-of-care
testing is to generate an accurate and quick result so that
appropriate treatment can be implemented immediately, leading to
an improved clinical
and/or
economic outcome. To demonstrate our platform, our tests in
development are designed for use by patients and healthcare
professionals in a number of
point-of-care
settings including doctors offices, emergency rooms, and
health clinics or, in some cases, at a patients home.
8
Point-of-care
tests in development and partnering strategy
To date, we have focused the majority of our efforts on the
development of blood glucose tests, by virtue of our business
relationship with LifeScan. Electrochemical cell technologies
have not been widely used in tests other than for blood glucose
testing due to technical issues which we are working to
overcome. Our strategy is to demonstrate we can apply the
electrochemical cell technology to other biomarkers and then to
enter into collaborative arrangements or strategic alliances
with third parties to complete the development and
commercialization of those products.
The following table summarizes the
point-of-care
tests we are currently developing and the applicable development
stage of the applicable test. All time periods set forth in the
table below refer to calendar years and anticipated milestone
dates are indicative only.
|
|
|
|
|
Point-of-Care
Test
|
|
Development Stage
|
|
Next Anticipated Milestones
|
|
Immunoassay C-reactive protein test
|
|
Development work undertaken since
2004
Working prototype developed
A minimum of one additional year of
development/ product validation work required
|
|
Commence product validation in 2010
Establish manufacturing process
Continue efforts to enter into
collaborative arrangements or strategic alliances with third
parties to complete the development and commercialization of
those products
|
Prothrombin time test
|
|
Development work undertaken since early
2005
Working prototype developed
A minimum of one additional year of
development/ product validation work required
|
|
We do not currently propose to complete
the remaining development steps for this test until we have
entered into a collaborative arrangement or strategic alliances
with a third party with respect to the completion of development
and commercialization of that product
|
D-dimer test
|
|
Development work undertaken since early
2008
A minimum of two additional years of
development/ product validation work required
|
|
Develop working prototype
Commence product validation in 2011
Establish manufacturing process
Continue efforts to enter into
collaborative arrangements or strategic alliances with a third
party with respect to the completion of development and
commercialization of that product
|
Facilities
Universal Biosensors Pty Ltd leases approximately
5,000 square meters of office, research and development and
manufacturing facilities at 1 Corporate Avenue, Rowville in
Melbourne, Australia. We have been at the facilities at 1
Corporate Avenue since August 2007. We have ISO 13485
certification continuously at that site since May 2007. The
lease for 1 Corporate Avenue expires on March 31, 2014 with
two options to renew the lease for successive five year periods.
We completed upgrading and fitting out this facility in 2008.
9
Manufacture
of test strips, handheld meters and control
solution
Although we will be the sole manufacturer of blood glucose test
strips during 2010, the Master Services and Supply Agreement
provides that we will generally act as a non-exclusive
manufacturer of the enhanced blood glucose test strips for
LifeScan. LifeScan will establish its own manufacturing
capability and, in the future, is likely to manufacture a large
proportion of its own requirements. We commenced manufacture of
the blood glucose test strips in our facility in Corporate
Avenue, Rowville, Melbourne, in December 2009. We intend to
manufacture the disposable test strips for each of our existing
and future
point-of-care
tests developed for partners using proprietary manufacturing
equipment. If we are successful in securing a partner for one or
more of our non-blood glucose tests and the development of that
test is successful, if our existing facilities and equipment
continue to be utilized for the manufacture of blood glucose
test strips, we will need to secure additional or alternative
facilities.
The raw material for the blood glucose test strips comprises
films and separators for constructing the strips and chemicals.
We obtain the films and separators from two established
companies and we anticipate regular supply of materials from
these suppliers. A number of non-reactive chemicals can be
sourced from any one of a number of chemical suppliers. The key
chemical in the test strips we have developed are enzymes which
we currently source from one supplier. We expect to have a
reliable supply of these enzymes.
LifeScan is responsible for the manufacture of the blood glucose
test meters and the supply of the control solution used to
confirm accurate operation of the meters. With respect to the
meters for our own products, we intend to outsource to
contractors, the manufacture of the reusable meters and the
control solution used to confirm accurate operation of the
meters. We believe that outsourcing the manufacture of the
meters and the control solution for our products will minimize
the capital investment required by us yet maintain quality
standards, help control costs and take advantage of the
expertise such third parties have in the design and production
of meters and control solutions.
Distribution
We manufacture and supply blood glucose tests strips on behalf
of LifeScan. LifeScan is responsible for the commercialization
and distribution of the blood glucose product.
Regulatory
clearances
In all major territories of the world, regulatory clearances are
required prior to marketing diagnostic tests. The regulatory
clearance requirements vary from country to country and product
to product, however, regulatory clearances typically require a
satisfactory technical file, which provides the
regulatory bodies with details of the design and previous
testing of the product including safety and efficacy data as
well as the details of the conduct of trials which show the
suitability for use of the product at the
point-of-care.
Regulators also require demonstration of continuing compliance
with an appropriate quality management system. There is no
common international regulatory body and we, or our partner,
would be required to submit for clearance to sell in each of the
major jurisdictions in which the relevant partners seeks to
market our products. For example, for Europe, a Notified
Body assesses the quality system and product technical
file, whereas in the United States, the Food and Drug
Administration, or FDA, is the regulatory body
responsible for the examination of the design and performance of
the device and for assessment of our quality system.
In the case of
point-of-care
tests, there are often additional requirements that a
manufacturer must meet such as an examination of certain aspects
affecting test suitability for non-professional users. In
Europe, certain codified standards describe the requirements of
tests whilst in the United States, tests to be used by
non-laboratory professionals must gain waiver status under the
United States Clinical Laboratory Improvement Amendments of
1988. Amongst other clearances, we will also require clearance
for export of medical devices from the Therapeutics Goods
Administration, or TGA, in Australia.
The blood glucose test has received regulatory clearance to sell
in Europe. LifeScan are responsible for determining the location
and timing of any future submissions for regulatory clearance to
sell the blood glucose product.
10
The
importance and duration of all our patents, trademarks and
licenses
We rely on a combination of patent, copyright, trademark and
trade secret laws, as well as confidentiality agreements, to
establish and protect our proprietary rights. Our continued
success depends to a large extent on our ability to protect and
maintain our owned and licensed patents and patent applications,
copyright, trademark and trade secrets.
Our
point-of-care
tests in development draw upon certain patents within an
extensive portfolio of patents and patent applications as well
as know-how. We patent the technology, inventions and
improvements that we consider important to the development of
our business. Pursuant to the License Agreement with LifeScan,
we have an exclusive license to a suite of patents, patent
applications and know-how to use and exploit the licensed
patents, patent applications and know-how in all fields of use
excluding the fields of diabetes and blood glucose management
generally, the rights to which are retained by LifeScan. The
exclusive license is subject to LifeScan having retained the
right to make, have made, use, and sell under and exploit in any
way the patents, patent applications and know-how owned by
LifeScan.
Pursuant to the Development and Research Agreement, we have a
limited license to the patents, patent applications and know-how
the subject of the License Agreement, in the field of diabetes
and blood glucose management generally but only for the purpose
of carrying out our obligations for LifeScan. Likewise, pursuant
to the Master Services and Supply Agreement we have a limited
license to intellectual property of LifeScan but only for the
purpose of performing our obligations under the Master Services
and Supply Agreement.
Universal Biosensors Pty Ltds owned patent applications
and the patents and patent applications licensed to us by
LifeScan are essential in the manufacturing and
commercialization of each of the
point-of-care
diagnostic tests being developed by us.
The following sets out details of our owned and licensed patents
and patent applications, based on information current as of
December 31, 2009.
Patent Family 1 Electrochemical Detection
Method. Patents under Patent Family 1 are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. Patent Family
1 relates to an electrochemical detection method for detecting
agglutination. The last of the patents to expire within Patent
Family 1 will expire on January 16, 2024.
Patent Family 2 Strip Ejection
System. Patents under Patent Family 2 are
currently pending or published in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to a system that enables a disposable strip for a
meter based sensor device to be transported within the device,
moved to a use position and ejected for disposal after use
without the operator directly contacting the disposable strip.
Patent Family 3 Patent Family Fluid
Transfer Fluid Transfer Mechanism (derived from
United States of America Provisional patent application
no. 60/774,678 and International Patent Application
No. PCT/IB2007/000370). Patents
under Patent Family 3 are currently pending or published in a
range of jurisdictions within the Americas, Europe, Asia and
Australasia. This patent family relates to a fluid transfer
device for transferring liquid from a first chamber to a second
chamber separated by a barrier having at least one opening
fluidly connecting the chambers with an opening sized so
retention force keeps the liquid in the first chamber until an
initiation input is introduced to the liquid that is sufficient
to overcome the retention force.
Patent Family 4 Patent Family Magnetic Particle
Mobility Electrochemical Detection of Magnetic
Particle Mobility (United States of America Provisional patent
application no. 60/831,240, International Patent
Application No. PCT/IB2007/001990, Taiwan and
Thailand). Patents under Patent Family 4 are
currently pending or published in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to a method for electrochemically monitoring the
mobility of particles in a fluid in response to an external
field by monitoring an electrical characteristic of the fluid in
an electrochemical cell.
11
Patent Family 5 Patent Family Protease
Sensor Apparatus and Method for Electrochemical
Protease Sensor, United States of America Provisional patent
application no. 60/983,029, International Patent
Application No. PCT/IB2008/002849 and
Taiwan. This patent family relates to a sensor to
detect cleavage of an electrochemical substrate for use in
measuring blood or plasma coagulation in assays such as
prothrombin time (PT) and thrombin potential. The PCT
application is published and is due for national stage entry in
April 2010.
Patent Family 6 Patent Family Automatic
Information Transfer Automatic Information Transfer
by Color Encoded Fields (United States of America Provisional
patent application no. 61/081,610, International Patent
Application No. PCT/IB2009/006634, Taiwan and
Thailand). Patents under Patent Family 6 are
currently pending in a range of jurisdictions within Asia. This
patent family relates to a method of transferring parametric
information from a test strip based on color encoded fields. The
PCT application is pending and due for national stage entry in
January of 2011.
Patent Family 7 Patent Family Enhanced
Immunoassay Sensor Enhanced immunoassay sensor
(United States of America Provisional patent application
no. 61/129,688, International Patent Application
No. PCT/IB2009/006688, Taiwan and
Thailand). Patents under Patent Family 7 are
currently pending in a range of jurisdictions within Asia. This
patent family relates to a biosensor for detecting target
analyte in a fluid sample based on electrochemical reactions.
The PCT application is pending due for national stage entry in
January of 2011.
Patent Family 8 Patent Family Electrochemical
On-Board Control Detection Electrochemical on-board
control detection (United States of America Provisional patent
application no. 61/170,440). A conversion to
non-provisional application is due in April of 2010. The PCT
application is pending and due for national stage entry in
January 2011.
Patent Family A Electrochemical
Cells. Patents under Patent Family A are
currently granted under the European Patent Convention, in
Australia and the Americas. This patent family relates to an
electrochemical cell which enables levels of analytes such as
glucose to be measured whilst using a small volume of sample.
The last of the patents to expire within Patent Family A will
expire on April 12, 2015.
Patent Family B Defining an Electrode
Area. Patents under Patent Family B are currently
granted in Australia, Singapore and the Americas. This patent
family relates to a method for defining an electrode area in an
electrochemical sensing device. The last of the patents to
expire within Patent Family B will expire on April 11, 2016.
Patent Family C Electrochemical
Cell. Patents under Patent Family C are currently
either pending or granted in a range of jurisdictions within the
Americas, Europe, Asia and Australasia. This patent family
relates to a method and an electrochemical biosensor for
determining the concentration of an analyte in a carrier. The
last of the patents to expire within Patent Family C will expire
on May 31, 2017.
Patent Family D1 Electrochemical
Method. Patents under Patent Family D1 are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family provides an improved method and biosensor for
determination of the concentration of an analyte in a carrier
which provides improved accuracy, reliability and speed over
prior techniques. The last of the patents to expire within
Patent Family D1 will expire on November 15, 2016.
Patent Family D2 Electrochemical
Cell. Patents under Patent Family D2 are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to an electrochemical cell for determining the
concentration of an analyte in a carrier. The last of the
patents to expire within Patent Family D2 will expire on
November 15, 2016.
Patent Family F Sensor Connector
Means. Patents under Patent Family F are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to a means for providing an electrical connection
between a measuring device and a disposable electrochemical
sensor of the type used for quantitative analysis, for example,
of glucose levels in blood, for pH measurement. The last of the
patents to expire within Patent Family F will expire on
March 4, 2019.
12
Patent Family G Method of Filling an Amperometric
Cell and Improved Electrochemical Cell. Patents
under Patent Family G are currently granted in a range of
jurisdictions within the Americas and Australasia. This patent
family relates to disposable electrochemical sensors of the type
used for quantitative analysis, for example, of glucose levels
in blood, or the like. The last of the patents to expire within
Patent Family G will expire on July 15, 2020.
Patent Family H Method and Apparatus for
Automatic Analysis. Patents under Patent Family H
are currently granted in a range of jurisdictions within the
Americas. This patent family relates to a method for analyzing
the concentration of an analyte in a sample and to an automatic
analyzing apparatus. The last of the patents to expire within
Patent Family H will expire on August 13, 2018.
Patent Family I Heated Electrochemical
Cell. Patents under Patent Family I are currently
granted in a range of jurisdictions within the Americas. This
patent family relates to a method and apparatus for determining
the concentration of an analyte in a sample by heating the
sample and measuring the concentration of the analyte or the
concentration of a species representative thereof in the sample
at a predetermined point on a reaction profile by means that are
substantially independent of temperature. The last of the
patents to expire within Patent Family I will expire on
March 11, 2019.
Patent Family J Sensor with Improved Shelf
Life. Patents under Patent Family J are currently
granted in a range of jurisdictions within the Americas. This
patent family relates to extending the shelf life of apparatus,
such as electrochemical cells, sensor elements and the like,
comprising one or more metal electrodes by stabilizing the metal
electrodes using a coating which includes a sulphur containing
moiety in its molecular structure. The last of the patents to
expire within Patent Family J will expire on March, 16, 2019.
Patent Family K Electrochemical Methods and
Devices for Use in the Determination of Haematocrit corrected
Analyte Concentrations. Patents under Patent
Family K are currently either pending or granted in a range of
jurisdictions within the Americas, Europe, Asia and Australasia.
This patent family relates to analyte determination,
particularly the electrochemical determination of blood
analytes. The last of the patents to expire within Patent Family
K will expire on January 25, 2021.
Patent Family M Method of Preventing Short
Sampling of a Capillary or Wicking Fill
Device. Patents under Patent Family M are
currently granted in a range of jurisdictions within the
Americas. This patent family relates to a device, and a method
for using the device, for ensuring that a capillary or wicking
fill device, such as a capillary or wicking action filled
electrochemical sensors suitable for use in analyzing blood or
interstitial fluids, is fully filled. The last of the patents to
expire within Patent Family M will expire on April 4, 2023.
Patent Family N1 Electrochemical Method for
Measuring Chemical Reaction Rates. Patents under
Patent Family N1 are currently either pending or granted in a
range of jurisdictions within the Americas, Europe, Asia and
Australasia. This patent family relates to the measurement of
the progress of a chemical reaction that generates an
electroactive reaction product that is subsequently detected at
an electrode amperometrically or coulometrically. The last of
the patents to expire within Patent Family N1 will expire on
January 1, 2022.
Patent Family N4
Immunosensor. Patents under Patent Family N4 are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to a device and method for performing
immunoassays. The device is a quantitative, inexpensive,
disposable immunosensor that requires no wash steps and thus
generates no liquid waste. The last of the patents to expire
within Patent Family N4 will expire on July 13, 2021.
Patent Family O Electrochemical
Cell. Patents under Patent Family O are currently
either pending or granted in a range of jurisdictions within the
Americas, Europe and Asia. This patent family relates to
electrochemical cells including two working and counter
electrodes for determining the concentration of a reduced or
oxidized form of a redox species with greater accuracy than can
be obtained using an electrochemical cell having a single
working and counter electrode. The last of the patents to expire
within Patent Family O will expire on January 22, 2026.
13
Patent Family P Electrochemical Cell
Connector. Patents under Patent Family P are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe and Asia. This patent family relates
to a connector to provide electrical connection between an
electrochemical cell of a strip type sensor and meter circuitry.
The last of the patents to expire within Patent Family P will
expire on January 6, 2023.
Patent Family Q Direct Immunosensor
Assay. Patents under Patent Family Q are
currently either pending or granted in a range of jurisdictions
within the Americas, Europe, Asia and Australasia. This patent
family relates to a disposable immunosensor and method for
performing immunoassays. The last of the patents to expire
within Patent Family Q will expire on March 20, 2023.
Patent Family R Mediator Stabilized Reagent
Compositions and Methods for Their Use in Electrochemical
Analyte Detection Assays. Patents under Patent
Family R are pending in a range of jurisdictions within the
Americas, Europe and Asia. This patent family relates to
electrochemical reagent formulations in which the mediator is
storage stabilized. The electrochemical reagent formulations
enable an extended storage life for test strips for analyte
determination, such as determination of blood glucose
concentration.
Patent Family S Method and Apparatus for
Electrochemical Analysis. Patents under Patent
Family S are published in the Americas.
Patent Application T Method and Apparatus for
Rapid Electrochemical Analysis. Patents under
Patent Family T are pending in a range of jurisdictions within
the Americas, Europe and Asia. This patent application relates
to an improved method and apparatus for electrochemical
analysis. The published United States Patent Application No. was
filed on September 30, 2005.
Patent Application U Methods and Apparatus for
Analyzing a Sample in the Presence of
Interferents. Patents under Patent Family U are
pending in a range of jurisdictions within the Americas, Europe,
Asia and Australasia. This patent application relates to methods
and apparatus for determining analyte concentrations in a rapid
and accurate manner. The published United States Patent
Application was filed on March 31, 2006.
Patent Application V Systems and Methods for
Discriminating Control Solution from a Physiological
Sample. Patents under Patent Family V are pending
in a range of jurisdictions within the Americas, Europe, Asia
and Australasia. This patent application relates to systems and
methods for discriminating between a control solution and a
blood sample. The published United States Patent Application was
filed on March 31, 2006.
Patent Application W Biosensor Apparatus and
Methods of Use. Patents under Patent Family W are
pending or published in a range of jurisdictions within the
Americas, Europe and Asia. The published United States Patent
Application was filed on November 21, 2005.
Patent Application X Systems and Methods of
Discriminating Control Solution from a Physiological
Sample. Patents under Patent Family X are pending
in a range of jurisdictions within the Americas, Europe, Asia
and Australasia. The United States Provisional Patent
Application was filed on September 28, 2007.
We will continue to file and prosecute patent applications when
and where appropriate to attempt to protect our rights in our
proprietary technologies.
Pursuant to the License Agreement, LifeScan has responsibility
for prosecution of the patent applications licensed to us by
them. In the event that LifeScan elects not to proceed with the
prosecution of a patent application licensed to us by them, we
have the right to assume and continue at our own expense the
prosecution of any patent or patent applications. LifeScan is
responsible for payment of maintenance fees for all patents
licensed to us by them in all agreed jurisdictions. In the event
LifeScan discontinues such maintenance payments, we may maintain
the licensed patent solely at our own expense. We will prosecute
and maintain such patents where appropriate to attempt to
protect our rights in our technologies.
Our ability to build and maintain our proprietary position for
our technology and products will depend on our success in
obtaining effective claims and those claims being enforced once
granted and, with respect to intellectual property licensed from
LifeScan, LifeScans success in obtaining effective claims
and those claims being enforced once granted. The patent
positions of companies like ours are generally uncertain and
involve
14
complex legal and factual questions for which important legal
principles remain unresolved. Some countries in which we or our
partners may seek approval to sell
point-of-care
tests that we have developed, or license our intellectual
property, may fail to protect our owned and licensed
intellectual property rights to the same extent as the
protection that may be afforded in the United States or
Australia. Some legal principles remain unresolved and there has
not been a consistent policy regarding the breadth or
interpretation of claims allowed in patents in the United
States, the United Kingdom, the European Union, Australia or
elsewhere. In addition, the specific content of patents and
patent applications that are necessary to support and interpret
patent claims is highly uncertain due to the complex nature of
the relevant legal, scientific and factual issues. Changes in
either patent laws or in interpretations of patent laws in the
United States, the United Kingdom, the European Union or
elsewhere may diminish the value of our intellectual property or
narrow the scope of our patent protection.
Seasonality
We do not expect sales of the diagnostic tests we develop to be
materially impacted by seasonality.
The
practices of the registrant and the industry (respective
industries) relating to working capital items.
We commenced manufacture of the blood glucose test strips in our
facility in Corporate Avenue, Rowville, Melbourne, in December
2009. We satisfy our contractual obligations with respect to
inventory and the supply of test strips as agreed in The Master
Services and Supply Agreement. The Master Services and Supply
Agreement sets out the circumstances under which LifeScan may
return defective products.
Dependence
on single customer.
As shown in the table below, we currently receive a significant
portion of our income from LifeScan pursuant to the Development
and Research Agreement and the Master Services and Supply
Agreement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Revenue from products
|
|
|
132,733
|
|
|
|
132,733
|
|
|
|
|
|
|
|
|
|
Revenue from services
|
|
|
5,971,825
|
|
|
|
2,850,071
|
|
|
|
3,121,754
|
|
|
|
|
|
Research and development income
|
|
|
14,415,089
|
|
|
|
1,337,125
|
|
|
|
1,170,190
|
|
|
|
1,192,015
|
|
Milestone payment
|
|
|
17,722,641
|
|
|
|
17,722,641
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
5,408,492
|
|
|
|
809,459
|
|
|
|
2,542,060
|
|
|
|
1,440,102
|
|
Fee income
|
|
|
1,131,222
|
|
|
|
|
|
|
|
1,131,222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income
|
|
|
44,782,002
|
|
|
|
22,852,029
|
|
|
|
7,965,226
|
|
|
|
2,632,117
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from LifeScan as a % of total income
|
|
|
88
|
%
|
|
|
96
|
%
|
|
|
68
|
%
|
|
|
45
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For fiscal 2010, the Development and Research Agreement sets out
a range of values that the Company or Universal Biosensors Pty
Ltd will be paid depending on the level of research and
development services required by LifeScan. In subsequent years,
the steering committee will recommend the level of funding
consistent with LifeScans requirements. The Development
and Research Agreement currently automatically renews for
successive one year periods each December on the same terms and
conditions unless either LifeScan or we give written notice of
termination not less than nine months prior to the end of the
relevant one year period (in which case the agreement terminates
at the end of the relevant one year period), or the agreement is
otherwise terminated in accordance with its terms.
In 2009, we received various inflows from LifeScan including
A$3,087,849 received in February in connection with the
provision by us to LifeScan of certain manufacturing support
services and a milestone payment of A$17,722,641 in December
which was triggered upon receipt of initial regulatory clearance
to sell the blood glucose product. The blood glucose monitoring
test was launched in the Netherlands in January 2010. We
anticipate that we will become increasingly dependent on
LifeScan for contract research services
15
and revenue from the manufacturing and supply of test strips for
the blood glucose test and from the sale of the blood glucose
tests strips by LifeScan. Our dependence on LifeScan for a
significant proportion of our revenue is likely to continue
until we enter into collaborative arrangements or strategic
alliances with third parties in connection with our non-glucose
products and those products are launched into the market.
Australian
Government Agreements
Universal Biosensors Pty Ltd currently receives grant funding
under two grant agreements with the Commonwealth of Australia
and the State of Victoria, Australia. We receive the
Commonwealth of Australia grant as compensation for expenses
incurred in respect of certain research activities into dry
chemistry immunosensors. This grant reduces the related research
and development expenses as and when the relevant research
expenses are incurred. We receive the State of Victoria Grant to
support the establishment of a medical diagnostic manufacturing
facility in Victoria, Australia. The State of Victoria grant
monies are recognized against the acquisition costs of the
related plant and equipment as and when the related assets are
purchased. We have received a reduction in our costs of
A$2,366,063 under the Commonwealth of Australian grant and
A$410,000 under the grant from the State of Victoria, Australia.
The Commonwealth of Australia and the State of Victoria may
terminate their respective grant agreement on different bases,
including by giving us written notice of termination if we are
in breach of the relevant agreement and if the breach is not
capable of being remedied, or if capable of being remedied it is
not remedied after receipt of written notice, if we fail to
submit reports as required under the relevant grant agreement,
if our research and development activities or the quality of
those activities do not satisfy the grant eligibility criteria,
if there is a change of control of us or if we become insolvent.
With respect to the Commonwealth of Australia R&D Start
Grant, in certain limited circumstances where we fail to use our
best endeavors to commercialize the development program within a
reasonable time of completion of the program or upon termination
of a grant due to our breach of agreement or our insolvency, we
may be required to repay some or all of the grant. If required
to repay the grant amounts, we may be required to reallocate
funds needed to continue the commercialization of our products
and such repayment may have a material adverse effect on our
cash position and us. To date, we have not been required to
repay any amounts paid to us under these grants. We consider
that the likelihood of being required to repay grant funding is
remote because we continue to act in good faith with respect to
the grants
Competitive
conditions of our business
Our revenue is highly dependent on the success of the blood
glucose product we have developed with LifeScan. LifeScan have
launched the blood glucose product in the Netherlands, named
One Touch Verio, in January 2010. LifeScan is
responsible for all sales and marketing decisions and any
decision to introduce the product to new territories and the
timing of those decisions. The global diabetes market place is
intensely competitive and dominated by multinationals such as
LifeScan, Roche, Abbott and Bayer. We do not yet know if the
product will be successful, whether customers will prefer it
over competitive offerings, nor the rate at which it might be
adopted. Furthermore, LifeScan has not yet launched the product
in other territories and the timing and choice remains
LifeScans. Although during 2010 we will be the sole
manufacturer of blood glucose test strips, the Master Services
and Supply Agreement provides that we will generally act as a
non-exclusive manufacturer of the enhanced blood glucose test
strips for LifeScan. We anticipate that in the future, LifeScan
will establish its own manufacturing capability and is likely to
manufacture a large proportion of its own requirements of any
blood glucose test strips we develop for them. Although we
developed the manufacturing process for the blood glucose tests
strips, our experience as a commercial manufacturer is limited.
There is a risk that our manufacturing costs may not be able to
compete with the cost at which LifeScan may be able to
manufacture the blood glucose test strips which we develop. If
we are unable to reduce our costs to compete effectively we may
not be able to win a manufacturing commitment from LifeScan and
therefore be faced with surplus capacity in our manufacturing
operations.
Core to our business strategy is to extend our intellectual
property platform to enable other tests currently done in the
central laboratory to be migrated to the
point-of-care
settings. Our belief is that much testing done
16
in the central lab can more efficiently and profitably be
performed at the
point-of-care.
Our intent is to develop tests that illustrate the platform
potential for the electrochemical cell technology as an enabling
technology.
With the exception of blood glucose testing, most
point-of-care
testing is currently conducted in professional settings where
the test requester is a health care professional. The health
care professional has a choice and can request tests from a
central laboratory, or services provider, or choose to have the
test performed at the
point-of-care.
Thus we face competition not just from other companies active in
the
point-of-care
space, but also the historic providers of testing who operate in
centralized settings.
We will face competition from approved and marketed products as
well as products in development, for both for
point-of-care
settings and the central laboratory environment. We expect our
C-reactive protein test to compete with existing
point-of-care
technologies from competitors such as Cholestech Corporation
(now part of Inverness Medical Innovations), Orion Corporation
and Axis-Shield plc. We will also have to compete with the tests
that run on automated analyzers. Companies providing systems
into the central laboratory which run reagents that will compete
with us include Siemens AG, Roche Holding Ltd, Olympus Medical
Systems Corporation, Abbott Laboratories and Beckman Coulter,
Inc. All these companies have well established brand
recognition, sales and marketing forces, and have significant
resources available to support their product. To compete, we
intend to establish collaborative arrangements or strategic
alliances with other life sciences companies and will need to
show that our C-reactive protein test is effective and is a time
and cost saving alternative. Even if we can show competitive
product advantages, customers may be resistant to changing their
supplier.
We have successfully taken our prothrombin time test to a point
where we believe that we have significantly reduced the risk of
technical failure of the product. We do not propose to complete
the remaining development steps until our partnering efforts are
successful and thus we have elected to deploy our resources away
from this project. Should our partnering efforts be successful,
and the product brought successfully to market, it will face
competition from approved and marketed products in both the
point-of-care
and central laboratory market places.
We expect any D-dimer test developed on our platform and brought
to market will have to compete with testing for D-dimer in
pathology laboratories from competitors such as Siemens AG,
Roche Holding Ltd, Instrumentation Laboratory, Diagnostica Stago
and Biomerieux, and with existing
point-of-care
technologies from competitors such as Biosite Diagnostics (now
part of Inverness Medical Innovations). All these companies have
well established brand recognition, sales and marketing forces,
and have significant resources available to support their
product. To compete, we will need to show potential partners
that our D-dimer test can be effective and is a time and cost
saving alternative. Even if we can show competitive product
advantages, customers may be resistant to changing their
supplier.
Employees
At March 16, 2010, we had 74 full time employees in our
Melbourne facility, spanning production, engineering, quality
and regulatory, research and development and administration.
Financial
information about geographic areas
We operate in one segment (the research, development and
manufacture of in vitro diagnostic test devices for
consumer and professional
point-of-care
use) and predominantly in one geographical area (Australia).
17
Investing in our shares or CDIs involves a high degree of
risk. Before you invest in our shares or CDIs, you should
understand the high degree of risk involved. You should
carefully consider the following risks and other information in
this
Form 10-K,
including our financial statements and related notes appearing
elsewhere in this
Form 10-K,
before you decide to invest in our shares or CDIs. If any of the
events described below actually occurs, our business, financial
condition and operating results could be harmed. In such an
event, the market price of our CDIs would likely decline and you
could lose part or all of your investment.
The
product developed with our partner, LifeScan, is yet to be
successful in the market place.
The global diabetes market place is intensely competitive and
dominated by multinationals such as LifeScan, Roche, Abbott and
Bayer. The first product we developed with LifeScan was launched
in the Netherlands in January 2010. To our knowledge, at the
date of this document, LifeScan has not yet launched the product
in other territories and the decision to introduce the product
to new territories and the timing of any such launch is
LifeScans. We do not yet know if the product will be
successful, whether customers will prefer it over competitive
offerings, nor the rate at which it might be adopted.
Our ability to become profitable or maintain profitability in
the future will be adversely affected if the blood glucose
product and any of the other products we develop with LifeScan
in the future fail to achieve or maintain market acceptance.
Revenue from services fees and strip manufacturing fees for the
blood glucose product are anticipated to account for a
significant part of our revenue for the foreseeable future. If
the blood glucose product and any future products we develop
with LifeScan are not successful in the market place, our
revenues from services fees and strip manufacturing fees will be
reduced or eliminated. We cannot be sure that the blood glucose
product and any future product will be successful in the
marketplace or that LifeScan will be successful in securing a
significant market share or that it will launch the products
into key markets. We believe that market acceptance will depend
on, amongst other things, the ability to provide and maintain
evidence of safety, efficacy and cost effectiveness of the
product and benefits over existing products. In addition, market
acceptance depends on the effectiveness of marketing strategies
employed by LifeScan to sell the products. LifeScan and
LifeScans competitors have products that are established
in the blood glucose testing market, and LifeScan may not be
able to convince users to switch to the new product or its
competitors may introduce a new product which impacts on sales
of the blood glucose test. Our commercial opportunity will be
reduced or eliminated if LifeScans competitors develop and
commercialize products that are safer, more effective, are more
convenient, are less expensive, or that reach markets sooner
than the blood glucose products we develop with LifeScan.
Scientific, clinical or technical developments by our
competitors may render the products we develop with LifeScan
obsolete or non-competitive. If the products we develop obtain
regulatory approvals, but are not successful and fail to compete
effectively in the marketplace, our business will suffer which
would have a material adverse effect on our business and
financial position.
LifeScan
has the sole rights to commercialize the blood glucose products
we develop with them and makes the key decisions on product
choice and product launch.
LifeScan has the sole rights to commercialize the blood glucose
products which we develop with them. LifeScan decides which
research and development programs it will pay for, the decision
whether or not to launch new blood glucose products we develop
with them and, if launched, the timing of such launch, the
jurisdictions in which the relevant product will be launched and
the nature of any such launch. Decisions made by LifeScan with
respect to the commercialization of the blood glucose products
we develop with them will affect the extent and timing of
revenues to us. LifeScan may choose not to launch new blood
glucose products we develop, may choose to launch the products
in a limited number of jurisdictions, may delay the launch of
products, or its sales and marketing efforts to commercialize
the products may not be successful, all of which would have a
material adverse effect on our business and financial position.
18
We
currently derive the vast majority of our revenue from the
initial blood glucose product and we anticipate this will
account for a significant part of our revenue for the
foreseeable future. There is no guarantee that we will receive
revenue under the Master Services and Supply Agreement, in a
timely fashion or at all.
The vast majority of our revenue is derived from LifeScan. Our
business is, therefore currently dependent on the level of
services we provide to LifeScan, the number of test strips that
we manufacture for LifeScan and the sales of the blood glucose
test strips. Our business will be directly affected by changes
in LifeScans requirements and the level of sales of the
blood glucose test strips. Our business will also be affected by
economic factors and other trends that affect LifeScan and the
blood glucose testing market generally. The market for blood
glucose testing is intensely competitive and is subject to rapid
change. If we or LifeScan are unable to anticipate or keep pace
with change in the market place and the direction of
technological innovation, our research and development
activities may become less useful for LifeScan. If LifeScan
utilizes less of our research and development services, our
operating results may suffer. Although we will be the sole
manufacturer with capacity to manufacture the blood glucose test
strips during 2010, we generally act as a non-exclusive
manufacturer of the blood glucose test strips we developed with
LifeScan. LifeScan will establish its own manufacturing
capability and, in the future, is likely to manufacture a large
proportion of its own requirements. There is a risk that our
manufacturing costs or product quality may not be able to
compete with LifeScans own operations. Our revenues will
decline if we manufacture less than we currently anticipate and
some of the manufacturing equipment we have acquired may need to
be redeployed to other programs.
Additionally, adverse economic and other factors may cause a
reduction in the overall demand for the blood glucose testing
product thereby decreasing our revenues. If such factors
adversely affect the industry, they may cause LifeScan to
decrease the number of services and products it requires from us
and may reduce the level of sales of the blood glucose test
strips, thereby reducing or eliminating our revenues from the
blood glucose market. There can be no assurance that economic
and other factors that might adversely affect LifeScan or the
blood glucose industry generally will not adversely affect our
results of operations.
We
currently only have limited revenue from the sale or
manufacturing of
point-of-care
tests.
We are at an early stage of our development as a specialist
medical devices company. We were incorporated in 2001 and have a
limited operating history on which to evaluate our business and
prospects. The blood glucose test product which we developed
with LifeScan has been launched and we are receiving some
initial revenues from the manufacture and sale of that product.
We do not have, and may never have, any of our own products that
generate revenues or substantial revenues. To date, we have
funded our operations primarily through the issue of shares,
from payments received under the Development and Research
Agreement, various payments received under the Master Services
and Supply Agreement and from government and state grants
received by Universal Biosensors Pty Ltd.
We made a net profit of A$1,430,463 for the year ended
December 31, 2009. Our accumulated losses from inception to
December 31, 2009 are A$22,922,688. These losses, among
other things, have had and will continue to have an adverse
effect on our stockholders equity and working capital.
Our ability to generate profits in the future will be subject to
a number of factors, including without limitation:
|
|
|
|
|
the market acceptance and the success of sales and marketing
efforts of the blood glucose product we developed with LifeScan
in key jurisdictions;
|
|
|
|
our ability to manufacture sufficient quality and quantity of
the blood glucose test strips for LifeScan at a cost effective
price;
|
|
|
|
our ability to perform the required services under the Master
Services and Supply Agreement and the level of revenue received
from those services;
|
|
|
|
LifeScan determining to launch future blood glucose products we
develop for them;
|
19
|
|
|
|
|
the level of revenue received by us from LifeScan from the
manufacture by us of blood glucose test strips and from service
fees calculated with reference to the sales of the blood glucose
tests strips by LifeScan;
|
|
|
|
the timing of any decision that LifeScan could potentially make
to pay out the service fee stream;
|
|
|
|
our ability to generate new blood glucose products for LifeScan
in the future and the terms upon which we undertake such
development activities;
|
|
|
|
continued income from LifeScan under our Development and
Research Agreement;
|
|
|
|
the occurrence and cost of any product liability claims or
recalls with respect to the blood glucose product;
|
|
|
|
our ability to enter into collaborative, licensing and other
arrangements in relation to our own products and the terms and
conditions of any such arrangements;
|
|
|
|
the successful development, product validation, regulatory
clearance and scale up and manufacture of our C-reactive
protein, prothrombin time, D-dimer tests and future
point-of-care
tests;
|
|
|
|
the timing and success of registration of our products and our
ability to maintain regulatory clearances, pass regular audits
and respond to any issues that are raised by regulators from
time to time;
|
|
|
|
the development of the C-reactive protein, prothrombin time and
D-dimer
point-of-care
test markets and
point-of-care
test markets in general;
|
|
|
|
successful market acceptance and the success of sales and
marketing efforts of our products by our collaboration partners
and the revenue generated by sales of products;
|
|
|
|
the ability of our products to be preferred over the products of
our competitors;
|
|
|
|
the emergence of competing technological developments;
|
|
|
|
the rate of progress and cost of our product development
activities;
|
|
|
|
the expenses we incur in manufacturing, and developing products;
|
|
|
|
the costs of filing, prosecuting, defending and enforcing any
patent claims and other intellectual property rights;
|
|
|
|
the costs of any litigation we may become involved in; and
|
|
|
|
the acquisition of businesses, products and technologies,
although we currently have no commitments or agreements relating
to any of these types of transactions.
|
As a result of the matters set out above and other risks and
uncertainties, we may experience significant fluctuations in our
operating results for the foreseeable future and we may
experience larger than expected future losses and may never
become profitable again. These fluctuations may be due to a
number of factors, many of which are outside of our control, and
may result in volatility of the price of our shares traded in
the form of CDIs on the Australian Securities Exchange. If we
fail to remain profitable, or if we are unable to fund our
losses, the holders of our shares could lose all or part of
their investment.
Increases
in our costs to manufacturing products for LifeScan may decrease
our margins or cause us to suffer a loss on the manufacture of
blood glucose test strips for LifeScan.
The Master Services and Supply Agreement contains a cap on the
amount we may charge per strip for the manufacture of the blood
glucose test strip. Our net income will decrease if our
manufacturing costs increase or are in excess of what we have
anticipated. If our costs of manufacture per strip exceed the
cap in the Master Services and Supply Agreement, we will suffer
a loss on the sale of those strips. In that event, the Master
Services and Supply Agreement provides a mechanism whereby the
issue can be referred to the steering committee which
administers the Master Services and Supply Agreement for
resolution. We have the
20
right to terminate the Master Services and Supply Agreement
should we not be able to negotiate suitable relief.
Termination
of our Master Services and Supply Agreement with LifeScan would
eliminate our ability to receive revenues from the
commercialization of blood glucose products.
The Master Services and Supply Agreement imposes a number of
material obligations on us. If the Master Services and Supply
Agreement with LifeScan was terminated as a result of either
party defaulting on its material obligations, either party
becoming insolvent, at LifeScans option after paying a
lump sum service fee, or as a result of other factors detailed
in the Master Services and Supply Agreement, upon termination we
would cease to have the potential to receive revenues from the
sale of blood glucose strips, which would have a material
adverse effect on us.
Termination
of our License Agreement would restrict or eliminate our ability
to develop our existing or future
point-of-care
tests.
Pursuant to a License Agreement, we currently hold a license
from LifeScan to a range of patents, patent applications and
know-how in all fields excluding the fields of diabetes and
blood glucose monitoring generally. The License Agreement
imposes material obligations on us, including a best endeavors
obligation to exploit the licensed intellectual property. If we
were to breach the License Agreement and LifeScan was entitled
to, and did, validly terminate the License Agreement, this would
seriously restrict or eliminate the ability to develop and
commercialize our C-reactive protein test, prothrombin time test
or our D-dimer test or any future tests we intend to develop.
The termination of the License Agreement would have a material
adverse effect on us as it would eliminate our existing
commercialization opportunities.
Our
Development and Research Agreement with LifeScan provides an
ongoing source of income for us, the termination of which would
result in the loss of that income.
We undertake contract research and development activities for
LifeScan pursuant to a Development and Research Agreement. We
receive income under the Development and Research Agreement. If
terminated, we would lose an important source of income.
We
have only manufactured limited commercial quantities of blood
glucose tests strips and therefore have limited experience as a
manufacturer.
We have only recently commenced manufacturing commercial
quantities of the blood glucose test strips for LifeScan. There
are technical challenges to increasing our manufacturing
capacity in a significant manner, including maintaining the
consistency of our incoming raw materials, equipment design and
automation, material procurement, production yields and quality
control and assurance. We may fail to achieve and maintain
required production yields or manufacturing standards which
could result in patient injury or death, product recalls or
withdrawals, product shortages, delays or failures in product
testing or delivery, breach of the Master Services and Supply
Agreement or other problems that could seriously harm our
business.
We
face the risk of product liability claims.
We, and our commercial partners, may be exposed to the risk of
product liability claims that are inherent in the testing,
manufacturing, marketing and sale of diagnostic tests. This risk
will relate to the products which we have or may develop with
LifeScan as well as other non-blood glucose products we develop.
Regardless of merit or eventual outcome, liability claims may
result in:
|
|
|
|
|
decreased demand for the product we have developed with LifeScan
or our own products;
|
|
|
|
injury to our reputation
and/or
injury to the reputation of LifeScan or other commercial
partners;
|
|
|
|
costs of related litigation;
|
21
|
|
|
|
|
managements attention and the attention of our commercial
partners being diverted to the claims;
|
|
|
|
substantial monetary awards to end users and others;
|
|
|
|
impairment of our ability to generate sales of the product the
subject of the litigation as well as our other potential
products, resulting in loss of revenues;
|
|
|
|
increases in insurance premiums or the inability to obtain or
maintain insurances on commercially acceptable terms; and
|
|
|
|
LifeScan being unable to commercialize the blood glucose
products we have developed with them or the inability for us to
commercialize our products.
|
We have obligations to LifeScan and indemnify LifeScan under the
Master Services and Supply Agreement with respect to liability
arising in connection with the blood glucose tests strips
supplied by us and with respect to certain matters concerning
the design, validation and manufacture of the blood glucose test
strips. We have obtained product liability insurance in
connection with the blood glucose test strips. We intend to seek
appropriate product liability insurance with respect to any
other products we take to market. However, we may not be able to
maintain insurance coverage at a reasonable cost, with coverage
that we consider reasonable or that will be adequate to satisfy
any liability that may arise. If we are unable to maintain our
insurance at an acceptable cost or on acceptable terms with
adequate coverage or otherwise protect against potential product
liability claims, we will be exposed to significant liabilities,
which may harm our business. A product liability claim or other
claim with respect to uninsured liabilities or for amounts in
excess of insured liabilities could result in significant costs
and significant harm to our business. Any claim for damages
under the Master Services and Supply Agreement or other claim
against us could be substantial. If we are not able to maintain
adequate coverage at a reasonable cost, our ability to perform
under the Master Services and Supply Agreement may be
compromised.
We
face the risk of recalls of our products or of the products we
have developed with LifeScan.
LifeScan may be exposed to product recalls and adverse public
relations if they determine the blood glucose product should be
recalled or the blood glucose products are alleged to cause
injury or illness, or if they are alleged to have violated
government regulations. To the extent such recall or action is
attributable to us, we may be liable to reimburse LifeScan for
the reasonable costs of such action. The costs of any such
action may be significant and may have a material adverse effect
on us. A product recall could result in substantial and
unexpected expenditures, which would reduce operating profit and
cash flow. In addition, a product recall may divert significant
of our and LifeScans management attention. Product recalls
may lead to decreased demand for the products we have developed
with LifeScan. Product recalls may also lead to increased
scrutiny by regulatory agencies and increased litigation.
We will likewise be exposed in the future to product recalls and
adverse public relations with respect to our own products if we
determine our products should be recalled or our products are
alleged to cause injury or illness, or if they are alleged to
have violated government regulations. The costs of any such
action may be significant and may have a material adverse effect
on us.
We have obtained recall liability insurance with respect to the
blood glucose product. However, as a third party supplier to
LifeScan of blood glucose strips, the coverage of recall
insurance available is limited and we may not be able to
maintain insurance coverage at a reasonable cost, with coverage
that we consider reasonable or that will be adequate to satisfy
any liability that may arise. If we are unable to maintain
insurance at an acceptable cost or on acceptable terms with
adequate coverage or otherwise protect against potential product
liability claims, we may not be able to satisfy our insurance
obligations under the Master Services and Supply Agreement and
may be exposed to significant liabilities, which may harm our
business.
22
We may
in the future manufacture defective test strips that have to be
discarded, or be subject to liability should product be
recalled, which increases our costs of operations and may delay
shipment of product to customers.
There are many elements to manufacturing each lot of blood
glucose test strips that can cause variability beyond acceptable
limits. We may be required to discard defective test strips
after we have incurred significant material and labor costs.
There may be delays in the manufacture and shipment of tests
strips to LifeScan.
We are dependent on our suppliers to deliver various components
in conformity with our specifications. If our suppliers are
unable to provide materials in conformance with specifications
we may be required to discard materials and there may be delays
in the manufacture and shipment of tests strips to LifeScan.
There
is a risk that we will not be able to enter into collaborative
arrangements or strategic alliances with respect to our products
which may mean that we are required to delay, reduce the scope
of or eliminate some or all of our development
programs.
Our business strategy involves demonstrating that our
electrochemical cell technology can be extended to create other
platforms and then to seek to enter into collaborative
arrangements, licensing agreements or strategic alliances with
other life sciences companies or other industry participants for
these platforms, or for the products we have developed as proof
of principle on those platforms. There is a risk we may not be
able to enter into such collaborative arrangements or alliances
on acceptable terms, if at all. As a result, we may have to
delay, reduce the scope of or eliminate some or all of our
development programs or liquidate some or all of our assets or
seek to raise additional capital. As a result, significant
monies invested and management time may be rendered unproductive
and worthless.
We have not established any internal sales and marketing
capacity and to achieve commercial success, we must enter into
and maintain successful arrangements with others to sell, market
and distribute our products.
To the extent we are able to enter into collaborative
arrangements or strategic alliances with respect to our
products, we will be exposed to risks and uncertainties related
to those collaborations and alliances. These arrangements may
result in us receiving less revenue than if we sold such
products directly, may place the development, sales and
marketing of our products outside our control, may require us to
relinquish important rights or may otherwise be on terms
unfavorable to us. Collaborative arrangements, licensing
agreements or strategic alliances will subject us to a number of
risks, including the risk that:
|
|
|
|
|
we may not be able to control the amount and timing of resources
that our strategic partner/collaborators may devote to our
products;
|
|
|
|
our strategic partner/collaborators may experience financial
difficulties;
|
|
|
|
we may be required to relinquish important rights such as
marketing and distribution rights;
|
|
|
|
business combinations or significant changes in a
collaborators business strategy may also adversely affect
a collaborators willingness or ability to complete its
obligations under any arrangement;
|
|
|
|
a collaborator could independently move forward with a competing
product developed either independently or in collaboration with
others, including our competitors; and
|
|
|
|
collaborative arrangements are often terminated or allowed to
expire, which would delay the development and may increase the
cost of developing our products.
|
There
is a significant degree of technical development risk associated
with the tests we are developing.
The development of our C-reactive protein test, D-dimer test
(and our immunoassay platform generally), and prothrombin time
test and any new diagnostic tests which we develop will take a
number of years to complete, will be costly to develop and the
outcomes of our development activities will be uncertain. Even
if funding is available for these projects, we still need to
undertake a significant amount of technical risk reduction and
product development of these tests. Some of these tests still
have a significant degree of technical risk and development work
and product validation may not be successful or the outcomes of
the
23
development activities may not warrant the commercialization of
the relevant product. As a result, significant monies invested
and management time may be rendered unproductive and worthless.
Although the development of the blood glucose test is completed,
there will be technical risk associated with any new blood
glucose products we may agree to develop with LifeScan. The
development of any such product will be time consuming and
costly and the outcomes of our development activities uncertain.
Development and validation of these products may not be
successful or the outcomes of the development activities may not
warrant the commercialization by LifeScan of the relevant
product. As a result, significant monies invested and management
time may be rendered unproductive and worthless.
Clinical
testing is a time consuming, expensive and uncertain
process.
Before the FDA or other regulatory agency approves a diagnostic
test for marketing, it must be tested for safety and performance
in laboratory and clinical trials. These studies can be costly,
time consuming and the results unpredictable. The completion of
any clinical trial could be delayed as a result of a number of
factors including slower than expected rates of patient
recruitment and enrollment, unforeseen safety issues or poor
performance. Our partner may not fully reimburse us for these
costs. Any unanticipated costs or delays in our clinical trial
could cause us to expend substantial additional funds that are
not reimbursed by a partner or cause us to miss milestones which
trigger a financial payment or cause us or a partner to delay or
modify our plans significantly, which would harm our business,
financial condition and results of operations.
Even if the clinical trials are complete, we do not know if they
will produce clinically meaningful results sufficient to support
an application for marketing approval. If we achieve success at
any stage of a study, that success may not continue. Interim
results of trials do not predict final results. There is a risk
that these clinical trials may not be successful or may not be
successful with respect to a particular condition or that
marketing authorization may not be granted in the future. If we
or a partner are not able to successfully complete clinical
trials of our products, and if we are unable to obtain marketing
authorization of those products, we may not be profitable or
poor results or failure in trials might trigger dissolution of
the termination of the partnership.
Diagnostic
tests are subject to extensive regulation and we or third
parties may not be successful in obtaining clearances for some
or all of the
point-of-care
tests we are developing.
The development, manufacturing, sales and marketing of
diagnostic tests are subject to extensive regulation in all
major markets. The process of obtaining regulatory clearance is
costly and time consuming and we or third parties may not be
successful in obtaining clearances for some or all of the
point-of-care
tests we are developing. Products cannot be sold without
regulatory clearance. LifeScan is responsible for determining
the commercialization strategy and is responsible for obtaining
all necessary regulatory clearances with respect to blood
glucose products. LifeScan has obtained regulatory clearances
for the initial blood glucose product in Europe. With respect to
any new tests we develop, if we or our partners are unable to
obtain the necessary clearances to sell or if the clearances are
delayed, revoked or subject to unacceptable conditions, the
product may not be able to be commercialized, which would have a
material adverse effect on us.
Regulatory oversight continues once products have been brought
to market. Failure to comply with regulatory requirements may
result in administrative or judicially imposed sanctions. There
may be a need in the future to recall released products which
have been developed by us in the event of material defects in
design or manufacture or quality-related issues, or failure by
us to comply with regulatory requirements. Any such recalls may
have a material adverse effect on us. Furthermore, regulatory
requirements are subject to change and some changes may have
adverse effects on us.
24
Even
if the products we develop for LifeScan, or others receive
regulatory approval, we may still face development and
regulatory difficulties that may delay or impair future sales
and we would be subject to ongoing regulatory obligations and
restrictions, which may result in significant expense and limit
our ability to commercialize our product.
Following regulatory authorization to sell products, relevant
regulatory authorities may, nevertheless, impose significant
restrictions on the indicated uses, manufacturing, labeling,
packaging, storage, advertising, promotion and record keeping or
impose ongoing requirements for post-approval studies and
adverse event reporting. In addition, regulatory agencies
subject a marketed product, its manufacturer and the
manufacturers facilities to continual review and periodic
inspections. Potentially costly responses may be required
including product modification, or
follow-up or
post-marketing clinical trial may be required as a condition of
approval to further substantiate safety or efficacy, or to
investigate specific issues of interest to the regulatory
authority. Previously unknown problems with a product, including
adverse events of unanticipated severity or frequency, may
result in restrictions on the marketing of the product, and
could include withdrawal of the product from the market. If we
discover previously unknown problems with a product or our
manufacturing facilities or the manufacturing facilities of a
contract manufacturer, a regulatory agency may impose
restrictions on that product, on us or on our third-party
contract manufacturers, including requiring us to withdraw the
product from the market.
If we or our commercial partners fail to comply with applicable
regulatory requirements, a regulatory agency may:
|
|
|
|
|
issue warning letters;
|
|
|
|
impose civil or criminal penalties;
|
|
|
|
suspend regulatory authorization;
|
|
|
|
suspend ongoing clinical trials;
|
|
|
|
refuse to approve pending applications or supplements to
approved applications filed;
|
|
|
|
impose restrictions on our operations, including closing our
manufacturing facilities or terminating licenses to
manufacture; or
|
|
|
|
seize or detain products or require a product recall.
|
Any of the foregoing could seriously harm the commercialization
of our products and our results and operations may be seriously
harmed.
In addition, the law or regulatory policies governing diagnostic
tests may change. New statutory requirements may be enacted or
additional regulations may be enacted that could prevent or
delay regulatory approval of our products. We cannot predict the
likelihood, nature or extent of adverse government guidance or
regulation that may arise from future legislation or
administrative action. If we are not able to maintain regulatory
compliance, we might not be permitted to market our products and
our business could suffer.
Our
products, even if approved by foreign regulatory agencies and
launched may not be accepted by customers.
Success of products developed by us are ultimately dependent on
the market acceptance and level of sales of those products. Our
ability to be or maintain profitability in the future will be
adversely affected if any of the products developed by us, after
receiving regulatory approval, fail to achieve or maintain
market acceptance. If products developed by us are not
successful in the market place, our revenues from sales of those
products will be reduced or eliminated. We believe that market
acceptance will depend on, amongst other things, the ability to
provide and maintain evidence of safety, efficacy and cost
effectiveness of the products. In addition, market acceptance
depends on the effectiveness of marketing strategies employed to
sell the products.
25
Adverse
economic conditions may harm our business.
Market and economic conditions have been challenging worldwide.
Continuing concerns have led to increased market volatility and
diminished expectations for world economies. Continued
turbulence in the US and international markets and economies may
adversely affect our ability to enter into collaborative
arrangements and the spending patterns of users of test strips
we are developing and the financial condition of our current and
any future partners. This may adversely impact demand for
products developed and services provided by us. In addition,
economic conditions could also impact our suppliers, which may
impact on their ability to provide us with materials and
components which in turn may negatively impact our business.
In addition, as a result of these conditions, our ability to
raise capital and the availability of credit, if required in the
future, may be adversely effected. If we are unable to raise
capital or secure credit when required, we may have to delay,
reduce the scope of or eliminate some or all of our development
programs or commercialization efforts or liquidate some or all
of our assets.
Currency
fluctuations may expose us to increased costs and decreases in
revenue.
Due to the global reach of our business, we are exposed to
market risk from changes in foreign currency exchange rates.
Our functional currency changed to Australian dollars with
effect from December 1, 2006. Prior to December 1,
2006, our functional currency was United States dollars. The
functional currency of Universal Biosensors Pty Ltd is and has
been Australian dollars for all years. For details in relation
to our functional currency, refer to our financial statements in
this
Form 10-K.
We are exposed to market risk from changes in foreign currency
rates causing increased costs, particularly changes in the
Australia, United States and Euro dollars. The majority of our
cash reserves are in Australian dollars and the majority of our
expenses are incurred in Australian dollars although we continue
to expend cash in other currencies. In particular, large scale
manufacturing equipment is purchased in both United States
dollars and Euros and any appreciation in these currencies
against the Australian dollar will increase our cost of
acquiring such equipment but may have a positive effect on any
revenues which we source from the U.S. or Europe (as
applicable). The same principles apply in respect of our costs
in other jurisdictions.
Similarly, we are exposed to market risk from changes in foreign
currency rates with respect to our revenues. Currently, the vast
majority of our revenue is in U.S. dollars. The
appreciation in the Australian dollar against the U.S. will
result in a decrease in our revenues.
We use financial instruments, primarily short term foreign
currency forward contracts to hedge certain forecasted foreign
currency commitments arising from trade accounts receivables,
trade accounts payable and fixed purchase obligations. Our
foreign currency hedging activities depend largely upon the
accuracy of our forecasts of future sales, expenses and monetary
assets and liabilities. As such, our foreign currency forward
contracts may exceed or not cover our full exposure to exchange
rate fluctuations. If these hedging activities are unsuccessful,
we may experience significant unexpected fluctuations in
exchange rates. Although we believe our foreign exchange
policies are reasonable and prudent under the circumstances, we
may experience losses from un-hedged currency fluctuations,
which could be significant.
The
failure to secure adequate supplies of the raw materials and
components required to manufacture products developed by us
could compromise the commercialization and manufacture of
products developed by us.
In common with most major manufacturers in our industry, certain
raw materials and components come from preferred suppliers,
making us vulnerable to supply disruption, which could harm our
business. Our suppliers may encounter problems during
manufacturing due to a variety of reasons, including failure to
follow our protocols and procedures, failure to comply with
applicable regulations, or equipment malfunction, any of which
could delay or impede their ability to meet our demand.
Additionally, we do not currently have long term contractual
arrangements with certain of our suppliers. As a result we may
not be able to guarantee the supply of certain of our materials
or the acceptability of the terms upon which those materials are
supplied.
26
We may have difficulty locating and qualifying on a timely basis
alternative suppliers for any preferred suppliers and switching
components may require product redesign and new submissions to
the FDA or other regulatory bodies, either of which could
significantly delay production. A failure of a supplier to
comply with their supply obligations may cause a delay in our
ability to supply product, which may have an adverse effect on
us. There may be delays in the manufacture and supply of product
if raw materials are not available on commercially acceptable
terms, if there is a supply interruption or if we are unable to
obtain alternative suppliers when required. LifeScan is likewise
subject to supply risks which may delay their ability to supply
customers with the blood glucose product, which may have a
consequential adverse effect on our business and results of
operations.
We
currently outsource some development and the manufacturing of
our meters.
We currently outsource some development and manufacturing
activities with respect to the meters for our non-blood glucose
tests. We anticipate that we will outsource commercial
manufacture of meters as our current manufacturing facilities
are not suitable for the commercial scale production of meters.
In circumstances where we seek to outsource the manufacture of
certain meters or other components, there is no guarantee that
we will be able to enter into any such arrangement on acceptable
terms, if at all, and as a result we are at risk of lengthy and
costly delays of bringing our products to market. We may be
required to enter into long-term manufacturing agreements that
contain exclusivity provisions
and/or
substantial termination penalties. In addition, contract
manufacturers may have a limited number of facilities in which
our products can be produced and any interruption of the
operation of those facilities could result in the cancellation
of shipments and loss of product, resulting in delays and
additional costs. Our contract manufacturers may fail to achieve
and maintain required production yields or manufacturing
standards which could result in patient injury or death, product
recalls or withdrawals, product shortages, delays or failures in
product testing or delivery or other problems that could
seriously harm our business. In addition, our contract
manufacturers will be subject to ongoing inspections and
regulation of regulatory authorities, including by the TGA and
the FDA.
In connection with the anticipated roll out of the blood glucose
product, LifeScan will need to order and have manufactured a
large quantity of meters from its existing suppliers. Blood
glucose meter shortages or manufacturing delays could result in
the reduction in sales of the blood glucose product and
consequent delays or reduction in our revenues, which would have
an adverse effect on us.
We,
and our contract manufacturers, are required to produce our
clinical product and commercial product under FDA and E.U.
current Good Manufacturing Practices in order to meet acceptable
standards. If such standards change, our ability and the ability
of contract manufacturers to produce our products when we
require may be affected.
Our contract manufacturer may not perform as agreed or may not
remain in the contract manufacturing business for the time
required to successfully produce, store and distribute our
products. The ability to find an acceptable manufacturer or to
change manufacturers may be difficult for a number of reasons,
including that the number of potential manufacturers for
specialty components is limited and we may not be able to
negotiate agreements with manufacturers on commercially
reasonable terms, the complex nature of the meters, and the
requirement for the FDA or other applicable regulatory bodies to
approve any replacement manufacturer prior to manufacturing,
which requires new testing and compliance inspections.
If we were required and able to change manufacturers, the FDA or
other applicable regulatory body would also require that we
demonstrate structural and functional comparability between the
same products manufactured by different organizations and may
require comparability studies.
We may
require substantial additional capital which may not be
available in the future.
If additional commercial manufacturing capacity was required or
if we are successful in advancing more than one
point-of-care
test to regulatory clearance, or if we are unable to enter into
collaborative arrangements or strategic alliances with respect
to our products, significant additional capital may be required.
There can be no assurance that the funds will be available on a
timely basis, on favorable terms, or at all. If we are unable
27
to raise adequate funds, we may have to delay, reduce the scope
of or eliminate some or all of our development programs or
commercialization efforts or liquidate some or all of our assets.
The
success of our business is dependent upon the growth of the
point-of-care
testing market. If that market fails to develop as we
anticipate, our results will be adversely
affected.
Our business plan relies on the development of both the existing
and emerging
point-of-care
testing market. We cannot be sure that this market will grow as
we anticipate, or to the point where it attracts the interest of
major companies. Such growth will require continued support and
demand from payers, patients and health care professionals and
the endorsement by professional bodies that influence the
practice of medicine. Research and clinical data may not
sufficiently support
point-of-care
testing, nor may the health economic benefits sufficiently
support
point-of-care
testing as an alternative to current practice. Even if the data
is compelling, significant resources may be required to educate
users and change in practice may be slower and more costly than
we anticipate.
Point-of-care
testing may not be endorsed by professional bodies that
influence the practice of medicine. Payers may not provide
coverage for new tests, or provide coverage at a favorable rate.
These factors may inhibit the adoption of
point-of-care
testing. If
point-of-care
testing fails to be adopted at the rate we expect, the sector
may remain unattractive to the size of partner we seek to
attract and as a consequence our business model may need to be
rewritten. This may require us to incur more cost
and/or our
anticipated growth will be adversely affected and our results
will suffer.
Even if we successfully secure a partner, the degree of market
acceptance of any approved products will depend on a variety of
factors, including:
|
|
|
|
|
timing of market introduction and the number and clinical
profile of competitive products;
|
|
|
|
our partners ability to secure the support of key
clinicians and physicians for products;
|
|
|
|
relative convenience and ease of administration;
|
|
|
|
cost-effectiveness compared to existing diagnostic tests;
|
|
|
|
availability of coverage, reimbursement and adequate payment
from health maintenance organizations and other
third-parties; and
|
|
|
|
other advantages over other test methods.
|
The
success of a C-reactive protein test is dependent upon the
acceptance of the use of C-reactive protein in a
point-of-care
setting for the management of inflammatory conditions. If that
use of C-reactive protein fails to develop as we anticipate, our
ability to secure a partner and our results will be adversely
affected.
The use of C-reactive protein as a marker for inflammatory
conditions is generally widely accepted, but is predominantly a
test performed in centralized laboratories. We cannot be sure
that the market will accept the use of a
point-of-care
C-reactive protein test for the management of inflammatory
conditions in the manner we anticipate. The emergence of this
market will require acceptance from health care professionals
and the endorsement by professional bodies that influence the
practice of medicine as well as support from payors and demand
from patients. Clinical data may not provide sufficient support
for the use of
point-of-care
C-reactive protein testing, nor may the health economic benefits
sufficiently support the introduction of
point-of-care
C-reactive
protein testing as an alternative to current practice. Even if
the data is compelling, significant resources may be required to
educate users and change in practice may be slower and more
costly than we anticipate. These factors may inhibit or
eliminate our ability to commercialize our C-reactive protein
testing.
The
market for a prothrombin time test may be significantly reduced
if new therapies appearing on the market are widely accepted and
significantly reduce the need for testing. This may render the
market for a
point-of-care
prothrombin time test unattractive for a partner.
A number of new oral anti coagulants are entering the market
which may eliminate or significantly reduce the need for
prothrombin time testing. It is not known how widespread the
acceptance of these new
28
medications will be, nor whether they will be successfully
reimbursed for long term use. Uncertainty as to the size and
longevity of the prothrombin test market may cause our efforts
to enter into a collaborative arrangement with respect to this
product unproductive.
The
performance of the
point-of-care
tests developed by us may not be perceived as being comparable
with established laboratory methods, which may limit our ability
to enter into partners with respect to these
products.
Health care professionals who perform
point-of-care
testing or recommend
point-of-care
testing for their patients will need to be convinced of the
health and economic benefits provided by
point-of-care
tests developed by us. These health care professionals will
always have the option of referring tests to centralized testing
if they are unconvinced by the performance of the tests
developed by us. If we are unable to demonstrate to healthcare
professionals satisfaction that the performance of our
point-of-care
tests closely match or provide some benefits over the testing
undertaken by hospitals and pathology laboratories, market
acceptance of our product will be limited and our business will
suffer.
If we are unable to anticipate or keep pace with change in the
market place and the direction of technological innovation and
customer demands, our products may become less useful or
obsolete and our operating results will suffer.
The
in vitro diagnostics market is a highly competitive market
and we and any partners face competition from large,
well-established medical device manufacturers with significant
resources.
Hundreds of technology companies globally are developing
technologies and products and many of these companies will
compete with us for the attention of the limited pool of global
multinationals. If our platforms or the attributes of the
products that can be produced by our platform are perceived to
be inadequate or uncompetitive with other offerings, potential
partners may prefer to partner with one of our competitors. If
we are unable to find a partner our business will suffer.
The market for in vitro diagnostics is intensely
competitive, price sensitive, subject to rapid change, and
affected by new product introductions and other activities of
industry participants. If we are unable to anticipate or keep
pace with change in the market place and the direction of
technological innovation and customer demands, products
developed by us may become less useful or obsolete and our
operating results will suffer. Because products developed by us
have long development and government approval cycles, we and any
partner must anticipate changes in the market place and the
direction of technological innovation and customer demands. We
and our partner may be unable to accurately anticipate changes
in the markets and the direction of technological innovation and
the demands of our customers, competitors may develop improved
technologies or the market place may conclude that our products
are obsolete. Any developments adversely affecting the markets
for products developed by us would force us to reduce production
or discontinue manufacturing which would cause our operating
results to suffer. If clinical trials call into question the
effectiveness of products developed by us, or if more effective
technologies are introduced, our business will suffer.
Point-of-care
tests are likely to experience significant and continuing
competition from traditional pathology laboratory based testing
as well as other
point-of-care
tests. We and any partner will face competition from approved
and marketed products as well as products in development. There
can be no assurances given with respect to our or any
partners ability to compete in the competitive markets in
which we operate.
Our commercial opportunity will be reduced or eliminated if our
competitors or LifeScans competitors develop and
commercialize products that are safer, more effective, are more
convenient, are less expensive, or that reach the market sooner
than our products. Scientific, clinical or technical
developments by our competitors may render products we develop
or the products we develop for LifeScan obsolete or
non-competitive. Further, public announcements regarding the
development of any such competing products could adversely
affect the market price of our shares. We anticipate that we
will face increased competition in the future as new companies
enter the markets and as scientific developments progress. If
the products we develop
29
obtain regulatory approvals, but do not compete effectively in
the marketplace, our business will suffer. Even if we or any
partner can show competitive product advantages, customers may
be resistant to changing their supplier.
Many of our competitors have significantly greater financial
resources and expertise in conducting clinical trials, obtaining
regulatory approvals, undertaking and managing manufacturing and
sales and marketing of products than we do. Early-stage
companies may also prove to be significant competitors,
particularly through collaborative arrangements they may have
with large and established companies. In addition, these third
parties compete with us in recruiting and retaining qualified
scientific and management personnel, establishing clinical trial
sites and patient registration for clinical trials, as well as
in acquiring therapies and therapy licenses complementary to our
programs or advantageous to our business.
Additionally, existing and potential competitors hold
intellectual property rights that could allow them to develop or
sell the right to develop new products that could compete
effectively with our
point-of-care
tests. Many of these companies are larger than we and can enjoy
several competitive advantages, including:
|
|
|
|
|
significantly greater name recognition;
|
|
|
|
established relationships with healthcare professionals,
patients and insurance providers;
|
|
|
|
large, direct sales forces
and/or
established independent distribution networks;
|
|
|
|
additional product lines and the ability to offer rebates,
bundled products, and higher discounts or incentives;
|
|
|
|
greater financial and human resources for product development,
sales and marketing and patent litigation.
|
If we or any partner are unable to compete effectively in the
in vitro diagnostics market place, our business will be
harmed. Our commercial opportunity will be reduced or eliminated
if competitors develop and commercialize products that are more
effective, are more convenient, are less expensive, that reach
the market sooner than products developed by us, or that are
otherwise preferred over our products. Developments by
competitors may render the products we develop obsolete or
noncompetitive. Further, public announcements regarding the
development of any such competing products could adversely
affect the market price of our securities on the ASX. If
products developed by us obtain regulatory clearances, but do
not compete effectively in the marketplace, our business will
suffer.
If we
are unable to maintain protection for our intellectual property
or if LifeScan is unable to maintain protection of the
intellectual property which it licenses to us, the value of our
technology and diagnostic tests may be adversely
affected.
Our ability to obtain patents, maintain trade secret protection
and operate without infringing the proprietary rights of third
parties is an integral part of our business. Our diagnostic
tests are based predominantly on intellectual property rights
that have been licensed to us from LifeScan. LifeScan has a
considerable degree of control in the manner that the
intellectual property licensed to us is maintained and protected
and, as a result, we have reduced control with respect of the
maintenance and protection of our licensed patent portfolio.
A number of companies, universities and research institutions
have or may be granted patents that cover technologies similar
to the technologies owned by or licensed to us, or they may have
technologies that we may need to complete development of a
particular product. We may choose to seek, or be required to
seek, licenses under third-party patents, which would likely
require the payment of license fees or royalties or both. A
license may not be available to us on commercially reasonable
terms, or at all. We may also be unaware of existing patents or
other proprietary rights of third parties that may be infringed
by our
point-of-care
tests. As patent applications can take many years to issue,
there may be other currently pending applications which may
later result in issued patents that are infringed by our
point-of-care
tests.
30
There has been substantial litigation and other proceedings
regarding patent and other intellectual property rights in the
medical devices industry. The prosecution and enforcement of
patents licensed to us by LifeScan are not within our control,
and without these technologies, our product may not be
successful and our business would be harmed if the patents were
infringed or misappropriated without action by such third
parties. LifeScan is responsible for the prosecution and
maintenance of the intellectual property it license to us and
are therefore to a large extent dependant on them with respect
to the defense of proceedings and the prosecution of infringers
of the licensed intellectual property rights. Without access to
these technologies, our ability to conduct our business would be
impaired significantly. Defending ourselves against third-party
claims, including litigation in particular, would be costly and
time consuming and would divert managements attention from
our business, which could lead to delays in our development or
commercialization efforts. If third parties are successful in
their claims, we might have to pay substantial damages, pay
license fees, stop marketing the infringing product or take
other actions that are adverse to our business.
Infringement actions may need to be brought if we or LifeScan
(with respect to the intellectual property licensed to us)
believe that a third party is infringing our protected
intellectual property. Any such litigation will be costly, time
consuming and divert managements attention, and the
outcome of any such litigation may not be favorable to us.
The
loss of a key employee or the inability to recruit and retain
high caliber staff to manage future anticipated growth could
have a material adverse effect on our business.
As with most growth companies, our future success is
substantially dependent on our key personnel. Certain key
personnel would be difficult to replace and the loss of any such
key personnel may adversely impact the achievement of our
objectives. Our ability to operate successfully and manage the
business depends significantly on attracting and retaining
additional highly qualified personnel. The loss of any key
personnel may be disruptive or have a material adverse effect on
the future of our business. The competition for qualified
employees in scientific research and medical diagnostic
industries is particularly intense and there are a limited
number of persons with the necessary skills and experience.
All of
our operations are conducted at a single location. Any
disruption at our facility could adversely affect our operations
and increase our expenses.
All of our operations are conducted at our Corporate Avenue
facility in Melbourne, Australia. We take precautions to
safeguard our facility, including security, health and safety
protocols and insurance. However, a natural disaster, such as a
fire, flood or earthquake, could cause substantial delays in our
operations, damage or destroy our manufacturing equipment or
inventory, and cause us to incur additional expenses. The
insurance we maintain against fires, floods, earthquakes and
other natural disasters may not be adequate to cover our losses
in any particular case.
Investors
may be subject to Australian
and/or US
taxation.
The receipt of dividends by Australian tax resident security
holders and any subsequent disposal of our securities by
Australian tax resident may have both United States and
Australian tax consequences depending upon their individual
circumstances. This may result in a security holder being
subject to tax in both jurisdictions and a tax credit may or may
not be available in one jurisdiction to offset the tax paid in
the other jurisdiction depending upon the security holders
individual circumstances. Security holders should obtain, and
only rely upon, their own independent taxation advice about the
United States and Australian consequences of receiving
distributions on our shares or CDIs and disposing of securities
in us having regard to their own specific circumstances. To
date, we have not declared or paid any cash dividends on our
shares or CDIs and currently intend to retain any future
earnings, if any, for funding growth. We do not anticipate
paying any dividends in the foreseeable future.
31
The
price of our shares is highly volatile and could decline
significantly.
Our shares of common stock in the form of CDIs were quoted on
the ASX and began trading on December 13, 2006. The price
of our shares is highly volatile and could decline
significantly. The market price of our shares historically has
been, and we expect will continue to be, subject to significant
fluctuations over short periods of time. These fluctuations may
be due to factors specific to us, to changes in analysts
recommendations and earnings estimates, or to factors affecting
the life sciences industry or the securities markets in general.
For example, from the initial quotation of our shares in the
form of CDIs on the Australian Securities Exchange on
December 13, 2006 until March 16, 2010, the closing
price per share of our shares ranged from a low of A$0.41 during
February 2009 to a high of A$2.02 during the first quarter of
the 2010 fiscal year and was A$1.60 on March 16, 2010. We
may experience a material decline in the market price of our
CDIs, regardless of our operating performance. Therefore, a
holder of our shares may not be able to sell those shares at or
above the price paid by such holder for such shares. Price
declines in our shares could result from a variety of factors,
including many outside our control.
Class action litigation has been brought in the past against
companies which have experienced volatility in the market price
of their securities. We may become involved in this type of
litigation in the future. Litigation of this type is often
extremely expensive and diverts managements attention and
our resources.
Our
securities are not currently traded on any United States public
markets and there are currently restrictions on the ability of
United States persons to acquire our securities on the
ASX.
There is no public market for our shares in the United States or
in any other jurisdiction other than Australia. We have not
determined whether we will seek the quotation of our shares on
any United States public trading market. We cannot assure you
that we will seek to be quoted on any United States public
trading market or that we would meet any applicable listing
requirements. Even if our shares are in the future listed on a
United States public market, the liquidity of our shares may not
improve, and the United States market price may not accurately
reflect the price or prices at which purchasers or sellers would
be willing to purchase or sell our common stock.
In addition, a substantial number of our shares are
restricted securities having been issued pursuant to
an exemption from the registration requirements of the
Securities Act of 1933, as amended (Securities Act)
or pursuant to Regulation S promulgated under the
Securities Act. Therefore, resale of these shares to
U.S. Persons as defined in Regulation S
may only be made in an offshore transaction in compliance with
Regulation S promulgated under the Securities Act, or
pursuant to an effective Registration Statement under the
Securities Act, or pursuant to an available exemption from the
registration requirements of the Securities Act, and in each
case, in accordance with all applicable securities laws.
We are
exposed to risks relating to evaluations of controls required by
Section 404 of the Sarbanes-Oxley Act.
Changing laws, regulations and standards relating to corporate
governance and public disclosure, including the Sarbanes-Oxley
Act of 2002 (Sarbanes-Oxley Act) and related
regulations implemented by the SEC, have substantially increased
legal and financial compliance costs. We expect that our ongoing
compliance with applicable laws and regulations, including the
Securities Exchange Act of 1934 as amended (Exchange
Act) and the Sarbanes-Oxley Act, will involve significant,
and potentially increasing costs. In particular, we must
annually evaluate our internal controls systems to allow
management to report on our internal controls. Additionally,
under current rules, beginning with our fiscal year ending in
2010, our independent auditors will have to attest to our
internal controls. We must perform the system and process
evaluation and testing (and any necessary remediation) required
to comply with the management certification and, when
applicable, auditor attestation requirements of Section 404
of the Sarbanes-Oxley Act. If we are not able to continue to
satisfy the requirements of Section 404 adequately, we may
be subject to sanctions or investigation by regulatory
authorities, including the SEC. Any action of this type could
adversely affect our
32
financial results, investors confidence in our company and
our ability to access capital markets, and could cause our stock
price to decline.
A
significant amount of our shares are controlled by individuals
or voting blocks, and the interests of such individuals or
voting blocks could conflict with those of the other
stockholders.
Single stockholders with significant holdings or relatively
small groups of stockholders has the power to influence matters
requiring the approval of stockholders. Approximately 14% of our
outstanding shares of common stock are owned by The Principals
Cornerstone Fund Pty Ltd, an Australian company, which
holds shares on trust for Messrs Denver, Hanley and Dr Adam, who
are directors. These directors also hold shares directly and
through other vehicles. In addition, a company called PFM
Cornerstone Limited, an Australian company, of which Messrs
Denver, Hanley and Dr Adam are directors, holds approximately 9%
of our shares. Messrs Denver, Hanley and Dr Adams interest
in the issued shares (excluding options) of PFM Cornerstone Ltd
are approximately 2%, 3% and 2% respectively. Mr. Heinberg
also holds approximately 0.22% of PFM Cornerstone Ltd.
Mr. Andrew Jane is one of our directors and a director of
CM Capital Investments Pty Ltd which holds approximately 11% of
our shares. As directors, these individuals have the power to
influence significantly all matters requiring the approval of
our stockholders, including the election of directors and the
approval of other significant resolutions, and their interests
may conflict with those of the other stockholders. In addition,
control of a significant amount of our common stock by insiders
could adversely affect the market price of shares.
Johnson & Johnson Development Corporation holds
approximately 12% of our shares. For details of our substantial
stockholders and the interests of our directors, refer to
Item 12 Security Ownership of Certain
beneficial Owners and Management and Related Stockholder
Matters.
We
have never paid a dividend and we do not intend to pay dividends
in the foreseeable future which means that holders of shares of
common stock and CDIs may not receive any return on their
investment from dividends.
To date, we have not declared or paid any cash dividends on our
shares or CDIs and currently intend to retain any future
earnings, if any, for funding growth. We do not anticipate
paying any dividends in the foreseeable future.
Our
holders of CDIs are not stockholders and do not have stockholder
rights.
The main difference between holding CDIs and holding our
underlying shares is that a CDI holder has beneficial ownership
of the equivalent number of shares instead of legal title. CDIs
are exchangeable, at the option of the holder, into shares of
our common stock at a ratio of 1:1. Legal title is held by CHESS
Depositary Nominees Pty Ltd (CDN) and the shares are
registered in the name of CDN and held by CDN on behalf of and
for the benefit of CDI Holders. CDN is a wholly owned subsidiary
of ASX. CDI holders will be entitled to all the economic
benefits of the shares underlying their CDIs, such as dividends
(if any), bonus issues or rights issues as though they were
holders of the legal title. CDN as a stockholder of record will
receive notice of stockholder meetings and be entitled to attend
and vote at stockholder meetings. CDI holders will likewise be
sent notices of stockholder meetings and are entitled to attend
stockholder meetings but are not permitted to vote other than by
giving directions on how to vote to CDN or as a proxy holder for
CDN.
Our
success is dependent on the accuracy, reliability and proper use
of sophisticated information processing systems and management
information technology and the interruption in these systems
could have a material adverse effect on our business, financial
condition and results of operations.
Our success is dependent on the accuracy, reliability and proper
use of sophisticated information processing systems and
management information technology. Our information technology
systems are designed and selected in order to facilitate the
entering of order entry, customer billing, to maintain customer
records, to provide product traceability, to accurately track
purchases, to manage accounting, finance, administration and
manufacturing, generate reports and provide customer service and
technical support. Any interruption in these systems could have
a material adverse effect on our business, financial condition
and results of operations.
33
Provisions
in our charter documents and under Delaware law could make the
possibility of our acquisition, which may be beneficial for our
stockholders, more difficult and may prevent attempts by our
stockholders to replace or remove current
management.
Provisions in our certificate of incorporation and our bylaws
may delay or prevent an acquisition of us or a change in our
management. In addition, these provisions may frustrate or may
prevent any attempts by our stockholders to replace or remove
our current management by making it more difficult to remove our
current directors. These provisions include:
|
|
|
|
|
the division of our Board into classes whose terms expire at
staggered intervals over a three year period and advance notice
requirements for nominations to our Board and proposing matters
that can be acted upon at shareholder meetings;
|
|
|
|
the requirement that actions by our stockholders by written
consent be unanimous;
|
|
|
|
the ability of our Board to issue preferred stock.
|
Limitation
on Independent Registered Public Accounting Firms
Liability
The liability of certain Australian independent registered
public accounting firms, such as PricewaterhouseCoopers
Australia (an Australian partnership which we refer to as
PwC Australia), with respect to claims arising out
of their audit reports on companies financial statement, is
subject to the limitations set forth in the Professional
Standards Act 1994 of New South Wales, Australia (the
Professional Standards Act), and The Institute of
Chartered Accountants in Australia (NSW) Scheme adopted by The
Institute of Chartered Accountants in Australia and approved by
the New South Wales Professional Standards Council pursuant to
the Professional Standards Act (the NSW Accountants
Scheme) or, in relation to matters occurring prior to
October 7, 2007, the predecessor scheme. The Professional
Standards Act and the NSW Accountants Scheme may limit the
liability of PwC Australia for damages with respect to certain
civil claims arising in, or governed by the laws of, New South
Wales directly or vicariously from anything done or omitted in
the performance of their professional services to us, in the
case of PwC Australia, including, without limitation, PwC
Australias audits of our financial statements, to the
lesser of (in the case of audit services) ten times the
reasonable charge for the service provided and a maximum
liability for audit work of A$75 million or, in relation to
matters occurring prior to October 7, 2007,
A$20 million. The limit does not apply to claims for breach
of trust, fraud or dishonesty.
In addition there is equivalent professional standards
legislation in place in each state and territory in Australia
and amendments have been made to a number of Australian federal
statutes to limit liability under those statutes to the same
extent as liability is limited under state and territory laws by
professional standards legislation.
These limitations of liability may limit recovery upon the
enforcement in Australian courts of any judgment under US or
other foreign laws rendered against PwC Australia based on or
related to its audit report on our financial statements.
Substantially all of PwC Australias assets are located in
Australia. However, the Professional Standards Act and the NSW
Accountants Scheme have not been subject to judicial
consideration and therefore how the limitation will be applied
by the courts and the effect of the limitation on the
enforcement of foreign judgments are untested.
Universal Biosensors Pty Ltd leases approximately
5,000 square meters of office, research and development and
manufacturing facilities at 1 Corporate Avenue, Rowville in
Melbourne, Australia. We relocated to the premises at 1
Corporate Avenue, Rowville in August 2007. We completed
upgrading and fit out of the capacity of this facility during
2008 at an estimated cost of A$1,829,923. The lease for the
premises at 1 Corporate Avenue Rowville expires on
March 31, 2014 with two options to renew the lease for
successive five year periods.
34
We manufacture the blood glucose test strips using custom
manufacturing equipment and we intend to manufacture the
disposable test strips for each of our future
point-of-care
tests using our own custom manufacturing equipment. We expended
cash of approximately A$2,990,007, A$9,594,920 and A$9,058,265
in the years ended December 31, 2009, 2008 and 2007,
respectively, in relation to the acquisition of manufacturing
equipment, upgrading our manufacturing facility and purchases of
other plant and equipment. In the period December 31, 2009
to March 16, 2010, we have committed an additional
A$1,000,000 to the acquisition of additional manufacturing
equipment.
Depending on the number of strips required to be manufactured,
it may become necessary in the future for us to acquire
additional large scale equipment to satisfy manufacturing
demand. Likewise, if we are successful in securing a partner for
one of our other tests and the development of that test is
successful, if our existing facilities and equipment continue to
be utilized for the manufacture of blood glucose test strips, we
will likewise need to secure additional or alternative
facilities and establish additional large scale equipment
sufficient to satisfy manufacturing requirements for the new
product.
|
|
ITEM 3.
|
LEGAL PROCEEDINGS.
|
There are no legal or arbitration proceedings pending against us
or Universal Biosensors Pty Ltd, which may have a material
effect on our business.
|
|
ITEM 4.
|
[REMOVED AND RESERVED]
|
PART II
|
|
ITEM 5.
|
MARKET
FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES.
|
Market
information
Our shares of common stock are not currently traded on any
established United States public trading market. We have not
determined whether we will seek the quotation of our shares of
common stock on any United States public trading market. We
cannot assure you that we will seek to be quoted on any United
States public trading market or that we would meet any
applicable listing requirements.
Our shares of common stock are traded on the ASX in the form of
CHESS Depositary Interests, or CDIs, under the ASX trading code
UBI. The Clearing House Electronic Subregister
System, or CHESS, is an electronic system which
manages the settlement of transactions executed on the ASX and
facilitates the paperless transfer of legal title to ASX quoted
securities. CHESS cannot be used directly for the transfer of
securities of companies, such as us, that are domiciled in
countries whose laws do not recognize uncertificated holdings or
electronic transfer of legal title. CDIs are used as a method of
holding and transferring the beneficial ownership of these
securities on the ASX which are not able to be electronically
traded in CHESS. CDIs are exchangeable, at the option of the
holder, into shares of our common stock at a ratio of 1:1. The
main difference between holding CDIs and holding the underlying
securities (in this case our shares) is that a holder of CDIs
has beneficial ownership of the equivalent number of our shares
instead of legal title. Legal title is held by CHESS Depositary
Nominees Pty Ltd, or CDN, and the shares are registered in the
name of CDN and held by CDN on behalf of and for the benefit of
the holders of CDIs. CDN is a wholly owned subsidiary of ASX.
Holders of CDIs who do not wish to have their trades settled in
CDIs on the ASX may request that their CDIs be converted into
shares, in which case legal title to the shares of common stock
are transferred to the holder of the CDIs. Likewise,
stockholders who wish to be able to trade on the ASX can do so
by requesting that their shares be converted into CDIs and by
lodging their applicable share certificate with our share
registrar and signing a share transfer form with respect to the
relevant shares. Our share registrar will then transfer the
shares from the stockholder to CDN and establish a CDI holding
in the name of the stockholder (now a CDI holder).
35
High and
low sale prices of our CDIs on the ASX
The sale prices of our shares traded in the form of CDIs are
quoted on the ASX in Australian dollars. Our CDIs were first
quoted on the ASX on December 13, 2006. Twenty minute
delayed trading prices of our CDIs are available through the ASX
at www.asx.com.au.
The following tables sets forth, for the periods indicated, the
highest and lowest market prices in Australian dollars for our
CDIs reported on the ASX:
|
|
|
|
|
|
|
|
|
|
|
High A$
|
|
Low A$
|
|
Fiscal Year 2008
|
|
|
|
|
|
|
|
|
First Quarter
|
|
A$
|
1.48
|
|
|
A$
|
0.83
|
|
Second Quarter
|
|
A$
|
0.95
|
|
|
A$
|
0.76
|
|
Third Quarter
|
|
A$
|
0.88
|
|
|
A$
|
0.70
|
|
Fourth Quarter
|
|
A$
|
0.78
|
|
|
A$
|
0.51
|
|
Fiscal Year 2009
|
|
|
|
|
|
|
|
|
First Quarter
|
|
A$
|
0.66
|
|
|
A$
|
0.41
|
|
Second Quarter
|
|
A$
|
1.20
|
|
|
A$
|
0.56
|
|
Third Quarter
|
|
A$
|
1.40
|
|
|
A$
|
0.83
|
|
Fourth Quarter
|
|
A$
|
1.98
|
|
|
A$
|
1.30
|
|
Security
details
As of March 16, 2010, there were 157,292,845 shares of
our common stock issued and outstanding and
9,952,576 employee options that are exercisable for an
equivalent number of shares of common stock (5,808,324 of which
were exercisable or exercisable within 60 days thereafter).
All of our issued and outstanding shares of common stock are
fully paid.
Under applicable U.S. securities laws all of the shares of
our common stock are restricted securities as that
term is defined in Rule 144 under the Securities Act.
Restricted securities may be resold to U.S. persons as
defined in Regulation S only if registered or if they
qualify for an exemption from registration under the Securities
Act, each as described in more detail below. We have not agreed
to register any of our common stock for resale by security
holders.
Rule 144(b)
Because there is no public trading market for the shares in the
United States, no sales in the United States under Rule 144
other than Rule 144(b)(1)(i) are likely to occur. Under
Rule 144(b)(1)(i), a person who is not deemed to have been
an affiliate of ours at any time during the 90 days
preceding a sale, and who has beneficially owned the shares
proposed to be sold for between six months and one year may sell
so long as the public information requirements of Rule 144
are, and, after one year, such person is entitled to sell the
shares without having to comply with the manner of sale, public
information or provisions of Rule 144. A person who is
deemed an affiliate during the 90 days preceding the sale
who has beneficially owned the shares proposed to be sold for at
least six months may sell so long as the conditions of
Rule 144 are met, including the manner of sale, public
information, volume limitation and notice filing provisions of
Rule 144.
Holders
Currently, CDN holds the majority of our shares on behalf of and
for the benefit of the holders of CDIs. The balance of the
shares are held by certain of our employees. Set out below is
the number of our registered holders of shares at specific dates:
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Holders that
|
|
|
Total Number of
|
|
are United States
|
Date
|
|
Registered Holders
|
|
Residents
|
|
At March 16, 2010
|
|
|
1,483
|
|
|
|
11
|
|
36
Dividends
To date, we have not declared or paid any cash dividends on our
shares or CDIs and currently intend to retain any future
earnings, if any, for funding growth. We do not anticipate
paying any dividends in the foreseeable future.
Securities
authorized for issuance under equity compensation
plans
Set out below are details of our Employee Option Plan as at
December 31, 2009.
Equity
Compensation Plan Information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Securities to be
|
|
|
|
|
|
|
|
|
|
Issued Upon Exercise of
|
|
|
Weighted Average Exercise
|
|
|
Number of Securities
|
|
|
|
Outstanding Options,
|
|
|
Price of Outstanding
|
|
|
Remaining for Future
|
|
Plan Category
|
|
Warrants and Rights
|
|
|
Options, Warrants and Rights
|
|
|
Issuance
|
|
|
|
|
|
|
(A$)
|
|
|
|
|
|
Equity compensation plans approved by security holders
|
|
|
10,039,486
|
|
|
|
0.85
|
|
|
|
(1
|
)
|
Equity compensation plans not approved by security holders(2)
|
|
|
330,000
|
|
|
|
0.78
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
10,369,486
|
|
|
|
0.85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The number of employee options able to be granted is limited to
the amount permitted to be granted at law, the ASX Listing Rules
and by the limits on our authorized share capital in our
certificate of incorporation. The Listing Rules of ASX generally
prohibit companies whose securities are quoted on the ASX from
issuing securities exceeding 15% of issued share capital in any
12 month period, without stockholder approval. |
|
(2) |
|
The grant of options and the issue of shares to any of our
directors requires stockholder approval. On May 15, 2009,
and June 29, 2009, our Board approved the grant of 37,500
and 142,500 zero price employee options (ZEPOs),
respectively, to our Executive Director/ Chief Executive
Officer, Mr. Mark Morrisson. On November 10, 2009 our
Board approved the grant of 150,000 market price employee
options and 581 restricted shares of common stock, to
Mr. Mark Morrisson. Shareholder approval for the grant of
the ZEPOs, Employee Options and the issue of Restricted Shares
to Mr. Mark Morrisson is being sought at the 2010 Annual
General Meeting. |
Recent
Sales of Unregistered Securities; Use of Proceeds from
Registered Securities
Renounceable
Rights Issue
On December 4, 2007, we closed a renounceable rights issue
of new shares of common stock to raise an aggregate total of
A$32,518,792 at an issue price of A$1.20 per share. The
renounceable rights issue was underwritten by Wilson HTM
Corporate Finance Ltd, an underwriter based in Brisbane,
Australia (Underwriter). We paid the Underwriter a
management fee of A$599,306 and an underwriting commission of
A$1,027,381 in connection with the renounceable rights issue. In
addition, we reimbursed the Underwriter for certain of their
outgoings, costs and expenses incurred in connection with the
renounceable rights issue. We raised A$30,892,105 net of
fees and commissions paid to the Underwriter in our renounceable
rights issue in Australia.
Our underwriter paid A$450,000 for
sub-underwriting
part of the renounceable rights issue to PFM Cornerstone Ltd., a
corporation of which our directors Messrs. Hanley, Denver
and Dr. Adam each held issued shares as at
December 31, 2007 representing approximately 2.6%, 2.5% and
2.3% interests (excluding granted options), respectively, and of
which each is a director and an executive officer. Our recently
appointed director, Mr. Heinberg, also holds a small
non-controlling number of shares in PFM Cornerstone Ltd. These
fees
37
represented more than 5% of the revenues of PFM Cornerstone Ltd.
for fiscal year 2007. In addition, PFM Cornerstone Ltd held
13,376,406 of our issued shares as at December 31, 2007.
Generally, as a result of securities law restrictions, only
shareholders with registered addresses in Australia and New
Zealand and United States based shareholders who are accredited
or institutional investors were able to subscribe for shares in
the rights offer. With respect to the shares issued outside of
the United States, we issued these shares in reliance upon
exemptions from registration under Regulation S under the
Securities Act, as modified by the January 7, 2000 No
Action Letter issued by the Securities Exchange Commission to
ASX. The renounceable rights issue constituted an offshore
transaction for the purposes of the Securities Act as
shares offered in the initial public offer were only available
to Australian residents. Restrictions have been applied to our
securities to prevent the resale of the securities into the
United States. With respect to a small number of shares issued
in the United States to accredited investors, we issued these
shares in reliance upon exemptions from registration under
Regulation D under the Securities Act. The shares purchased
pursuant to Regulation D are restricted
securities that are only able to be re-sold in the United
States if such shares are sold pursuant to an exemption from
registration or are registered under the Securities Act. All
shares issued in the private placement in the United States rank
equally in all respects with all other shares on issue. All
shares issued in the renounceable rights offer rank equally in
all respects with all other shares on issue.
The funds raised under the renounceable rights issue were for
working capital requirements which enabled us to continue to
expand our manufacturing capability, acquire inventory and
otherwise perform our obligations under the Master Services and
Supply Agreement with LifeScan. The funds were also used for the
continued development of our existing pipeline of
point-of-care
tests and to identify and develop additional tests.
38
Exercise
of Employee Stock Options
The table below sets forth the number of employee stock options
exercised and the number of shares of common stock issued in the
period from January 1, 2007 to December 31, 2009. We
issued these shares in reliance upon exemptions from
registration under Regulation S under the Securities Act of
1933, as amended.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Options
|
|
|
|
|
|
|
|
|
|
Exercised and
|
|
|
|
|
|
|
|
|
|
Corresponding Number
|
|
|
|
|
|
|
|
Period Ending
|
|
of Shares Issued
|
|
|
Option Exercise Price
|
|
|
Proceeds Received
|
|
|
|
|
|
|
(A$)
|
|
|
(A$)
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
January, 2007
|
|
|
79,745
|
|
|
$
|
0.33
|
|
|
|
26,571
|
|
April, 2007
|
|
|
7,250
|
|
|
$
|
0.38
|
|
|
|
2,722
|
|
July, 2007
|
|
|
28,998
|
|
|
$
|
0.38
|
|
|
|
10,889
|
|
August, 2007
|
|
|
10,874
|
|
|
$
|
0.37
|
|
|
|
4,070
|
|
August, 2007
|
|
|
79,745
|
|
|
$
|
0.33
|
|
|
|
26,590
|
|
November, 2007
|
|
|
36,248
|
|
|
$
|
0.33
|
|
|
|
11,924
|
|
November, 2007
|
|
|
18,124
|
|
|
$
|
0.33
|
|
|
|
5,962
|
|
November, 2007
|
|
|
159,490
|
|
|
$
|
0.37
|
|
|
|
59,699
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
420,474
|
|
|
|
|
|
|
|
148,428
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
May, 2008
|
|
|
18,124
|
|
|
$
|
0.35
|
|
|
|
5,047
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
August, 2009
|
|
|
36,248
|
|
|
$
|
0.31
|
|
|
|
11,221
|
|
September, 2009
|
|
|
25,374
|
|
|
$
|
0.31
|
|
|
|
7,853
|
|
November, 2009
|
|
|
13,332
|
|
|
$
|
0.89
|
|
|
|
11,865
|
|
November, 2009
|
|
|
25,373
|
|
|
$
|
0.28
|
|
|
|
7,059
|
|
November, 2009
|
|
|
8,000
|
|
|
$
|
0.70
|
|
|
|
5,600
|
|
November, 2009
|
|
|
30,000
|
|
|
$
|
1.18
|
|
|
|
35,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,327
|
|
|
|
|
|
|
|
78,998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The funds raised will be used for working capital requirements
including the continued development of our existing pipeline of
point-of-care
tests and to identify and develop additional tests.
Restricted
Employee Shares Issued to Employees
Our Employee Share Plan was adopted by the Board of Directors in
2009. The Employee Share Plan permits our Board to grant shares
of our common stock to our employees and directors. The number
of shares able to be granted is limited to the amount permitted
to be granted at law, the ASX Listing Rules and by the limits on
our authorized share capital in our certificate of
incorporation. All our employees are eligible for shares under
the Employee Plan. The Company currently proposes to issue
A$1,000 worth of restricted shares of common stock to employees
of the Company on a recurring basis, but no more frequently than
annually. The restricted shares have the same terms of issue as
our existing shares of common stock but are not able to be
traded until the earlier of three years from the date on which
the shares are issued or the date the relevant employee ceases
to be an employee of the Company or any of its associated group
of companies. We issue these shares in reliance upon exemptions
from registration under Regulation S under the Securities
Act of 1933, as amended.
The table below sets forth the restricted shares issued by the
Company:
|
|
|
|
|
|
|
|
|
|
|
|
|
Market Value of
|
|
|
Number of Restricted
|
|
Restricted Shares
|
|
|
Shares Issued
|
|
Issued
|
|
November 10, 2009
|
|
|
40,670
|
|
|
A$
|
69,952
|
|
39
Purchases
of Equity Securities by the Issuer and Affiliated
Purchasers
There were no repurchases of equity securities in 2009.
|
|
ITEM 6.
|
SELECTED
FINANCIAL DATA.
|
The following table represents our selected financial data for
the dates and periods indicated. This data should be read
together with, and is qualified in its entirety by reference to,
Item 7. Managements Discussion and Analysis of
Financial Condition and Results of Operations as well as
our financial statements and notes thereto appearing in
Item 15. Financial Statement Schedules of this
Form 10-K.
The selected financial data for the fiscal years ended
December 31, 2009, 2008 and 2007 and the period from
inception to December 31, 2009 has been derived from our
consolidated audited financial statements, included elsewhere
herein. The selected financial data for the fiscal years ended
December 31, 2005 and 2006 have been derived from our
consolidated audited financial statements which are not included
herein. Such financial statements are prepared in accordance
with United States generally accepted accounting principles
(U.S. GAAP) and are presented in Australian
dollars (except as otherwise noted) following our election in
October 2008 to change our reporting currency from
U.S. Dollars to Australian Dollars (refer to Financial
Statement Footnote 3 Summary of Significant Accounting
Policies.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(September 14,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2001) to
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from products
|
|
$
|
132,733
|
|
|
$
|
132,733
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Revenue from services
|
|
|
5,971,825
|
|
|
|
2,850,071
|
|
|
|
3,121,754
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development income
|
|
|
14,415,089
|
|
|
|
1,337,125
|
|
|
|
1,170,190
|
|
|
|
1,192,015
|
|
|
|
2,654,280
|
|
|
|
2,757,817
|
|
Milestone payment
|
|
|
17,722,641
|
|
|
|
17,722,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
38,242,288
|
|
|
|
22,042,570
|
|
|
|
4,291,944
|
|
|
|
1,192,015
|
|
|
|
2,654,280
|
|
|
|
2,757,817
|
|
Operating costs & expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold(1)
|
|
|
458,162
|
|
|
|
458,162
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of services
|
|
|
3,290,995
|
|
|
|
169,241
|
|
|
|
3,121,754
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development (2 and 3)
|
|
|
43,814,091
|
|
|
|
14,898,072
|
|
|
|
11,585,258
|
|
|
|
7,157,216
|
|
|
|
3,466,604
|
|
|
|
2,086,824
|
|
General and administrative(4)
|
|
|
19,998,333
|
|
|
|
5,635,569
|
|
|
|
5,510,127
|
|
|
|
4,226,757
|
|
|
|
2,511,182
|
|
|
|
922,088
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs & expenses
|
|
|
67,561,581
|
|
|
|
21,161,044
|
|
|
|
20,217,139
|
|
|
|
11,383,973
|
|
|
|
5,977,786
|
|
|
|
3,008,912
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) from operations
|
|
|
(29,319,293
|
)
|
|
|
881,526
|
|
|
|
(15,925,195
|
)
|
|
|
(10,191,958
|
)
|
|
|
(3,323,506
|
)
|
|
|
(251,095
|
)
|
Other income/(expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
5,408,492
|
|
|
|
809,459
|
|
|
|
2,542,060
|
|
|
|
1,440,102
|
|
|
|
443,769
|
|
|
|
128,282
|
|
Interest expense
|
|
|
(19,125
|
)
|
|
|
(9,636
|
)
|
|
|
(9,489
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Fee income
|
|
|
1,131,222
|
|
|
|
|
|
|
|
1,131,222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
(106,190
|
)
|
|
|
(250,886
|
)
|
|
|
265,310
|
|
|
|
(210,382
|
)
|
|
|
87,076
|
|
|
|
(6,147
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income/(expense)
|
|
|
6,414,399
|
|
|
|
548,937
|
|
|
|
3,929,103
|
|
|
|
1,229,720
|
|
|
|
530,845
|
|
|
|
122,135
|
|
Net profit/(loss) before tax
|
|
|
(22,904,894
|
)
|
|
|
1,430,463
|
|
|
|
(11,996,092
|
)
|
|
|
(8,962,238
|
)
|
|
|
(2,792,661
|
)
|
|
|
(128,960
|
)
|
Income tax benefit/(expense)
|
|
|
(17,794
|
)
|
|
|
|
|
|
|
206
|
|
|
|
145,000
|
|
|
|
(163,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit/(loss)
|
|
$
|
(22,922,688
|
)
|
|
$
|
1,430,463
|
|
|
$
|
(11,995,886
|
)
|
|
$
|
(8,817,238
|
)
|
|
$
|
(2,955,661
|
)
|
|
$
|
(128,960
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net profit/(loss) per share
|
|
$
|
(0.28
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.06
|
)
|
|
$
|
|
|
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
157,013,578
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
|
|
49,408,822
|
|
|
|
43,573,580
|
|
Diluted net profit/(loss) per share
|
|
$
|
(0.28
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.06
|
)
|
|
$
|
|
|
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
161,354,802
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
|
|
49,408,822
|
|
|
|
43,573,580
|
|
40
Notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Includes non-cash compensation expense (cost of goods sold)
|
|
$
|
21,207
|
|
|
$
|
21,207
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
2 Net of research grant income in these amounts
|
|
$
|
2,366,063
|
|
|
$
|
|
|
|
$
|
300,613
|
|
|
$
|
872,513
|
|
|
$
|
578,653
|
|
|
$
|
614,284
|
|
3 Includes non-cash compensation expense (research and
development)
|
|
$
|
1,802,226
|
|
|
$
|
653,474
|
|
|
$
|
661,497
|
|
|
$
|
339,882
|
|
|
$
|
147,373
|
|
|
$
|
|
|
4 Includes non-cash compensation expense (general and
administrative)
|
|
$
|
1,255,228
|
|
|
$
|
404,090
|
|
|
$
|
299,611
|
|
|
$
|
277,833
|
|
|
$
|
273,694
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
|
A$
|
|
A$
|
|
A$
|
|
A$
|
|
A$
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
31,291,011
|
|
|
|
28,334,864
|
|
|
|
41,958,285
|
|
|
|
30,184,756
|
|
|
|
4,434,274
|
|
Total assets
|
|
|
56,083,468
|
|
|
|
52,505,321
|
|
|
|
63,512,160
|
|
|
|
37,879,601
|
|
|
|
6,203,277
|
|
Long-term debt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible preference shares(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000,000
|
|
Total stockholders (deficit) equity
|
|
|
51,314,002
|
|
|
|
48,703,230
|
|
|
|
59,749,624
|
|
|
|
35,281,927
|
|
|
|
5,683,519
|
|
|
|
|
(1) |
|
Convertible preference shares were converted to shares of common
stock immediately prior to the issue of shares in our initial
public offering in Australian and concurrent US private
placement in December 2006. |
|
|
ITEM 7.
|
MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
The following discussion and analysis of our financial condition
and results of operations should be read in conjunction with our
financial statements and related notes that appear elsewhere in
this
Form 10-K.
In addition to historical financial information, the following
discussion contains forward-looking statements that reflect our
plans, estimates and beliefs. Our actual results may differ
materially from those discussed in the forward-looking
statements. Factors that could cause or contribute to these
differences include those discussed below and elsewhere in this
Form 10-K,
particularly in Risk Factors.
Results
of Operations
Overview
Established in 2001, we are a specialist medical diagnostics
company focused on the research, development and manufacture of
in vitro diagnostic test devices for consumer and
professional
point-of-care
use. The diagnostic blood test devices we are developing
comprise a novel disposable test strip and a reusable meter.
These simple to use portable devices require a finger prick of
blood and are designed to be used beside the patient (at the
point-of-care)
to provide accurate and quick results to enable treatment to be
immediately reviewed. We have rights to an extensive patent
portfolio comprising of certain patent applications owned by our
wholly owned Australian subsidiary, Universal Biosensors Pty
Ltd, and a large number of patents and patent applications
licensed to us by LifeScan, Inc., an affiliate of
Johnson & Johnson.
41
We have developed a blood glucose test (used in the management
of diabetes) with LifeScan which was launched by LifeScan in the
Netherlands in January 2010. We intend to develop other tests in
the field of diabetes and blood glucose management generally,
for LifeScan.
We are developing an immunoassay
point-of-care
test to measure the amount of C-reactive protein in the blood to
assist in the diagnosis and management of inflammatory
conditions. We have also undertaken work on a second
point-of-care
dry immunoassay to measure the amount of D-dimer in the blood.
D-dimer is a well established marker currently being used as a
point-of-care
test for the detection and monitoring of several potentially
life threatening conditions associated with thrombotic disease,
particularly deep venous thrombosis (clots in the leg) and
pulmonary embolism (clots in the lung). We also intend to
leverage our intellectual property platform to develop
additional immunoassay based
point-of-care
test devices by taking proven disease biomarkers currently used
in the central laboratory environment and adapting those
diagnostic tests to the
point-of-care
setting.
We have also undertaken development work on a prothrombin time
test for monitoring the therapeutic range of the anticoagulant,
warfarin. We have successfully taken our prothrombin time test
to a point where we believe that we have significantly reduced
the risk of technical failure of the product. We do not
currently propose to complete the remaining development steps
for this test until the path to commercialization for this
product is assured and thus we have elected to deploy our
resources away from this project until our partnering efforts
have been successful.
All of our operating activities are undertaken through our
wholly-owned subsidiary, Universal Biosensors Pty Ltd which is
located in Australia. We have funded our operations primarily
through the sale of our equity securities, payments from
LifeScan, Inc., an affiliate of Johnson & Johnson
(LifeScan), in connection with the Development and
Research Agreement, various payments under the Master Services
and Supply Agreement and revenue from certain services provided
to LifeScan and government and state grants.
Master
Services and Supply Agreement with LifeScan
On October 29, 2007, we entered into a Master Services and
Supply Agreement which contains the terms pursuant to which
Universal Biosensors Pty Ltd would provide certain services in
the field of blood glucose monitoring to LifeScan and would
generally act as a non-exclusive manufacturer of an original
version of the initial blood glucose test strips we developed
for LifeScan (Master Services and Supply Agreement).
On December 11, 2008, the Master Services and Supply
Agreement was amended to reflect certain definitional matters in
the document. On May 15, 2009, the agreement was amended
and restated to incorporate the amendments made in December 2008
and to reflect changes resulting from a change to the blood
glucose test strip. The Master Services and Supply Agreement is
structured as an umbrella agreement which enables LifeScan and
us to enter into a series of additional arrangements for the
supply by us of additional services and products in the field of
blood glucose monitoring. We commenced manufacture of the
initial blood glucose test strips in our facility in Corporate
Avenue, Rowville, Melbourne, in December 2009.
Development
and Research Agreement with LifeScan
On April 1, 2002, we entered into a Development and
Research Agreement with LifeScan pursuant to which we agreed to
perform certain research and development activities for LifeScan
in the area of diabetes management to extend and develop the
glucose sensor technology owned by LifeScan. At the time of
execution of the Master Services and Supply Agreement, the
Development and Research Agreement was amended to conform the
intellectual property provisions in the Development and Research
Agreement with those in the Master Services and Supply Agreement
such that LifeScan would own all intellectual property developed
by us under the Development and Research Agreement and we would
receive a license to such intellectual property outside of the
LifeScan field of diabetes and blood glucose management
generally. In May 2009, the Development and Research Agreement
was further amended to increase the range of development and
research funding that LifeScan may pay us in 2010 and to include
a new mechanism for determining research and development
programs whereby we propose development and research work, and
then the program of development and research is approved by the
joint steering committee.
42
In consideration of undertaking the development and research,
LifeScan makes quarterly payments to us. From April 2002 to
December 31, 2009, we have received aggregate contract
research funding from LifeScan of A$14,415,089. We received
A$1,337,125, A$1,170,190 and A$1,192,015 in 2009, 2008 and 2007,
respectively. In subsequent years, the steering committee will
recommend the level of funding consistent with LifeScans
requirements. The Development and Research Agreement
automatically renews for successive one year period on the same
terms and conditions unless either party has given to the other
party prior written notice of termination not less than nine
months prior to the end of the relevant one year period, in
which case the Development and Research Agreement will terminate
at the end of the relevant one year period, or the agreement is
otherwise terminated in accordance with its terms.
License
Agreement with LifeScan
In 2002, we entered into a License Agreement with LifeScan
pursuant to which LifeScan granted to us a worldwide, royalty
free, exclusive license to certain electrochemical cell
technologies in all fields of use excluding the LifeScan Fields
of diabetes and blood glucose management generally. LifeScan has
retained all rights in the LifeScan Field. Under the License
Agreement, we have a right to
sub-license,
make, have made, use, and sell under and exploit in any way a
range of key patents, patent applications and know-how owned by
LifeScan, relating to electrochemical cell technologies in all
fields excluding the LifeScan Fields, the rights to which are
retained by LifeScan. We must pay LifeScan 50% of any royalties
or payments we receive under any such sublicense. We are also
contractually bound to use our best efforts to exploit the
licensed intellectual property outside the LifeScan Fields, for
example, in our C-reactive protein, prothrombin time tests and
D-dimer tests. At the time of execution of the Master Services
and Supply Agreement, the License Agreement was amended to:
a) clarify the scope of the LifeScan Field in which
LifeScan have exclusive rights to the relevant patents; and
b) to grant us a license to certain new patents outside of
the LifeScan Field.
The License Agreement may be terminated by LifeScan in the event
that we fail to exploit the licensed patents and patent
applications or if we are liquidated or wound up or commit a
persistent and material breach of our obligations under the
License Agreement and fail to rectify the breach within
90 days of written notice from LifeScan requiring it to do
so. The License Agreement otherwise continues on a perpetual
basis until the expiration of the last licensed LifeScan patent
or patent application. LifeScan may also convert the license
from an exclusive license to a non-exclusive license in certain
limited circumstances where we fail to comply with the
requirements of the License Agreement.
R&D
Start Grant
On October 1, 2004, Universal Biosensors Pty Ltd entered
into a grant agreement with the Commonwealth of Australia under
the R&D Start Grant Program. The Commonwealth of Australia
has provided Universal Biosensors Pty Ltd with a grant of 50% of
the eligible expenditure on a program for the development of a
single step, disposable immunosensor platform up to a maximum
grant amount of A$2,366,063 payable over the period to
September 30, 2007, at which time the grant was to formally
terminate. Universal Biosensors Pty Ltd submitted for and
received approval for the grant to be extended to
September 30, 2009. We have ongoing obligations beyond the
program completion date, including continuing to use our best
endeavors to commercialize the immunosensor platform on normal
commercial terms within a reasonable time of completion of the
program.
Grant payments are made in accordance with an agreed schedule
and are subject to the satisfaction by Universal Biosensors Pty
Ltd of certain specified technical milestones and conditions and
the Commonwealth of Australia having sufficient funding
available. In addition, we are required to commit the necessary
eligible expenditure, submit all progress reports due and
demonstrate satisfactory progress and expenditure on the
program. The Commonwealth of Australia may terminate the grant
agreement for breach of the agreement by us, for failure to
undertake the required research, if there is a change in control
of Universal Biosensors Pty Ltd or us, or on the grounds of
insolvency. In certain limited circumstances where Universal
Biosensors Pty Ltd fails to use its best endeavors to
commercialize the program within a reasonable time of completion
or upon termination of the grant due to breach or insolvency,
the Commonwealth of Australia may require Universal Biosensors
Pty Ltd to repay some or the entire grant. We consider that the
likelihood of being
43
required to repay any of the grant funding is remote because we
continue to act in good faith with respect to the grant.
Research and development grants received were Nil, A$300,613 and
A$872,513 in the fiscal years ended December 31, 2009,
2008, 2007 and A$2,366,063 from inception to December 31,
2009, respectively.
Victorian
State Government Grant
On October 28, 2006, Universal Biosensors Pty Ltd entered
into an agreement with the State of Victoria acting through its
Department of Innovation, Industry and Regional Development. The
State of Victoria has agreed to grant payments up to A$540,000
to support the establishment of a medical diagnostic
manufacturing facility in Victoria for the manufacture of new
technologies for disease monitoring and to increase support of
local and export markets. These payments are subject to the
achievement of milestones, which include capital expenditure by
us of predetermined minimum amounts. The State of Victoria may
require Universal Biosensors Pty Ltd to refund any amounts paid
under the grant together with interest should we commit a breach
of its obligations under the grant agreement. The State of
Victoria may also withhold, suspend, cancel or terminate any
payment or payments upon a failure to comply with obligations or
if we choose not to proceed with these initiatives or if we
become insolvent. We consider that the likelihood of being
required to repay any of the grant funding is remote because we
continue to act in good faith with respect to the grant.
Victorian State government grants received were A$130,000,
A$130,000 and A$150,000 in the fiscal years ended
December 31, 2009, 2008, 2007 and A$410,000 from inception
to December 31, 2009, respectively.
Critical
Accounting Estimates and Judgments
Our consolidated financial statements are prepared in accordance
with U.S. GAAP. The preparation of these consolidated
financial statements requires us to make estimates and
assumptions that affect the reported amounts of assets,
liabilities, income, costs and expenses, and related
disclosures. We evaluate our estimates and assumptions on an
ongoing basis. Our actual results may differ from these
estimates.
We believe that of our significant accounting policies, which
are described in the notes to our consolidated financial
statements, the following accounting policies involve a greater
degree of judgment and complexity. Accordingly, we believe that
the following accounting policies are the most critical to aid
in fully understanding and evaluating our consolidated financial
condition and results of operations.
Stock-Based
Compensation
We account for stock-based employee compensation arrangements
using the modified prospective method as prescribed in
accordance with the provisions of ASC 718
Compensation Stock Compensation (formerly Statement
of Financial Accounting Standards No. 123(R)
Accounting for Stock-Based Compensation).
Each of the inputs to the Trinomial Lattice model is discussed
below.
Share
price at valuation date
In order to value options over shares of common stock which we
granted in 2003 and 2006, by virtue of the fact that our
securities were not traded at that time on any public exchange,
we have valued our options consistent with the shares that were
issued in certain private capital raisings undertaken by the
Company around the respective valuation dates of the options, as
these prices are most indicative of the fair value of the
Companys equity in the market to a willing participant at
and around the applicable valuation date of the options.
Although we raised capital by issuing preferred shares, for the
purposes of valuing our options we regarded our ordinary and
preferred shares as being equivalent in relevant economic
aspects and therefore the capital raisings served as a suitable
valuation point with respect to the valuation of our options. In
this regard we note that the preference shares carried the right
to convert to ordinary basis on a one to one basis, and all were
converted during 2006 in conjunction with our initial public
offering.
We consider that value of the shares we issued in the capital
raisings undertaken by us in 2003 and 2006 (as applicable) most
accurately represent the value of our common stock for valuation
purposes at the time of
44
those capital raisings. We summarize the per-share subscription
value of the relevant shares issued by us below.
|
|
|
|
|
Date of Capital Raising
|
|
Value per Preferred Stock
|
|
|
A$
|
|
December 2003
|
|
|
0.39
|
|
June 2006
|
|
|
0.45
|
|
August 2006
|
|
|
0.45
|
|
Based on these valuation points, we applied an assumed per share
price of A$0.39 with respect to the options we granted in 2003
and A$0.45 for the options we granted in 2006.
The value of the options granted post 2007 have been determined
using the closing price of our common stock trading in the form
of CDIs on ASX at the time of grant of the options. The ASX is
the only exchange upon which our securities are quoted.
On December 12, 2007 as a result of the impact of the
closing of the rights offering, the exercise prices of each
option granted by the Company prior to November 19, 2007
was reduced by a maximum of A$0.10 in accordance with the terms
of the options and a formula set out in the Listing Rules of the
ASX. The table below reflects the changes to the exercise price
and the fair value of option as a result of the rights offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre Rights Offering
|
|
Post Rights Offering
|
Grant Date of Option
|
|
Exercise Price
|
|
Fair Value of Option
|
|
Exercise Price
|
|
Fair Value of Option
|
|
|
A$
|
|
A$
|
|
A$
|
|
A$
|
|
Dec-03
|
|
$
|
0.39
|
|
|
$
|
0.11
|
|
|
$
|
0.30
|
|
|
$
|
0.11
|
|
Jan-06
|
|
$
|
0.45
|
|
|
$
|
0.30
|
|
|
$
|
0.35
|
|
|
$
|
0.27
|
|
Mar-07
|
|
$
|
1.25
|
|
|
$
|
0.78
|
|
|
$
|
1.18
|
|
|
$
|
0.79
|
|
Sep-07
|
|
$
|
1.27
|
|
|
$
|
0.77
|
|
|
$
|
1.20
|
|
|
$
|
0.78
|
|
Oct-07
|
|
$
|
1.20
|
|
|
$
|
0.77
|
|
|
$
|
1.13
|
|
|
$
|
0.78
|
|
Volatility
With respect to the options granted in 2003 and 2006, we had
insufficient available share price data to accurately estimate
the volatility of our shares of common stock. As a result, we
examined and based our volatility for these options by reference
to the annual volatilities of a number of ASX listed companies
of a similar size and with similar operations to us, over a
range of historic estimation periods. Based on our analysis we
selected an annual volatility of 40%-45% for the options granted
in 2003 and 55% for the options granted in 2006. These figures
were within the range of observed volatilities for comparable
listed companies.
With respect to the options granted post 2007, we applied an
annual volatility determined partially by reference to the
annual volatilities of a number of ASX listed companies of a
similar size and with similar operations but also having regard
to the volatility on the trading data of our shares in the form
of CDIs
45
available from the ASX. Our shares in the form of CDIs were
first quoted on ASX on December 13, 2006 with an initial
offering price of A$0.50. The share price at valuation date was
as follows:
|
|
|
|
|
|
|
|
|
Option Grant Date
|
|
Share Price
|
|
Volatility
|
|
|
A$
|
|
|
|
March 23, 2007
|
|
$
|
1.21
|
|
|
|
74
|
%
|
September 19, 2007
|
|
$
|
1.21
|
|
|
|
72
|
%
|
October 29, 2007
|
|
$
|
1.19
|
|
|
|
76
|
%
|
March 17. 2008
|
|
$
|
0.91
|
|
|
|
76
|
%
|
August 20, 2008
|
|
$
|
0.71
|
|
|
|
71
|
%
|
February 17, 2009
|
|
$
|
0.43
|
|
|
|
77
|
%
|
May 15, 2009
|
|
$
|
1.04
|
|
|
|
81
|
%
|
June 29, 2009
|
|
$
|
0.95
|
|
|
|
80
|
%
|
November 10, 2009
|
|
$
|
1.73
|
|
|
|
78
|
%
|
Consequently, the high level and varying movement on our shares
was the key driver for the volatility increasing from 55% at
December 31, 2006 to volatility in the 70% 80%
range for options issued subsequent to December 2006.
Time
to expiry
All options granted under our share option plan have a maximum
10 year term and are non-transferable.
Risk
free rate
The risk free rate which we applied is equivalent to the yield
on an Australian government bond with a time to expiry
approximately equal to the expected time to expiry on the
options being valued.
Research
and Development Expenditure
Research and development expenses consists of costs incurred to
further our research and development activities and include
salaries and related employee benefits, costs associated with
clinical trial and preclinical development, regulatory
activities, research-related overhead expenses, costs associated
with the manufacture of clinical trial material, costs
associated with developing a commercial manufacturing process,
costs for consultants and related contract research, facility
costs and depreciation. Research and development costs are
expensed as incurred.
We receive grant funding under government research grant
agreements to undertake work on the applicable grant programs.
In order to receive the grant funding, our existing grant
agreements require us to incur specified eligible expenditure in
the conduct of the applicable grant program. There are
circumstances where grant funding may not be payable and there
are certain limited circumstances, such as when we fail to use
our best endeavors to commercialize the program within a
reasonable time of completion of the program or upon termination
of a grant due to our breach of the agreement or our insolvency,
where we may be required to repay some or all of the research
grants. The grants are recognized against the related research
and development expenses as and when the relevant research
expenditure is incurred. Grants received in advance of incurring
the relevant expenditure are treated as deferred research grants
and included in Current Liabilities on the balance
sheet as we do not control the monies until the relevant
expenditure has been incurred. Grants due to us are included in
Current Assets as accrued income on the balance
sheet.
Income
Taxes
We apply ASC 740 Income Taxes (formerly Statement of
Financial Accounting Standards No. 109
Accounting for Income Taxes) which establishes
financial accounting and reporting standards for the effects of
income taxes that result from a companys activities during
the current and preceding years. Deferred tax assets and
liabilities are recognized for the future tax consequences
attributable to differences between the
46
financial statement carrying amounts of existing assets and
liabilities and their respective tax bases and operating loss
and tax credit carry forwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect
on deferred tax assets and liabilities of a change in tax rates
is recognized in income in the period that includes the
enactment date.
Where it is more likely than not that some portion or all of the
deferred tax assets will not be realized the deferred tax assets
are reduced by a valuation allowance. The valuation allowance is
sufficient to reduce the deferred tax assets to the amount that
is more likely than not to be realized.
The Company adopted ASC 740 (formerly
FIN No. 48 Accounting for Uncertainty in
Income Taxes) effective January 1, 2007 which has not had a
material impact on the Companys consolidated financial
statements.
Impairment
of Long-Lived Assets
We review our capital assets, including patents and licenses,
for impairment whenever events or changes in business
circumstances indicate that the carrying amount of the assets
may not be fully recoverable. In performing the review, we
estimate undiscounted cash flows from products under development
that are covered by these patents and licenses. An impairment
loss would be recognized when estimated undiscounted future cash
flows expected to result from the use of the asset and its
eventual disposition is less than the carrying amount of the
asset. If the evaluation indicates that the carrying value of an
asset is not recoverable from its undiscounted cash flows, an
impairment loss is measured by comparing the carrying value of
the asset to its fair value, based on discounted cash flows.
Results
for the Year Ended December 31, 2009
Revenue
from Products
In November 2009, LifeScan received initial regulatory clearance
to sell their blood glucose product which we have been assisting
to develop. We commenced manufacture of the blood glucose test
strips required for this product in our facility in Rowville,
Melbourne, in December 2009, ahead of the January 2010 market
launch in the Netherlands.
Pursuant to the Master Services and Supply Agreement we have
with LifeScan, one of two pricing methodologies will apply
depending on whether we are manufacturing above or below a
specified quantity of blood glucose tests strips in a quarter.
As we produced less than the specified quantity of test strips
for the December 2009 quarter, we are considered to be in the
interim costing period. In the interim costing
period, the Company is establishing its commercial scale
manufacturing and therefore is not expected to generate any
profit, but is expected to recover most of its glucose
manufacturing costs. As manufactured volumes increase beyond the
specified quantity of blood glucose test strips per quarter, the
interim costing period will cease to apply and a different
pricing methodology will apply, at which time we expect to be
profitable in the sale of blood glucose test strips.
Revenue
from Services
During the year ended December 31, 2009, we performed
various services for LifeScan based on their requirements.
Different remuneration arrangement applied depending on the
service provided. The major service provided to LifeScan during
the 2009 financial year was to enable LifeScan to establish its
own manufacturing line for blood glucose sensor strips. There
were various other minor services provided in the blood glucose
field.
Milestone
Payment
The Company received a milestone payment of A$17,722,641
triggered by the first grant to LifeScan of regulatory clearance
to sell the blood glucose product.
47
Research
and Development Income
We receive research and development income under the Development
and Research Agreement with LifeScan. The Development and
Research Agreement provides details of the amount to be charged
to LifeScan each year for the research and development services
carried out by us. The annual research and development income
received from LifeScan is agreed with LifeScan from time to time
and is subject to us continuing our research and development
activities in the blood glucose area, the provision of quarterly
reports and other obligations under the Development and Research
Agreement. We have and continue to satisfy the requirements of
the Development and Research Agreement.
Income is recognized when services have been performed, the
amount of the payment can be reliably measured and
collectability is reasonably assured. The recognition is not
based on the completion of any milestones, or on a percentage of
completion basis. The income derived from the Development and
Research Agreement is recognized over the period in which the
agreed upon research services are completed. Under the
Development and Research Agreement, we are not matching the
income to a specific expenditure but to a specified period of
research.
Research and development income for the fiscal years ended
December 31, 2009, 2008 and 2007 were primarily derived
from LifeScan under the Development and Research Agreement and
totaled A$1,337,125, A$1,170,190 and A$1,192,015, respectively.
Research
and Development Expenses
Our operating expenses to date have substantially been for
research and development activities. All research and
development costs, including those funded by an Australian
research and development grant program, are expensed as incurred.
These expenses are related to developing our electrochemical
cell platform technologies. Research and development expenses
consist of costs associated with research activities, as well as
costs associated with our product development efforts, including
pilot manufacturing costs. Research and development expenses
include:
|
|
|
|
|
consultant and employee related expenses, which include salary
and benefits;
|
|
|
|
materials and consumables acquired for the research and
development activities;
|
|
|
|
external research and development expenses incurred under
agreements with third party organizations and
universities; and
|
|
|
|
facilities, depreciation and other allocated expenses, which
include direct and allocated expenses for rent and maintenance
of facilities, depreciation of leasehold improvements and
equipment and laboratory and other supplies.
|
Research and development expenses for the fiscal years ended
December 31, 2009, 2008, 2007 and for period from inception
to December 31, 2009 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Research and development expenses
|
|
|
46,180,154
|
|
|
|
14,898,072
|
|
|
|
11,885,871
|
|
|
|
8,029,729
|
|
Research grants received recognized against related research and
development expenses
|
|
|
(2,366,063
|
)
|
|
|
|
|
|
|
(300,613
|
)
|
|
|
(872,513
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses as reported
|
|
|
43,814,091
|
|
|
|
14,898,072
|
|
|
|
11,585,258
|
|
|
|
7,157,216
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A significant portion of our research and development expenses
relate to activities undertaken to achieve the deliverable
included in milestone payment.
48
We expect that our expenses will increase during 2010 as we
expand our research and development programs and expand our
organizations manufacturing capability.
We cannot predict what it will cost to complete our research and
development programs or when or if they will be completed and
commercialized. The timing and cost of any program is dependent
upon achieving technical objectives, which are inherently
uncertain. In addition, our business strategy contemplates that
we may enter into collaborative arrangements with third parties
for one or more of our programs. In the event that third parties
assume responsibility for certain research or development
activities, the estimated completion dates of those activities
will be under the control of the third party rather than with
us. We cannot forecast with any certainty, which programs, if
any, will be subject to future collaborative arrangements, in
whole, or in part, and how such arrangements would affect our
research and development plans or capital requirements.
General
and administrative expenses
General and administrative expenses currently consist
principally of salaries and related costs, including stock
option expense, for personnel in executive, finance, accounting,
information technology and human resources functions. Other
general and administrative expenses include depreciation,
repairs and maintenance, insurance, facility costs not otherwise
included in research and development expenses, consultancy fees
and professional fees for legal, audit and accounting services.
General and administrative expenses were A$5,635,569,
A$5,510,127 and A$4,226,757 in 2009, 2008 and 2007,
respectively. We expect that our general and administrative
expenses will increase as we expand our legal, accounting,
marketing and sales staff, add infrastructure and incur
additional costs related to operating as a company whose shares
in the form of CDIs are quoted on the ASX and compliance costs
associated with being a domestic United States issuer subject to
SEC reporting requirements.
Fair
value of stock options issued to employees
As of January 1, 2006, we adopted ASC 718 (formerly
Statement No. 123(R) Share Based Payment). The
impact of the change in accounting policy applied prospectively
resulted in the stock option expense being A$1,078,771,
A$961,108, A$617,715 and A$3,078,661 for the years ended
December 31, 2009, 2008, 2007 and for the period from
inception to December 31, 2009.
Comparison
of the Years Ended December 31, 2009 and 2008
Revenue
In the last quarter of 2009, we commenced the manufacture of the
blood glucose strips in our facility and we also received a
milestone payment of A$17,722,641 triggered by the first grant
to LifeScan of regulatory clearance to sell the blood glucose.
In relation to our manufacturing operations, pursuant to the
Master Services and Supply Agreement we have with LifeScan, one
of two pricing methodologies will apply depending on whether we
are manufacturing above or below a specified quantity of blood
glucose tests strips in a quarter. As we produced less than the
specified quantity of test strips for the December 2009 quarter,
we are considered to be in the interim costing
period. In the interim costing period, the Company is
establishing its commercial scale manufacturing and therefore is
not expected to generate any profit, but is expected to recover
most of its glucose manufacturing costs. As manufactured volumes
increase beyond the specified quantity of blood glucose test
strips per quarter, the interim costing period will cease to
apply and a different pricing methodology will apply, at which
time we expect to be profitable in the sale of blood glucose
test strips. Revenue from services in 2009 is primarily in
connection with the provisions by us to Lifescan of certain
manufacturing support services.
Our research and development income for 2009 and 2008 was
A$1,337,125 and A$1,170,190, respectively, recognized
pursuant to the Development and Research Agreement.
During the 2008 financial year, the only other income we
generated was from LifeScan for the provision of certain
services relating to the development and scale up of the
production of a blood glucose sensor strip. Under this
arrangement, no margin was earned as the costs of providing the
services were equal to the revenue recognized.
49
Research
and development expenses
Research and development expenses include:
|
|
|
|
|
consultant and employee related expenses, which include salary
and benefits;
|
|
|
|
materials and consumables acquired for the research and
development activities;
|
|
|
|
external research and development expenses incurred under
agreements with third party organizations and
universities; and
|
|
|
|
facilities, depreciation and other allocated expenses, which
include direct and allocated expenses for rent and maintenance
of facilities, depreciation of leasehold improvements and
equipment and laboratory and other supplies.
|
Our research and development expenses increased in 2009, as
reflected below:
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
A$
|
|
|
A$
|
|
|
Research and development expenses
|
|
|
14,898,072
|
|
|
|
11,885,871
|
|
Research grants received recognized against related research and
development expenses
|
|
|
|
|
|
|
(300,613
|
)
|
|
|
|
|
|
|
|
|
|
Research and development expenses as reported
|
|
|
14,898,072
|
|
|
|
11,585,258
|
|
|
|
|
|
|
|
|
|
|
A substantial portion of our research and development
expenditure was expended towards finalizing our research and
development program for the blood glucose project which
concluded towards the end of 2009. We also worked on three
non-glucose development programs, including two programs to
develop immunoassay based tests (one immunoassay test being a
test for C-reactive protein and the other being a test for
D-dimer) and a prothrombin time test. Our strategy is to enter
into collaborative arrangements or strategic alliances with life
sciences companies or other industry participants to complete
the development and commercialization of our products. In the
second half of 2009 we commenced business development efforts to
establish partnerships in fields outside the area of blood
glucose and diabetes. To date we have not secured a partnership
and cannot predict with any certainty when our efforts might be
successful.
General
and administrative expenses
General and administrative expenses increased to A$5,635,569 in
2009 from A$5,510,127 in 2008. General and administrative
expenses consist principally of salaries and related costs,
including stock options expense, for personnel in executive,
finance, accounting, information technology and human resources
functions. Other general and administrative expenses include
depreciation, repairs and maintenance, insurance, facility costs
not otherwise included in research and development expenses,
consultancy fees and professional fees for legal, audit and
accounting services. This increase in expenses reflects growth
in the size and complexity of our operations, as well as the
incremental costs of having our shares in the form of CDIs
quoted on the ASX and compliance costs associated with being a
domestic United States issuer subject to SEC reporting
requirements. We expect that our general and administrative
expenses will increase as we expand our legal, accounting,
marketing and sales staff, add infrastructure and incur
additional costs related to operating as a company whose shares
in the form of CDIs are quoted on the ASX, including
directors and officers insurance, investor relations
programs, increased director fees and increased professional
fees.
Interest
income
Interest income decreased to A$809,459 in 2009 from A$2,542,060
in 2008. The decrease in interest income is attributable to
lower returns and the lower level of funds invested for most of
the year. We commenced the 2008 financial year with A$28,334,864
in cash and short-term investments. The cash and bank balance at
the end of the 2009 financial year was A$31,291,011. Of this,
the milestone payment of A$17,722,641 was received in December
2009 upon the receipt of regulatory clearance of the blood
glucose product.
50
Fee
Income
The Company received an initial non-refundable fee of
A$1,131,222 in January 2008 in consideration for the grant of
certain rights to LifeScan pursuant to the Master Services and
Supply Agreement. This revenue is recorded under the caption
Other income in the consolidated statements of
operations.
Fair
value of stock options issued to employees
The non-cash compensation expense increased to A$1,078,771 in
2009 from A$961,108 in 2008 as a result of options granted to
employees on a consistent basis and increase in the number of
personnel.
Net
profit
The Company made a net profit of A$1,430,463 in 2009 largely as
a result of increased revenue.
Comparison
of the Years Ended December 31, 2008 and 2007
Revenue
Under the terms of our arrangement with LifeScan, during 2008 we
provided certain services relating to the development and scale
up of the production of a blood glucose sensor strip. Production
scale up includes activities such as producing strips and
testing strips. Under this arrangement, no margin was earned as
the costs of providing the services were equal to the revenue
recognized.
Amounts billed to LifeScan have been recorded under the caption
Revenue from services in the consolidated statements
of operations. Research and development expenditure attributable
to services performed on behalf of LifeScan have been recorded
separately under the caption Cost of services in the
consolidated condensed statements of operations.
No such services were provided in 2007.
Our research and development income for 2008 and 2007 was
A$1,170,190 and A$1,192,015, respectively, recognized pursuant
to the Development and Research Agreement.
Research
and development expenses
Research and development expenses increased to A$11,585,258 in
2008 from A$7,157,216 in 2007. Our operating expenses were
substantially for research and development activities. Research
and development expenses consist of costs associated with
research activities, as well as costs associated with our
product development efforts, including pilot manufacturing
costs. All research and development costs, including those
funded by an Australian research and development grant program,
are expensed as incurred. Included in the research and
development expenses are Australian research grants of A$300,613
and A$872,513 received for the R&D Start Grant Program for
2008 and 2007, respectively.
Research and development expenses include:
|
|
|
|
|
consultant and employee related expenses, which include salary
and benefits;
|
|
|
|
materials and consumables acquired for the research and
development activities;
|
|
|
|
external research and development expenses incurred under
agreements with third party organizations and
universities; and
|
|
|
|
facilities, depreciation and other allocated expenses, which
include direct and allocated expenses for rent and maintenance
of facilities, depreciation of leasehold improvements and
equipment and laboratory and other supplies.
|
General
and administrative expenses
General and administrative expenses increased to A$5,510,127 in
2008 from A$4,226,757 in 2007. General and administrative
expenses consist principally of salaries and related costs,
including stock options expense, for
51
personnel in executive, finance, accounting, information
technology and human resources functions. Other general and
administrative expenses include depreciation, repairs and
maintenance, insurance, facility costs not otherwise included in
research and development expenses, consultancy fees and
professional fees for legal, audit and accounting services. This
increase in expenses reflects growth in the size and complexity
of our operations, as well as the incremental costs of having
our shares in the form of CDIs quoted on the ASX and compliance
costs associated with being a domestic United States issuer
subject to SEC reporting requirements.
Interest
income
Interest income increased to A$2,542,060 in 2008 from
A$1,440,102 in 2007. The increase in interest income is
attributable to the greater level of funds invested during the
year. We commenced the 2007 financial year with A$41,958,285 in
cash and short-term investments. Of this A$34,246,043 was raised
by way of a renounceable rights issue in November and December
2007. The cash and bank balance at the end of the 2008 financial
year was A$28,334,864.
Fee
Income
The Company received an initial non-refundable fee of
A$1,131,222 in January 2008 in consideration for the grant of
certain rights to LifeScan pursuant to the Master Services and
Supply Agreement. This revenue is recorded under the caption
Other income in the consolidated statements of
operations.
Fair
value of stock options issued to employees
The non-cash compensation expense increased by 56% from 2007 to
2008 as a result of options granted to employees on a consistent
basis and increase in the number of personnel granted options.
Income
tax benefit
Income tax benefit during the 2007 and 2008 year relates to
the reversal of provision for income tax.
Net
loss
Net loss increased to A$11,995,886 in 2008 from A$8,817,238 in
2007 as a result of increased activity during the 2008 financial
year thus resulting in increased research and development
expenses and general and administrative expenses. The loss was
partially offset by revenues received from LifeScan for
provision of certain services.
Liquidity
and Capital Resources
Since inception, our operations have mainly been financed
through the issuance of equity securities. Additional funding
has come through payments received from LifeScan under the
Development and Research Agreement, revenue from services,
various payments under the Master Services and Supply Agreement
and a one-time payment for manufacturing process support and
research grants and interest on investments. Through to
December 31, 2009, we had received aggregate net cash
proceeds from the following: (a) A$32,502,129 from the
renounceable rights issue; (b) A$37,178,516 from the
issuance of equity securities other than those issued under the
renounceable rights offer; (c) A$14,415,089 from LifeScan
under our Development and Research Agreement;
(d) A$5,971,825 from LifeScan as revenue from services
performed; (e) A$2,776,063 as contributions from government
and state grants; (f) A$1,131,222 from LifeScan as an
initial fee under our Master Services and Supply Agreement;
(g) A$17,722,641 from LifeScan received on regulatory
clearance to sell the blood glucose product and
(g) A$5,408,492 from interest on investments. As of
December 31, 2009, we had A$31,291,011 in cash, cash
equivalents and short-term investments. Our cash and investment
balances are held in money market accounts and short-term
instruments. Cash in excess of immediate requirements is
invested in short-term instruments with regard to liquidity and
capital preservation.
For the year ended December 31, 2009, net cash provided by
operating activities was A$5,867,156. This consisted of a
milestone payment of A$17,722,641 received on regulatory
clearance of the blood glucose product and a net profit for the
period of A$1,430,463 which included A$2,851,285 of non-cash
depreciation
52
and amortization and non-cash stock option expense of
A$1,078,771. Net cash used in investing activities during the
year ended December 31, 2009 was A$2,990,007, which
included purchase of plant and equipment of A$844,199 and the
balance deposits towards manufacturing equipment. These deposits
have not been treated as Property, plant and
equipment in the balance sheet but as
Prepayments as title has not yet passed to us. Net
cash provided by financing activities during the year ended
December 31, 2009 was A$78,998.
For the year ended December 31, 2008, we used net cash of
A$7,140,386 for operating activities. This consisted of a net
loss for the period of A$11,995,886, which included A$2,266,847
of non-cash depreciation and amortization and non-cash stock
option expense of A$961,108. Net cash used in investing
activities during the year ended December 31, 2008 was
A$6,471,419, which included additional fit out of our new
facilities and purchase of plant and equipment of A$5,978,685,
transfer of term investments with initial maturity between four
to six months to term investments having a maturity of less than
three months and deposits towards manufacturing equipment. The
term investments had a face value of A$3,123,501. We also made
deposits towards manufacturing equipment of A$3,616,235. These
deposits have not been treated as Property, plant and
equipment in the balance sheet but as
Prepayments as title has not yet passed to us. Net
cash used in financing activities during the year ended
December 31, 2008 was A$11,616.
For the year ended December 31, 2007, we used net cash of
A$7,769,274 for operating activities. This consisted of a net
loss for the period of A$8,817,238, which included A$708,699 of
non-cash depreciation and amortization, and non-cash stock
option expense of A$617,715. Net cash used in investing
activities during the year ended December 31, 2007 was
A$12,181,766, which included purchase of plant and equipment of
A$9,058,265 reflecting the commencement of the expansion of our
manufacturing capabilities and leasehold improvements to the
Rowville premises and A$3,123,501 placed as term investments
with maturity between four to six months. Net cash provided by
financing activities during the year ended December 31,
2007 was A$32,667,220 resulting from the renounceable rights
offer which raised A$32,518,792 and A$148,428 raised by way of
employees exercising their options.
As at December 31, 2009, we had cash and cash equivalents
of A$31,291,011 as compared to A$28,334,864 as of
December 31, 2008. The increase in cash and cash
equivalents balance is predominantly as a result of the receipt
of the milestone payment of A$17,722,641 which was triggered on
regulatory clearance of the blood glucose product.
In October 2007, we entered into a Master Services and Supply
Agreement with LifeScan. The Master Services and Supply
Agreement was amended and restated in May 2009. In February
2009, we received A$3,087,849 in connection with the provision
by us to LifeScan of certain manufacturing support services. In
December 2009, we received a milestone payment of A$17,722,641
which was triggered on regulatory clearance to sell the blood
glucose product. The receipt and timing of any further revenue
under the Master Services and Supply Agreement, which was
amended and restated on May 15, 2009, is uncertain and is
largely dependent on the volume of blood glucose strips
manufactured by us and LifeScan and ultimately sold by LifeScan
and the level of contract research work awarded to us by
LifeScan.
Choice and timing of market entry(ies) for blood glucose
products covered by the Master Services and Supply Agreement are
at LifeScans discretion. If at any time LifeScan indicates
that it will not proceed with the rollout of the blood glucose
test covered by the Master Services and Supply Agreement, or if
the product does not obtain regulatory approval in any other
jurisdictions, we will use the installed manufacturing equipment
for the products we are developing for other biomarkers, subject
to us having entered into collaborative arrangements or
strategic alliances with respect to the relevant products. To
reach that point, development efforts will need to continue to
be successful. Our strategy is to enter into collaborative
arrangements or strategic alliances with life sciences companies
or other industry participants to complete the development and
commercialization of our products. In the second half of 2009 we
commenced business development efforts to establish partnerships
in fields outside the area of blood glucose and diabetes. To
date we have not secured a partnership and cannot predict with
any certainty when our efforts might be successful.
The total cost of the projects which we are undertaking is
subject to a range of factors. As a result, we consider that at
this stage of our development we are unable to provide investors
with reliable details in relation
53
to the potential cost of our project to us. We believe that with
our cash, cash equivalents and the interest we earn on these
balances, the Company will be able to perform under the Master
Services and Supply Agreement and to progress the Companys
other development programs. In the event we are unable to
generate revenue from the manufacturing and supply of the blood
glucose test, we will need to revise our business plans.
Notwithstanding this, by actively managing our cash flows,
controlling costs and revising our development plans as
necessary we believe we have sufficient cash reserves to
continue as a going concern through the next 12 months. In
order to achieve our objectives, we may require additional
funding
and/or to
revise our business plans. The amount and timing of these future
funding requirements, if any, is uncertain. To meet these
financing requirements, we may raise funds through public or
private equity offerings, debt financings, and through other
means, including collaborations and license agreements or other
means determined by the Directors at that time.
We note our forecasted ability to maintain our financial
resources to support our operations for this period is a
forward-looking statement that involves risks and uncertainties,
and actual results could vary materially. If we are unable to
raise additional capital when required or on acceptable terms,
we may have to significantly delay, scale back or discontinue
one or more of our planned research, development and
manufacturing activities.
Operating
Capital and Capital Expenditure Requirement
The sale of additional equity securities, if undertaken, may
result in dilution to our shareholders. If we raise additional
funds in the future through the issuance of debt securities or
preferred stock, these securities could have rights senior to
those of our common stock and could contain covenants that would
restrict our operations. Any such required additional capital
may not be available on reasonable terms, if at all. If we are
unable to obtain additional financing, we may be required to
reduce the scope of, delay or eliminate some or all of our
planned research, development and manufacturing activities,
which could materially harm our business.
As a result of the numerous risks and uncertainties associated
with our business strategy, we are unable to estimate the exact
amounts of our capital and working capital requirements. We
estimate our total capital expenditures in 2010 to be in the
range of A$3,000,000 to A$4,000,000 for the purchase of
equipment to support our activities under the Master Services
and Supply Agreement, capacity expansion, for ongoing
development of our existing products, and for other ongoing
research and development activities. Our future funding
requirements will depend on many factors, including, but not
limited to:
|
|
|
|
|
our business and product development strategies;
|
|
|
|
expenses we incur in manufacturing and developing products and
the services and development programs we undertake from LifeScan;
|
|
|
|
changes to our operations to enable us to perform services
required under the Master Services and Supply Agreement;
|
|
|
|
the sales of blood glucose test strips by LifeScan and the
quantities of blood glucose test strips to be manufactured by us
for LifeScan;
|
|
|
|
the timing and amount of receipts of revenue from LifeScan under
the Master Services and Supply Agreement;
|
|
|
|
costs and timing of regulatory approvals and market launches of
the blood glucose test;
|
|
|
|
the costs of undertaking and success of our research and
development efforts;
|
|
|
|
any need to further scale up of our manufacturing operations to
meet demand for blood glucose strips under the Master Services
and Supply Agreement, or for our
point-of-care
tests, including additional costs related to the fit out of our
manufacturing facility in Melbourne, Australia and the
acquisition of additional manufacturing equipment;
|
|
|
|
the rate of progress and cost of our product development
activities;
|
|
|
|
the timing and success of any corporate collaborations or
strategic alliances with respect to our tests in development,
including revenues expected from such collaborations;
|
54
|
|
|
|
|
the timing and amount of revenue generated by sales of our
point-of-care
tests;
|
|
|
|
costs of filing, prosecuting, defending and enforcing any patent
claims and other intellectual property rights;
|
|
|
|
the terms and timing of any collaborative, licensing and other
arrangements that we may establish; and
|
|
|
|
the acquisition of businesses, products and technologies,
although we currently have no commitments or agreements relating
to any of these types of transactions.
|
Off-Balance
Sheet Arrangement
As of December 31, 2009, the future minimum lease payments
under non-cancelable operating leases (with initial or remaining
lease terms in excess of one year) are:
|
|
|
|
|
|
|
A$
|
|
|
Less than 1 year
|
|
|
519,598
|
|
1 3 years
|
|
|
1,093,608
|
|
3 5 years
|
|
|
714,243
|
|
More than 5 years
|
|
|
|
|
|
|
|
|
|
Total minimum lease payments
|
|
|
2,327,449
|
|
|
|
|
|
|
The above relates to our operating lease obligations in relation
to the lease of our premises.
Contractual
Obligations
Our future contractual obligations primarily for future rental
payment obligations on the current office and manufacturing
space, including financing costs, at December 31, 2009 were
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
|
|
|
|
|
Less than
|
|
|
|
|
|
|
|
|
More than
|
|
|
|
Total
|
|
|
1 Year
|
|
|
1-3 Years
|
|
|
3-5 Years
|
|
|
5 Years
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Long-Term Debt Obligations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset Retirement Obligations(1)
|
|
|
1,842,547
|
|
|
|
|
|
|
|
|
|
|
|
1,842,547
|
|
|
|
|
|
Operating Lease Obligations(2)
|
|
|
2,327,449
|
|
|
|
519,598
|
|
|
|
1,093,608
|
|
|
|
714,243
|
|
|
|
|
|
Purchase Obligations(3)
|
|
|
1,000,000
|
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Long-Term Liabilities on Balance Sheet under GAAP(4)
|
|
|
262,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
262,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
5,432,432
|
|
|
|
1,519,598
|
|
|
|
1,093,608
|
|
|
|
2,556,790
|
|
|
|
262,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents legal obligations associated with the retirement and
removal of long-lived assets. |
|
(2) |
|
Our operating lease obligations relate to the lease of our
premises and certain office equipment. |
|
(3) |
|
Represents commitments for plant and equipment |
|
(4) |
|
Represents long service leave owing to the employees. |
Segments
We operate in one segment. Our principal activities are research
and development, commercial manufacture of approved medical or
testing devices and the provision of services such as those
specified under the Master Services and Supply Agreement
including contract research work. We operate predominantly in
one geographical area, being Australia.
55
Recent
Accounting Pronouncements
In March 2008, the Financial Accounting Standards Board
(FASB) issued SFAS No. 161,
Disclosures about Derivative Instruments and Hedging
Activities. The new standard is intended to improve
financial reporting about derivative instruments and hedging
activities by requiring enhanced disclosures to enable investors
to better understand their effects on an entitys financial
position, financial performance, and cash flows. The Company
adopted ASC 815 Derivative and Hedging (formerly
SFAS No. 161) effective January 1, 2009
which has not had a material impact on the Companys
consolidated financial statements.
In January, 2009, the company adopted ASC 808
Collaborative Arrangements (formerly EITF Issue
07-01:
Accounting for Collaborative Arrangements Related to the
Development and Commercialization of Intellectual
Property). This issue addresses the income statement
classification of payments made between parties in a
collaborative arrangement. ASC 808 has not had a material impact
on the Companys consolidated financial statements.
On July 1, 2009, the FASB issued SFAS No. 168,
The FASB Accounting Standards Codification and the
Hierarchy of Generally Accepted Accounting Principles,
also known as FASB Accounting Standards Codification
(ASC) 105, Generally Accepted Accounting
Principles (ASC 105) (the Codification).
ASC 105 establishes the exclusive authoritative reference for
U.S. GAAP for use in financial statements, except for SEC
rules and interpretive releases, which are also authoritative
GAAP for SEC registrants. The Codification will supersede all
existing non-SEC accounting and reporting standards. For
convenience, we have provided references to the Codification
throughout this report in addition to the current GAAP source
reference.
In April 2009, the FASB issued ASC 825 Financial
Instruments (formerly Staff Position
No. FAS 107-1
and APB
28-1,
Interim Disclosures about Fair Value of Financial
Instruments) (ASC 825). ASC 825 amends FASB
Statement No. 107, Disclosures about Fair Value of
Financial Instruments to require disclosures about fair
value of financial instruments in interim reporting periods.
These disclosures were previously only required in annual
financial statements. The adoption of ASC 825 did not have a
material impact on our consolidated financial statements as this
only requires additional disclosures.
In May 2009, the FASB issued ASC 855 Subsequent
Events (formerly SFAS No. 165 Subsequent
Events), which is effective for interim and annual periods
ending after June 15, 2009 (ASC 855). ASC 855
establishes general standards of accounting for and disclosure
of events that occur after the balance sheet date but before
financial statements are issued or are available to be issued.
ASC 855 did not have a material impact on our consolidated
financial statements.
In October 2009, the FASB issued Accounting Standards Update
No. 2009-13,
Multiple-Deliverable Revenue Arrangements (ASU
No. 2009-13).
ASU
No. 2009-13
amends guidance included within ASC Topic
605-25 to
require an entity to use an estimated selling price when vendor
specific objective evidence or acceptable third party evidence
does not exist for any products or services included in a
multiple element arrangement. The arrangement consideration
should be allocated among the products and services based upon
their relative selling prices, thus eliminating the use of the
residual method of allocation. ASU
No. 2009-13
also requires expanded qualitative and quantitative disclosures
regarding significant judgments made and changes in applying
this guidance. ASU
No. 2009-13
is effective prospectively for revenue arrangements entered into
or materially modified in fiscal years beginning on or after
June 15, 2010. Early adoption and retrospective application
are also permitted. The company elected to early adopt the
provisions of ASU
No. 2009-13
in fiscal 2009.
|
|
ITEM 7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Foreign
Currency Market Risk
We transact business in various foreign currencies, including
U.S. dollars and Euros. We have established a foreign
currency hedging program using forward contracts to hedge the
net projected exposure for each currency and the anticipated
sales and purchases in U.S. dollars and Euros. The goal of
this hedging program is to economically guarantee or lock-in the
exchange rates on our foreign exchange exposures. The Company
56
does not hold or issue derivative financial instruments for
trading purposes. However, derivatives that do not qualify for
hedge accounting are accounted for as trading instruments.
The following table sets out the notional amounts and weighted
average exchange rates by expected (contractual) maturity dates.
These notional amounts generally are used to calculate the
contractual payments to be exchanged under the contract.
|
|
|
|
|
|
|
|
|
|
|
2009 (*)
|
|
Fair Value
|
|
Anticipated Transactions and Related Derivatives
|
|
|
|
|
|
|
|
|
AUD Functional Currency:
|
|
|
|
|
|
|
|
|
Forward exchange agreements (Sell AUD/Buy Euros)
|
|
|
|
|
|
|
|
|
Contract amount
|
|
A$
|
811,303
|
|
|
A$
|
763,891
|
|
Average contractual exchange rate
|
|
|
0.5865
|
|
|
|
|
|
|
|
|
* |
|
Expected maturity or transaction date |
As at balance date, there were no anticipated transactions and
related derivatives which extended beyond the 2010 financial
year.
Interest
Rate Risk
Our exposure to interest income sensitivity, which is affected
by changes in the general level of Australian interest rates,
particularly because the majority of our investments are in AUD
in cash and cash equivalents. The primary objective of our
investment activities is to preserve principal while at the same
time maximizing the income we receive without significantly
increasing risk. Our investment portfolio is subject to interest
rate risk and will fall in value in the event market interest
rates increase. Due to the short duration of our investment
portfolio, we believe an immediate 10% change in interest rates
would not be material to our financial condition or results of
operations.
|
|
ITEM 8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
The financial statements we are required to include in this
Item 8 are included in this report beginning on
page F-1.
57
Supplementary
Financial Information
The following is a summary of the unaudited quarterly results of
operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2009
|
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from products
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
132,733
|
|
Revenue from services
|
|
|
1,467,464
|
|
|
|
312,590
|
|
|
|
819,181
|
|
|
|
250,836
|
|
Research and development income
|
|
|
388,319
|
|
|
|
349,848
|
|
|
|
310,945
|
|
|
|
288,013
|
|
Milestone payment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17,722,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
1,855,783
|
|
|
|
662,438
|
|
|
|
1,130,126
|
|
|
|
18,394,223
|
|
Operating costs & expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
458,162
|
|
Cost of services
|
|
|
14,835
|
|
|
|
47,285
|
|
|
|
80,136
|
|
|
|
26,985
|
|
Research and development(2)
|
|
|
3,233,635
|
|
|
|
4,104,205
|
|
|
|
3,681,701
|
|
|
|
3,878,531
|
|
General and administrative(3)
|
|
|
1,190,592
|
|
|
|
1,395,286
|
|
|
|
1,543,305
|
|
|
|
1,506,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs & expenses
|
|
|
4,439,062
|
|
|
|
5,546,776
|
|
|
|
5,305,142
|
|
|
|
5,870,064
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) from operations
|
|
|
(2,583,279
|
)
|
|
|
(4,884,338
|
)
|
|
|
(4,175,016
|
)
|
|
|
12,524,159
|
|
Other income/(expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
267,074
|
|
|
|
193,184
|
|
|
|
161,041
|
|
|
|
188,160
|
|
Interest expense
|
|
|
(3,613
|
)
|
|
|
(3,614
|
)
|
|
|
(2,409
|
)
|
|
|
|
|
Fee income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
(33,778
|
)
|
|
|
52,265
|
|
|
|
5,368
|
|
|
|
(274,741
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income/(expense)
|
|
|
229,683
|
|
|
|
241,835
|
|
|
|
164,000
|
|
|
|
(86,581
|
)
|
Net profit/(loss) before tax
|
|
|
(2,353,596
|
)
|
|
|
(4,642,503
|
)
|
|
|
(4,011,016
|
)
|
|
|
12,437,578
|
|
Income tax benefit/(expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit/(loss)
|
|
$
|
(2,353,596
|
)
|
|
$
|
(4,642,503
|
)
|
|
$
|
(4,011,016
|
)
|
|
$
|
12,437,578
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net profit/(loss) per share
|
|
$
|
(0.01
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
0.08
|
|
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
|
|
156,976,936
|
|
|
|
156,976,936
|
|
|
|
157,004,871
|
|
|
|
157,094,376
|
|
Diluted net profit/(loss) per share
|
|
$
|
(0.01
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
(0.03
|
)
|
|
$
|
0.08
|
|
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
|
|
156,976,936
|
|
|
|
156,976,936
|
|
|
|
157,004,871
|
|
|
|
161,828,109
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Includes non-cash compensation expense (cost of goods sold)
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
21,207
|
|
2 Includes non-cash compensation expense (research and
development)
|
|
$
|
95,997
|
|
|
$
|
81,024
|
|
|
$
|
229,637
|
|
|
$
|
246,816
|
|
3 Includes non-cash compensation expense (general and
administrative)
|
|
$
|
44,451
|
|
|
$
|
35,506
|
|
|
$
|
172,253
|
|
|
$
|
151,880
|
|
58
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2008
|
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
Quarter
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
March 31
|
|
|
June 30
|
|
|
September 30
|
|
|
December 31
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from products
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Revenue from services
|
|
|
|
|
|
|
1,240,801
|
|
|
|
1,880,953
|
|
|
|
|
|
Research and development income
|
|
|
279,298
|
|
|
|
274,213
|
|
|
|
259,740
|
|
|
|
356,939
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
279,298
|
|
|
|
1,515,014
|
|
|
|
2,140,693
|
|
|
|
356,939
|
|
Operating costs & expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of services
|
|
|
|
|
|
|
1,240,801
|
|
|
|
1,880,953
|
|
|
|
|
|
Research and development (1 and 2)
|
|
|
1,940,629
|
|
|
|
2,065,317
|
|
|
|
1,234,887
|
|
|
|
6,344,425
|
|
General and administrative(3)
|
|
|
1,389,013
|
|
|
|
1,432,689
|
|
|
|
1,303,981
|
|
|
|
1,384,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs & expenses
|
|
|
3,329,642
|
|
|
|
4,738,807
|
|
|
|
4,419,821
|
|
|
|
7,728,869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(3,050,344
|
)
|
|
|
(3,223,793
|
)
|
|
|
(2,279,128
|
)
|
|
|
(7,371,930
|
)
|
Other income/(expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
773,957
|
|
|
|
702,517
|
|
|
|
634,275
|
|
|
|
431,311
|
|
Interest expense
|
|
|
|
|
|
|
(9,489
|
)
|
|
|
|
|
|
|
|
|
Fee income
|
|
|
1,131,222
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
(16,228
|
)
|
|
|
(67,433
|
)
|
|
|
314,405
|
|
|
|
34,566
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income/(expense)
|
|
|
1,888,951
|
|
|
|
625,595
|
|
|
|
948,680
|
|
|
|
465,877
|
|
Net loss before tax
|
|
|
(1,161,393
|
)
|
|
|
(2,598,198
|
)
|
|
|
(1,330,448
|
)
|
|
|
(6,906,053
|
)
|
Income tax benefit/(expense)
|
|
|
3,054
|
|
|
|
(2,848
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(1,158,339
|
)
|
|
$
|
(2,601,046
|
)
|
|
$
|
(1,330,448
|
)
|
|
$
|
(6,906,053
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share
|
|
$
|
(0.01
|
)
|
|
$
|
(0.02
|
)
|
|
$
|
(0.01
|
)
|
|
$
|
(0.04
|
)
|
Average weighted number of shares used to compute per share data
|
|
|
156,958,812
|
|
|
|
156,969,888
|
|
|
|
156,976,936
|
|
|
|
156,976,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Net of research grant income in these amounts
|
|
$
|
240,751
|
|
|
$
|
59,862
|
|
|
$
|
|
|
|
$
|
|
|
2. Includes non-cash compensation expense (research and
development)
|
|
$
|
77,844
|
|
|
$
|
253,212
|
|
|
$
|
152,495
|
|
|
$
|
177,946
|
|
3. Includes non-cash compensation expense (general and
administrative)
|
|
$
|
95,764
|
|
|
$
|
55,910
|
|
|
$
|
67,340
|
|
|
$
|
80,597
|
|
59
|
|
ITEM 9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
|
None.
|
|
ITEM 9A(T).
|
CONTROLS
AND PROCEDURES
|
Evaluation of Disclosure Controls and
Procedures. With the participation of our
management, including the Companys principal executive
officer and principal financial officer, our management has
evaluated the effectiveness of our disclosure controls and
procedures (as defined in
Rule 13a-15(e)
under the Securities Exchange Act of 1934 (the Exchange
Act)) as of the end of the period covered by this report.
Based upon that evaluation, the Companys principal
executive officer and principal financial officer have concluded
that:
|
|
|
|
|
information required to be disclosed by the Company in this
report and other reports that the Company files or submits under
the Exchange Act would be accumulated and communicated to the
Companys management, including its principal executive
officer and principal financial officer, as appropriate to allow
timely decisions regarding required disclosure;
|
|
|
|
information required to be disclosed by the Company in this
report and other reports that the Company files or submits under
the Exchange Act would be recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms; and
|
|
|
|
the Companys disclosure controls and procedures are
effective as of the end of the period covered by this report to
ensure that material information relating to the Company and its
consolidated subsidiaries is made known to them, particularly
during the period in which the periodic reports of the Company,
including this report, are being prepared.
|
Changes in Internal Control Over Financial
Reporting. During the most recent quarter ended
December 31, 2009, there has been no change in our internal
control over financial reporting (as defined in
Rule 13a-15(f)
and
15d-15(f)
under the Exchange Act) that has materially affected, or is
reasonably likely to materially affect, our internal control
over financial reporting.
60
MANAGEMENTS
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
Our management is responsible for establishing and maintaining
adequate internal control over financial reporting (as defined
in
Rule 13a-15(f)
under the Exchange Act). Our internal control over financial
reporting is a process designed to provide reasonable assurance
regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting principles and
includes those policies and procedures that:
|
|
|
|
|
Pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and the
dispositions of the assets of the Company;
|
|
|
|
Provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and
that receipts and expenditures of the Company are being made
only in accordance with authorization of management and the
board of directors of the Company; and
|
|
|
|
Provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of
the Companys assets that could have a material effect on
the financial statements.
|
Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements.
Also, projections of any evaluations of effectiveness to future
periods are subject to risk that controls may become inadequate
because of changes in conditions or because of declines in the
degree of compliance with the policies or procedures.
Our management, with the participation of the Chief Executive
Officer and Chief Financial Officer, assessed the effectiveness
of the Companys internal control over financial reporting
as of December 31, 2009. In making this assessment, the
Companys management used the criteria set forth by the
Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control-Integrated Framework.
Based on this evaluation, our management, with the participation
of the Chief Executive Officer and Chief Financial Officer,
concluded that, as of December 31, 2009, our internal
control over financial reporting was effective.
This annual report on
Form 10-K
does not include an attestation report of our registered public
accounting firm regarding internal controls over financial
reporting. Managements report was not subject to
attestation by our registered public accounting firm pursuant to
temporary rules of the SEC that permit us to provide only
managements report in this annual report on
Form 10-K.
|
|
|
Mark Morrisson
|
|
Salesh Balak
|
Chief Executive Officer and Executive Director
|
|
Chief Financial Officer
|
March 16, 2010
|
|
ITEM 9B.
|
OTHER
INFORMATION
|
None.
PART III
|
|
ITEM 10.
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
|
The information required by this item regarding our directors
and executive officers is incorporated by reference to our
Definitive Proxy Statement to be filed with the Securities and
Exchange Commission in connection with our Annual Meeting of
Stockholders in 2010 (the 2010 Proxy Statement)
under the caption Management of the Company.
61
The information required by this item regarding Compliance
with Section 16(a) of the Exchange Act is
incorporated by reference to the 2010 Proxy Statement under the
caption Other Matters Beneficial Ownership
Reporting Compliance.
We have adopted our Code of Ethics for Senior Financial
Officers, a code of ethics that applies to our Chief Executive
Officer and Chief Financial Officer. This code of ethics may be
accessed and reviewed through our website at
www.universalbiosensors.com. We intend to satisfy any disclosure
requirement under item 5.05 of
Form 8-K
regarding an amendment to, or waiver from, a provision of the
Code of Ethics for our Chief Executive Officer and Chief
Financial Officer, by posting such information on our website at
www.universalbiosensors.com
The information required by this item regarding any material
changes to the procedures by which security holders may
recommend nominees to our Board of Directors is incorporated by
reference to the 2010 Proxy Statement under the caption
Management of the Company Board
Committees Remuneration and Nomination
Committee.
The information required by this item regarding our Audit
Committee is incorporated by reference to the 2010 Proxy
Statement under the caption Management of the
Company Board Committees Audit and
Compliance Committee.
|
|
ITEM 11.
|
EXECUTIVE
COMPENSATION.
|
The information required by this item is incorporated by
reference to the 2010 Proxy Statement under the captions
Management of the Company Compensation of
Directors, Executive Compensation and
Management of the Company Board
Committees Compensation Committee Interlocks and
Insider Participation.
|
|
ITEM 12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.
|
The information regarding the security ownership of certain
beneficial owners and management is incorporated by reference to
the 2010 Proxy Statement under the caption Security
Ownership of Certain Beneficial Owners and Management.
The information regarding Securities Authorized for
Issuance under Equity Compensation Plans is incorporated
by reference to our 2010 Proxy Statement under the caption
Executive Compensation Equity Compensation
Plan Information.
|
|
ITEM 13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.
|
The information required by this item is incorporated by
reference to the 2010 Proxy Statement under the caption
Certain Relationships and Related Transactions, and
Management of the Company.
|
|
ITEM 14.
|
PRINCIPAL
ACCOUNTING FEES AND SERVICES.
|
The information required by this item is incorporated by
reference to the 2010 Proxy Statement under the caption
Independent Public Accountants Audit
Fees.
62
PART IV
|
|
ITEM 15.
|
EXHIBITS,
FINANCIAL STATEMENTS AND SCHEDULES.
|
|
|
(a)(1)
|
Financial
Statements
|
Index to
Financial Statements
|
|
|
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
|
|
|
F-36
|
|
|
|
(a)(2)
|
Financial
Statement Schedules All financial statement
schedules are omitted because they are not applicable, not
required under the instructions or all the information required
is set forth in the financial statements or notes thereto.
|
|
|
(a)(3)
|
and
(b) Exhibits See accompanying Index to Exhibits.
|
63
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this
Form 10-K
to be signed on its behalf by the undersigned, thereunto duly
authorized.
Universal Biosensors, Inc.
(Registrant)
Mark Morrisson
Chief Executive Officer and Executive Director
Date: March 16, 2010
POWER OF
ATTORNEY
Each person whose signature appears below hereby constitutes and
appoints Mark Morrisson and Salesh Balak and each of them, his
or her attorneys-in-fact, each with the power of substitution,
for him or her and in his or her name, place and stead, in any
and all capacities, to sign any and all amendments to this
report on
Form 10-K,
and to file the same, with all exhibits thereto and all
documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and
agents, and each of them full power and authority to do and
perform each and every act and all intents and purposes as he or
she might or could do in person, hereby ratifying and confirming
all that such attorneys in-fact and agents or any of them or his
or their substitute or substitutes, may lawfully do or cause to
be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed by the following on behalf of
the registrant and in the capacities and on the dates indicated:
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Mark
Morrisson
Mark
Morrisson
|
|
Chief Executive Officer and
Executive Director
(Principal Executive Officer)
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Salesh
Balak
Salesh
Balak
|
|
Chief Financial Officer
(Principal Financial Officer)
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Andrew
Denver
Andrew
Denver
|
|
Director
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Denis
Hanley
Denis
Hanley
|
|
Director
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Andrew
Jane
Andrew
Jane
|
|
Director
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Elizabeth
Wilson
Elizabeth
Wilson
|
|
Director
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Colin
Adam
Colin
Adam
|
|
Director
|
|
March 16, 2010
|
|
|
|
|
|
/s/ Marshall
Heinberg
Marshall
Heinberg
|
|
Director
|
|
March 16, 2010
|
64
Consolidated
Financial Statements and Schedules
UNIVERSAL
BIOSENSORS, INC.
(A
Development Stage Enterprise)
|
|
|
|
|
Contents
|
|
|
|
|
|
|
F-2
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
|
|
|
F-36
|
|
F-1
|
|
|
|
|
|
|
|
PricewaterhouseCoopers
ABN 52 780 433 757
|
|
|
|
|
|
|
|
Darling Park Tower 2
201 Sussex Street
GPO BOX 2650
SYDNEY NSW 1171
DX 77 Sydney
Australia
Telephone +61 2 8266 0000
Facsimile +61 2 8266 9999
www.pwc.com/au
|
Report of
Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Universal
Biosensors, Inc.:
In our opinion, the accompanying consolidated balance sheets and
the related consolidated statement of operations, changes in
stockholders equity and comprehensive income and cash
flows present fairly, in all material respects, the financial
position of Universal Biosensors, Inc. and its subsidiaries (a
development stage enterprise) at December 31, 2009 and
December 31, 2008, and the results of their operations and
their cash flows for each of the three years in the period ended
December 31, 2009 and cumulatively, for the period from
September 14, 2001 (date of inception) to December 31,
2009 in conformity with accounting principles generally accepted
in the United States of America. These financial statements are
the responsibility of the Companys management. Our
responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these
statements in accordance with the standards of the Public
Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles
used and significant estimates made by management, and
evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our
opinion.
PricewaterhouseCoopers
March 16 , 2010
Sydney
F-2
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
A$
|
|
|
A$
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
31,291,011
|
|
|
|
28,334,864
|
|
Inventories, net
|
|
|
305,124
|
|
|
|
|
|
Accrued income
|
|
|
118,305
|
|
|
|
118,305
|
|
Accounts receivables
|
|
|
415,397
|
|
|
|
31,657
|
|
Prepayments
|
|
|
2,289,149
|
|
|
|
3,730,246
|
|
Other current assets
|
|
|
364,339
|
|
|
|
535,000
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
34,783,325
|
|
|
|
32,750,072
|
|
Property, plant and equipment
|
|
|
27,898,099
|
|
|
|
23,522,706
|
|
Less accumulated depreciation
|
|
|
(6,597,956
|
)
|
|
|
(3,767,457
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment net
|
|
|
21,300,143
|
|
|
|
19,755,249
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
56,083,468
|
|
|
|
52,505,321
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
434,207
|
|
|
|
630,977
|
|
Accrued expenses
|
|
|
1,201,893
|
|
|
|
838,697
|
|
Financial instruments
|
|
|
47,412
|
|
|
|
|
|
Deferred income
|
|
|
559,931
|
|
|
|
|
|
Employee entitlements provision
|
|
|
421,040
|
|
|
|
435,387
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
2,664,483
|
|
|
|
1,905,061
|
|
Non-current liabilities:
|
|
|
|
|
|
|
|
|
Asset retirement obligations
|
|
|
1,842,547
|
|
|
|
1,699,133
|
|
Employee entitlements provision
|
|
|
262,436
|
|
|
|
197,897
|
|
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
2,104,983
|
|
|
|
1,897,030
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
4,769,466
|
|
|
|
3,802,091
|
|
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value. Authorized
1,000,000 shares; issued and outstanding nil in 2009 (2008:
nil) Common stock, $0.0001 par value. Authorized
300,000,000 shares; issued and outstanding 157,155,933 shares in
2009 (2008: 156,976,936)
|
|
|
15,716
|
|
|
|
15,698
|
|
Additional paid-in capital
|
|
|
74,566,698
|
|
|
|
73,338,995
|
|
Accumulated deficit
|
|
|
(24,353,151
|
)
|
|
|
(12,357,265
|
)
|
Current year earnings/(loss)
|
|
|
1,430,463
|
|
|
|
(11,995,886
|
)
|
Accumulated other comprehensive income
|
|
|
(345,724
|
)
|
|
|
(298,312
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
51,314,002
|
|
|
|
48,703,230
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
|
56,083,468
|
|
|
|
52,505,321
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the financial statements
F-3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception
|
|
|
|
|
|
|
|
|
|
|
|
|
(September 14,
|
|
|
|
|
|
|
|
|
|
|
|
|
2001) to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from products
|
|
$
|
132,733
|
|
|
$
|
132,733
|
|
|
$
|
|
|
|
$
|
|
|
Revenue from services
|
|
|
5,971,825
|
|
|
|
2,850,071
|
|
|
|
3,121,754
|
|
|
|
|
|
Research and development income
|
|
|
14,415,089
|
|
|
|
1,337,125
|
|
|
|
1,170,190
|
|
|
|
1,192,015
|
|
Milestone payment
|
|
|
17,722,641
|
|
|
|
17,722,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
38,242,288
|
|
|
|
22,042,570
|
|
|
|
4,291,944
|
|
|
|
1,192,015
|
|
Operating costs & expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold(1)
|
|
|
458,162
|
|
|
|
458,162
|
|
|
|
|
|
|
|
|
|
Cost of services
|
|
|
3,290,995
|
|
|
|
169,241
|
|
|
|
3,121,754
|
|
|
|
|
|
Research and development (2 and 3)
|
|
|
43,814,091
|
|
|
|
14,898,072
|
|
|
|
11,585,258
|
|
|
|
7,157,216
|
|
General and administrative(4)
|
|
|
19,998,333
|
|
|
|
5,635,569
|
|
|
|
5,510,127
|
|
|
|
4,226,757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs & expenses
|
|
|
67,561,581
|
|
|
|
21,161,044
|
|
|
|
20,217,139
|
|
|
|
11,383,973
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit/(loss) from operations
|
|
|
(29,319,293
|
)
|
|
|
881,526
|
|
|
|
(15,925,195
|
)
|
|
|
(10,191,958
|
)
|
Other income/(expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
5,408,492
|
|
|
|
809,459
|
|
|
|
2,542,060
|
|
|
|
1,440,102
|
|
Interest expense
|
|
|
(19,125
|
)
|
|
|
(9,636
|
)
|
|
|
(9,489
|
)
|
|
|
|
|
Fee income
|
|
|
1,131,222
|
|
|
|
|
|
|
|
1,131,222
|
|
|
|
|
|
Other
|
|
|
(106,190
|
)
|
|
|
(250,886
|
)
|
|
|
265,310
|
|
|
|
(210,382
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income/(expense)
|
|
|
6,414,399
|
|
|
|
548,937
|
|
|
|
3,929,103
|
|
|
|
1,229,720
|
|
Net profit/(loss) before tax
|
|
|
(22,904,894
|
)
|
|
|
1,430,463
|
|
|
|
(11,996,092
|
)
|
|
|
(8,962,238
|
)
|
Income tax benefit/(expense)
|
|
|
(17,794
|
)
|
|
|
|
|
|
|
206
|
|
|
|
145,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit/(loss)
|
|
$
|
(22,922,688
|
)
|
|
$
|
1,430,463
|
|
|
$
|
(11,995,886
|
)
|
|
$
|
(8,817,238
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net profit/(loss) per share
|
|
$
|
(0.28
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.07
|
)
|
Average weighted number of shares used as denominator in
calculating basic net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
157,013,578
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
Diluted net profit/(loss) per share
|
|
$
|
(0.28
|
)
|
|
$
|
0.01
|
|
|
$
|
(0.08
|
)
|
|
$
|
(0.07
|
)
|
Average weighted number of shares used as denominator in
calculating diluted net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
161,354,802
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Includes non-cash compensation expense (cost of goods sold)
|
|
$
|
21,207
|
|
|
$
|
21,207
|
|
|
$
|
|
|
|
$
|
|
|
2 Net of research grant income in these amounts
|
|
$
|
2,366,063
|
|
|
$
|
|
|
|
$
|
300,613
|
|
|
$
|
872,513
|
|
3 Includes non-cash compensation expense (research and
development)
|
|
$
|
1,802,226
|
|
|
$
|
653,474
|
|
|
$
|
661,497
|
|
|
$
|
339,882
|
|
4 Includes non-cash compensation expense (general and
administrative)
|
|
$
|
1,255,228
|
|
|
$
|
404,090
|
|
|
$
|
299,611
|
|
|
$
|
277,833
|
|
See accompanying notes to the financial statements.
F-4
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY
AND COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
Other
|
|
|
Total
|
|
|
|
Preference Shares
|
|
|
Ordinary shares
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Comprehensive
|
|
|
Stockholders
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income
|
|
|
Equity
|
|
|
|
|
|
|
A$
|
|
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Balance at inception (September 14, 2001)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of ordinary shares at $0.0001 per share for cash on
incorporation of the Company in September 2001
|
|
|
|
|
|
|
|
|
|
|
29,179,253
|
|
|
|
2,918
|
|
|
|
(2,685
|
)
|
|
|
|
|
|
|
|
|
|
|
233
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2001
|
|
|
|
|
|
|
|
|
|
|
29,179,253
|
|
|
|
2,918
|
|
|
|
(2,685
|
)
|
|
|
|
|
|
|
|
|
|
|
233
|
|
Issuance of ordinary shares at A$0.05 per share for cash between
January to March 2002
|
|
|
|
|
|
|
|
|
|
|
10,729,264
|
|
|
|
1,073
|
|
|
|
570,168
|
|
|
|
|
|
|
|
|
|
|
|
571,241
|
|
Issuance of ordinary shares at A $0.48 per share for cash in
June 2002
|
|
|
|
|
|
|
|
|
|
|
3,624,752
|
|
|
|
362
|
|
|
|
1,752,794
|
|
|
|
|
|
|
|
|
|
|
|
1,753,156
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit for period from inception to December 31, 2002
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
130,134
|
|
|
|
|
|
|
|
130,134
|
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(48,035
|
)
|
|
|
(48,035
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
82,099
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2002
|
|
|
|
|
|
|
|
|
|
|
43,533,269
|
|
|
|
4,353
|
|
|
|
2,320,277
|
|
|
|
130,134
|
|
|
|
(48,035
|
)
|
|
|
2,406,729
|
|
Issuance of preference shares at A$0.40 per share for cash in
December 2003
|
|
|
10,210,926
|
|
|
|
4,076,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,076,641
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss for period from inception to December 31, 2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(416,871
|
)
|
|
|
|
|
|
|
(416,871
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(188,877
|
)
|
|
|
(188,877
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(605,748
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2003
|
|
|
10,210,926
|
|
|
|
4,076,641
|
|
|
|
43,533,269
|
|
|
|
4,353
|
|
|
|
2,320,277
|
|
|
|
(286,737
|
)
|
|
|
(236,912
|
)
|
|
|
5,877,622
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(168,669
|
)
|
|
|
|
|
|
|
(168,669
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(153,615
|
)
|
|
|
(153,615
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(322,284
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2004
|
|
|
10,210,926
|
|
|
|
4,076,641
|
|
|
|
43,533,269
|
|
|
|
4,353
|
|
|
|
2,320,277
|
|
|
|
(455,406
|
)
|
|
|
(390,527
|
)
|
|
|
5,555,338
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(128,960
|
)
|
|
|
|
|
|
|
(128,960
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,571
|
|
|
|
226,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97,611
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of stock options issued to employees
|
|
|
|
|
|
|
|
|
|
|
79,745
|
|
|
|
8
|
|
|
|
30,562
|
|
|
|
|
|
|
|
|
|
|
|
30,570
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2005
|
|
|
10,210,926
|
|
|
|
4,076,641
|
|
|
|
43,613,014
|
|
|
|
4,361
|
|
|
|
2,350,839
|
|
|
|
(584,366
|
)
|
|
|
(163,956
|
)
|
|
|
5,683,519
|
|
Issuance of preference shares at A$0.45 per share for cash
|
|
|
30,176,036
|
|
|
|
12,624,795
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,624,795
|
|
Conversion of preference shares to ordinary shares
|
|
|
(40,386,962
|
)
|
|
|
(16,701,436
|
)
|
|
|
40,386,962
|
|
|
|
4,039
|
|
|
|
16,697,397
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of ordinary shares at A$0.50 per share in private
placement to American institutional and sophisticated investors
in December 2006, net of issuance costs
|
|
|
|
|
|
|
|
|
|
|
8,000,000
|
|
|
|
800
|
|
|
|
3,999,200
|
|
|
|
|
|
|
|
|
|
|
|
4,000,000
|
|
Issuance of ordinary shares at A$0.50 per share in a public
offering in Australia and a concurrent placement in the US to
institutional and sophisticated investors in December 2006, net
of issuance costs
|
|
|
|
|
|
|
|
|
|
|
36,000,000
|
|
|
|
3,600
|
|
|
|
15,638,963
|
|
|
|
|
|
|
|
|
|
|
|
15,642,563
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,955,661
|
)
|
|
|
|
|
|
|
(2,955,661
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(134,356
|
)
|
|
|
(134,356
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,090,017
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock option expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
421,067
|
|
|
|
|
|
|
|
|
|
|
|
421,067
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2006
|
|
|
|
|
|
|
|
|
|
|
127,999,976
|
|
|
|
12,800
|
|
|
|
39,107,466
|
|
|
|
(3,540,027
|
)
|
|
|
(298,312
|
)
|
|
|
35,281,927
|
|
Issuance of ordinary shares at A$1.20 per share, net of issuance
costs
|
|
|
|
|
|
|
|
|
|
|
28,538,362
|
|
|
|
2,854
|
|
|
|
32,515,938
|
|
|
|
|
|
|
|
|
|
|
|
32,518,792
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8,817,238
|
)
|
|
|
|
|
|
|
(8,817,238
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(8,817,238
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of stock options issued to employees
|
|
|
|
|
|
|
|
|
|
|
420,474
|
|
|
|
42
|
|
|
|
148,386
|
|
|
|
|
|
|
|
|
|
|
|
148,428
|
|
Stock option expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
617,715
|
|
|
|
|
|
|
|
|
|
|
|
617,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
156,958,812
|
|
|
|
15,696
|
|
|
|
72,389,505
|
|
|
|
(12,357,265
|
)
|
|
|
(298,312
|
)
|
|
|
59,749,624
|
|
Transaction costs on shares issued in 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(16,663
|
)
|
|
|
|
|
|
|
|
|
|
|
(16,663
|
)
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,995,886
|
)
|
|
|
|
|
|
|
(11,995,886
|
)
|
Foreign currency translation reserve, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,995,886
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of stock options issued to employees
|
|
|
|
|
|
|
|
|
|
|
18,124
|
|
|
|
2
|
|
|
|
5,045
|
|
|
|
|
|
|
|
|
|
|
|
5,047
|
|
Stock option expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
156,976,936
|
|
|
|
15,698
|
|
|
|
72,377,887
|
|
|
|
(24,353,151
|
)
|
|
|
(298,312
|
)
|
|
|
47,742,122
|
|
Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,430,463
|
|
|
|
|
|
|
|
1,430,463
|
|
Loss on derivatives and hedges, net of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(47,412
|
)
|
|
|
(47,412
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,383,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise of stock options issued to employees
|
|
|
|
|
|
|
|
|
|
|
138,327
|
|
|
|
14
|
|
|
|
78,984
|
|
|
|
|
|
|
|
|
|
|
|
78,998
|
|
Shares issued to employees
|
|
|
|
|
|
|
|
|
|
|
40,670
|
|
|
|
4
|
|
|
|
69,948
|
|
|
|
|
|
|
|
|
|
|
|
69,952
|
|
Stock option expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,078,771
|
|
|
|
|
|
|
|
|
|
|
|
1,078,771
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
157,155,933
|
|
|
|
15,716
|
|
|
|
73,605,590
|
|
|
|
(22,922,688
|
)
|
|
|
(345,724
|
)
|
|
|
50,352,894
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note
|
|
|
|
|
Note Common stock has a par value of US$0.0001.
All share and per share amounts from inception
to December 31, 2006 presented have been retroactively
adjusted to give effect to a stock split undertaken in 2006. The
par value of common stock was altered after the share split |
See accompanying notes to the financial statements.
F-5
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Cash flows from operating activities provided by/(used
in):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit/(loss)
|
|
|
(22,922,688
|
)
|
|
|
1,430,463
|
|
|
|
(11,995,886
|
)
|
|
|
(8,817,238
|
)
|
Adjustments to reconcile net profit/(loss) to net cash provided
by/(used in) operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net exchange difference
|
|
|
1,102,572
|
|
|
|
|
|
|
|
|
|
|
|
983,991
|
|
Depreciation and impairment of plant & equipment
|
|
|
7,132,568
|
|
|
|
2,851,285
|
|
|
|
2,266,847
|
|
|
|
708,699
|
|
Share based payments expense
|
|
|
3,078,661
|
|
|
|
1,078,771
|
|
|
|
961,108
|
|
|
|
617,715
|
|
Loss on fixed assets disposal
|
|
|
211,343
|
|
|
|
60,658
|
|
|
|
34,207
|
|
|
|
116,478
|
|
Change in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory
|
|
|
(305,124
|
)
|
|
|
(305,124
|
)
|
|
|
486,633
|
|
|
|
(486,633
|
)
|
Accounts receivables
|
|
|
(1,053,698
|
)
|
|
|
(114,713
|
)
|
|
|
439,691
|
|
|
|
(931,864
|
)
|
Prepaid expenses and other current assets
|
|
|
333,059
|
|
|
|
141,331
|
|
|
|
191,728
|
|
|
|
|
|
Accrued income
|
|
|
(108,855
|
)
|
|
|
|
|
|
|
(38,494
|
)
|
|
|
31,786
|
|
Income tax payable
|
|
|
|
|
|
|
|
|
|
|
(18,000
|
)
|
|
|
(145,000
|
)
|
Deferred revenue
|
|
|
290,904
|
|
|
|
290,904
|
|
|
|
|
|
|
|
|
|
Employee entitlements
|
|
|
683,476
|
|
|
|
50,192
|
|
|
|
264,286
|
|
|
|
5,835
|
|
Accounts payable and accrued expenses
|
|
|
1,875,921
|
|
|
|
383,389
|
|
|
|
267,494
|
|
|
|
146,957
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by/(used in) operating activities
|
|
|
(9,681,861
|
)
|
|
|
5,867,156
|
|
|
|
(7,140,386
|
)
|
|
|
(7,769,274
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds/(purchases) from sale of investment securities
|
|
|
|
|
|
|
|
|
|
|
3,123,501
|
|
|
|
(3,123,501
|
)
|
Instalment payments to acquire plant and equipment
|
|
|
(5,762,043
|
)
|
|
|
(2,145,808
|
)
|
|
|
(3,616,235
|
)
|
|
|
|
|
Purchases of property, plant and equipment
|
|
|
(21,588,097
|
)
|
|
|
(844,199
|
)
|
|
|
(5,978,685
|
)
|
|
|
(9,058,265
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(27,350,140
|
)
|
|
|
(2,990,007
|
)
|
|
|
(6,471,419
|
)
|
|
|
(12,181,766
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross proceeds from share issue
|
|
|
73,517,472
|
|
|
|
|
|
|
|
|
|
|
|
34,246,043
|
|
Transaction costs on share issue
|
|
|
(4,099,870
|
)
|
|
|
|
|
|
|
(16,663
|
)
|
|
|
(1,727,251
|
)
|
Proceeds from borrowings
|
|
|
479,673
|
|
|
|
479,673
|
|
|
|
|
|
|
|
|
|
Repayment of borrowings
|
|
|
(479,673
|
)
|
|
|
(479,673
|
)
|
|
|
|
|
|
|
|
|
Proceeds from stock options exercised
|
|
|
263,043
|
|
|
|
78,998
|
|
|
|
5,047
|
|
|
|
148,428
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by/(used in) financing activities
|
|
|
69,680,645
|
|
|
|
78,998
|
|
|
|
(11,616
|
)
|
|
|
32,667,220
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase/(decrease) in cash and cash equivalents
|
|
|
32,648,644
|
|
|
|
2,956,147
|
|
|
|
(13,623,421
|
)
|
|
|
12,716,180
|
|
Cash and cash equivalent at beginning of period
|
|
|
|
|
|
|
28,334,864
|
|
|
|
41,958,285
|
|
|
|
30,184,756
|
|
Effect of exchange rate fluctuations on the balances of cash
held in foreign currencies
|
|
|
(1,357,633
|
)
|
|
|
|
|
|
|
|
|
|
|
(942,651
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
|
31,291,011
|
|
|
|
31,291,011
|
|
|
|
28,334,864
|
|
|
|
41,958,285
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the financial statements
F-6
(for the years ended December 31, 2007, 2008 and 2009
and for the period from inception
(September 14, 2001) to December 31, 2009)
|
|
(1)
|
Organization
of the Company
|
Universal Biosensors, Inc. (the Company) was
incorporated on September 14, 2001 in the United States,
and its wholly owned subsidiary and operating vehicle, Universal
Biosensors Pty Ltd, was incorporated in Australia on
September 21, 2001. Collectively, the Company and its
wholly owned subsidiary Universal Biosensors Pty Ltd are
referred to as Universal Biosensors or the
Group. The Companys shares of common stock in
the form of CHESS Depositary Interests (CDIs) were
quoted on the Australian Securities Exchange (ASX)
on December 13, 2006 following the initial public offering
in Australia of the Companys shares of common stock. Our
securities are not currently traded on any other public market.
The Company is a specialist medical diagnostics company focused
on the research and development, manufacture and
commercialization of a range of in vitro diagnostic tests
for consumer and professional
point-of-care
use. The blood test devices we are developing comprise a novel
disposable test strip and a reusable meter. These simple to use
portable test devices require a finger prick of blood and are
designed to be used by the patient
(point-of-care)
to provide accurate and quick results to enable new treatment or
an existing treatment to be immediately reviewed.
Universal Biosensors has rights to an extensive patent portfolio
comprising certain patent applications owned by its wholly owned
Australian subsidiary, Universal Biosensors Pty Ltd, and a large
number of patents and patent applications licensed to us by
LifeScan, Inc. (LifeScan), an affiliate of
Johnson & Johnson Corporation.
Universal Biosensors has developed a blood glucose test (used in
the management of diabetes) with LifeScan which was launched by
LifeScan in The Netherlands in January 2010. Subject to mutually
agreed terms, we intend to develop other tests in the field of
diabetes and blood glucose management generally, for LifeScan.
On October 29, 2007 Universal Biosensors entered into a
Master Services and Supply Agreement which contains the terms
pursuant to which Universal Biosensors Pty Ltd would provide
certain services in the field of blood glucose monitoring to
LifeScan and would generally act as a non-exclusive manufacturer
of an original version of the initial blood glucose test strips
we developed for LifeScan (Master Services and Supply
Agreement). On December 11, 2008, Universal
Biosensors entered into an additional services addendum to
provide manufacturing process support to assist LifeScan to
establish LifeScans own manufacturing line for blood
glucose test strips at a location of its choosing. On
December 11, 2008, the Master Services and Supply Agreement
was amended to reflect certain definitional matters in the
document. On May 15, 2009, the agreement was amended and
restated to incorporate the amendments made in December 2008 and
to update the commercial terms of the agreement to reflect a
change from the original version of the initial blood glucose
test strip to an enhanced version of the initial blood glucose
test strip. The Master Services and Supply Agreement is
structured as an umbrella agreement which enables LifeScan and
the Company to enter into a series of additional arrangements
for the supply by the Company of additional services and
products in the field of blood glucose monitoring. The Company
commenced manufacture of the initial blood glucose test strips
in its facility in Corporate Avenue, Rowville, Melbourne, in
December 2009.
Additionally, the Group will continue to provide research and
development services to LifeScan in the area of diabetes
management to extend and develop the glucose sensor technology
owned by LifeScan under a development and research agreement
(Development and Research Agreement).
The Company uses its technology base to develop other
electrochemical-cell based tests. The Company does not currently
intend to establish its own sales and marketing force to
commercialize any of the non-blood glucose products which it
develops. Rather, the Companys efforts are focused on
establishing collaborative partnerships for the tests derived
from the platform. The Company is developing a C-reactive
protein test on
F-7
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
its dry immunoassay platform to assist in the diagnosis and
management of inflammatory conditions. The Company is also
developing a D-dimer test for detection and monitoring of
several conditions associated with thrombotic disease,
particularly deep venous thrombosis (clots in the leg) and
pulmonary embolism (clots in the lung). The Company has also
undertaken development work on a prothrombin time test for
monitoring the therapeutic range of the anticoagulant, warfarin,
based on measuring activity of the enzyme thrombin. The Company
has successfully taken the prothrombin time test to a point
where the Company considers it has been significantly
technically de-risked. The Company does not currently propose to
complete the remaining development steps for this test until the
path to commercialization for this product is assured and the
partnering efforts for the test have been successful.
All business operations and research and development activities
are undertaken in Melbourne, Australia by the Companys
wholly owned subsidiary, Universal Biosensors Pty Ltd, under the
Master Services and Supply Agreement and a research and
development
sub-contract
and
sub-license
agreement between Universal Biosensors Pty Ltd and the Company.
The Group is considered a development stage enterprise as it is
not generating significant revenue or positive cash flows from
its commercial manufacturing operations.
|
|
(2)
|
Basis of
Presentation
|
These financial statements are presented in accordance with
accounting principles generally accepted in the United States of
America (U.S. GAAP). All amounts are expressed
in Australian dollars (AUD or A$) unless
otherwise stated.
The Companys financial statements have been prepared
assuming the Company will continue as a going concern. The
Company made a net profit of A$1,430,463 for the year ended
December 31, 2009. The Company recognized a net loss of
A$11,995,886 and A$8,817,238 in the years ended
December 31, 2008 and 2007, respectively. The
Companys accumulated losses from inception to
December 31, 2009 are A$22,922,688. The Companys
ability to generate future profits is dependant on its ability
to generate sufficient revenues under the Master Services and
Supply Agreement and/ or from the sale of any of its own
products.
|
|
(3)
|
Summary
of Significant Accounting Policies
|
Principles
of Consolidation
The consolidated financial statements include the financial
statements of the Company and its wholly owned subsidiary
Universal Biosensors Pty Ltd. All intercompany balances and
transactions have been eliminated on consolidation.
Use of
Estimates
The preparation of the consolidated financial statements
requires management of the Company to make a number of estimates
and assumptions relating to the reported amount of assets and
liabilities and the disclosure of contingent assets and
liabilities at the date of the consolidated financial statements
and the reported amounts of revenues and expenses during the
period. Significant items subject to such estimates and
assumptions include the carrying amount of property, plant and
equipment, deferred income taxes, asset retirement obligations
and obligations related to employee benefits. Actual results
could differ from those estimates.
F-8
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Cash &
Cash Equivalents
The Company considers all highly liquid investments purchased
with an initial maturity of three months or less to be cash
equivalents. For cash and cash equivalents, the carrying amount
approximates fair value due to the short maturity of those
instruments.
Short-Term
Investments
(Held-to-maturity)
Short-term investments constitute all highly liquid investments
with term to maturity from three months to twelve months. The
carrying amount of short-term investments is equivalent to its
fair value.
Concentration
of Credit Risk and Other Risks and Uncertainties
Cash and cash equivalents consists of financial instruments that
potentially subject the Company to concentration of credit risk
to the extent of the amount recorded on the balance sheet. The
Companys cash and cash equivalents are invested with two
of Australias four largest banks. The Company is exposed
to credit risk in the event of default by the banks holding the
cash or cash equivalents to the extent of the amount recorded on
the balance sheets. The Company has not experienced any losses
on its deposits of cash and cash equivalents.
Product candidates developed by the Company may require
approvals or clearances from the U.S. Food and Drug
Administration or other international regulatory agencies prior
to commercialized sales. There can be no assurance that the
Companys product candidates will receive any of the
required approvals or clearances. If the Company was denied
approval or clearance of such approval was delayed, it may have
a material adverse impact on the Company.
Derivative
Instruments and Hedging Activities
Derivative
financial instruments
The Company uses derivative financial instruments to hedge its
exposure to foreign exchange arising from operating, investing
and financing activities. The Company does not hold or issue
derivative financial instruments for trading purposes. However,
derivatives that do not qualify for hedge accounting are
accounted for as trading instruments.
Derivative financial instruments are recognized initially at
fair value. Subsequent to initial recognition, derivative
financial instruments are stated at fair value. The gain or loss
on remeasurement to fair value is recognized immediately in the
income statement. However, where derivatives qualify for hedge
accounting, recognition of any resultant gain or loss depends on
the nature of the item being hedged.
Cash flow
hedges
Exposure to foreign exchange risks arises in the normal course
of the Companys business and it is the Companys
policy to use forward exchange contracts to hedge anticipated
sales and purchases in foreign currencies. The amount of forward
cover taken is in accordance with approved policy and internal
forecasts.
Where a derivative financial instrument is designated as a hedge
of the variability in cash flows of a recognized asset or
liability, or a highly probable forecast transaction, the
effective part of any gain or loss on the derivative financial
instrument is recognized directly in equity. When the forecast
transaction subsequently results in the recognition of a
non-financial asset or non-financial liability, the associated
cumulative gain or loss is removed from equity and included in
the initial cost or other carrying amount of the non-financial
asset
F-9
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
or liability. If a hedge of a forecast transaction subsequently
results in the recognition of a financial asset or a financial
liability, then the associated gains and losses that were
recognized directly in equity are reclassified into the income
statement in the same period or periods during which the asset
acquired or liability assumed affects the income statement.
For cash flow hedges, other than those covered by the preceding
statement, the associated cumulative gain or loss is removed
from equity and recognized in the income statement in the same
period or periods during which the hedged forecast transaction
affects the income statement and on the same line item as that
hedged forecast transaction. The ineffective part of any gain or
loss is recognized immediately in the income statement.
When a hedging instrument expires or is sold, terminated or
exercised, or the Company revokes designation of the hedge
relationship but the hedged forecast transaction is still
probable to occur, the cumulative gain or loss at that point
remains in equity and is recognized in accordance with the above
policy when the transaction occurs. If the hedged transaction is
no longer expected to take place, then the cumulative unrealized
gain or loss recognized in equity is recognized immediately in
the income statement.
Inventory
Inventories are stated at the lower of cost or market value.
Inventories are principally determined under the average cost
method.
Receivables
Trade accounts receivable are recorded at the invoiced amount
and do not bear interest. The allowance for doubtful accounts is
the best estimate of the amount of probable credit losses in the
existing accounts receivable. The allowance is determined based
on a review of individual accounts for collectibility, generally
focusing on those accounts that are past due. The current year
expense to adjust the allowance for doubtful accounts, if any,
is recorded within general and administrative expenses in the
consolidated statements of operations. Account balances are
charged against the allowance when it is probable the receivable
will not be recovered.
Property,
Plant, and Equipment
Property, plant, and equipment are recorded at acquisition cost,
less accumulated depreciation.
Depreciation on plant and equipment is calculated using the
straight-line method over the estimated useful lives of the
assets. The estimated useful life of machinery and equipment is
3 to 10 years. Leasehold improvements are amortized on the
straight-line method over the shorter of the remaining lease
term or estimated useful life of the asset. Maintenance and
repairs are charged to operations as incurred and include minor
corrections and normal services and does not include items of a
capital nature.
The Company receives Victorian government grant monies under a
grant agreement to support the establishment of a medical
diagnostic manufacturing facility in Victoria through the
purchase of plant and equipment. Plant and equipment is
presented net of the government grant. The grant monies are
recognized against the acquisition costs of the related plant
and equipment as and when the related assets are purchased.
Grant monies received in advance of the relevant expenditure are
treated as deferred income and included in Current
Liabilities on the balance sheet as the Company does not
control the monies until the relevant expenditure has been
incurred. Grants due to the Company under the grant agreement
are recorded as Currents Assets on the balance sheet.
F-10
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Research
and Development
Research and development expenses consist of costs incurred to
further the Groups research and development activities and
include salaries and related employee benefits, costs associated
with clinical trial and preclinical development, regulatory
activities, research-related overhead expenses, costs associated
with the manufacture of clinical trial material, costs
associated with developing a commercial manufacturing process,
costs for consultants and related contract research, facility
costs and depreciation. Research and development costs are
expensed as incurred.
The Group receives Australian Commonwealth government grant
funding under an R&D Start Grant Agreement as compensation
for expenses incurred in respect of certain research activities
into dry chemistry immunosensors. Such grants reduce the related
research and development expenses as and when the relevant
research expenses are incurred. Grants received in advance of
incurring the relevant expenditure are treated as deferred
research grants and included in Current Liabilities
on the balance sheet as the Group has not earned these amounts
until the relevant expenditure has been incurred. Grants due to
the Group under research agreements are included in
Current Assets as accrued income on the balance
sheet.
Research and development expenses for years ended
December 31, 2009, 2008, 2007 and for period from inception
to December 31, 2009 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Research and development expenses
|
|
|
46,180,154
|
|
|
|
14,898,072
|
|
|
|
11,885,871
|
|
|
|
8,029,729
|
|
Research grants received recognized against related research and
development expenses
|
|
|
(2,366,063
|
)
|
|
|
|
|
|
|
(300,613
|
)
|
|
|
(872,513
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses as reported
|
|
|
43,814,091
|
|
|
|
14,898,072
|
|
|
|
11,585,258
|
|
|
|
7,157,216
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A significant portion of our research and development expenses
relate to activities undertaken to achieve the deliverable
included in milestone payment.
Income
Taxes
The Company applies ASC 740 Income Taxes (formerly
Statement of Financial Accounting Standards
No. 109 Accounting for Income Taxes) which
establishes financial accounting and reporting standards for the
effects of income taxes that result from a companys
activities during the current and preceding years. Deferred tax
assets and liabilities are recognized for the future tax
consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities
and their respective tax bases and operating loss and tax credit
carry forwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in
the period that includes the enactment date.
Where it is more likely than not that some portion or all of the
deferred tax assets will not be realized the deferred tax assets
are reduced by a valuation allowance. The valuation allowance is
sufficient to reduce the
F-11
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
deferred tax assets to the amount that is more likely than not
to be realized. A reconciliation of the valuation and qualifying
accounts is attached as Schedule ii.
The Company adopted ASC 740 Income Taxes (formerly
FASB Interpretation FIN No. 48 - Accounting for
Uncertainty in Income Taxes) effective January 1, 2007
which has not had a material impact on the Companys
consolidated financial statements.
We are subject to income taxes in the United States and
Australia. U.S. federal income tax returns up to the 2008
financial year have been lodged. Internationally, consolidated
income tax returns up to the 2008 financial year have been
lodged.
Asset
Retirement Obligations
Asset retirement obligations (ARO) are legal
obligations associated with the retirement and removal of
long-lived assets. ASC 410 Asset Retirement and
Environmental Obligations (formerly
SFAS No. 143 Accounting for Asset
Retirement Obligations) requires entities to record the fair
value of a liability for an asset retirement obligation when it
is incurred. When the liability is initially recorded, the
Company capitalizes the cost by increasing the carrying amounts
of the related property, plant and equipment. Over time, the
liability increases for the change in its present value, while
the capitalized cost depreciates over the useful life of the
asset. The Company derecognizes ARO liabilities when the related
obligations are settled.
The ARO is in relation to our premises wherein in accordance
with the terms of the lease, the lessee has to restore part of
the building upon vacating the premises.
Our overall ARO changed as follows:
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
A$
|
|
|
A$
|
|
|
Movement in ARO
|
|
|
|
|
|
|
|
|
Opening balance at January 1
|
|
|
1,699,133
|
|
|
|
1,566,892
|
|
New obligations
|
|
|
|
|
|
|
|
|
Accretion expense
|
|
|
143,414
|
|
|
|
132,241
|
|
|
|
|
|
|
|
|
|
|
Ending balance at December 31
|
|
|
1,842,547
|
|
|
|
1,699,133
|
|
|
|
|
|
|
|
|
|
|
Fair
Value of Financial Instruments
The carrying value of all current assets and current liabilities
approximates fair value because of their short-term nature. The
estimated fair value of all other amounts has been determined by
using available market information and appropriate valuation
methodologies.
Impairment
of Long-Lived Assets
The Company reviews its capital assets, including patents and
licenses, for impairment whenever events or changes in business
circumstances indicate that the carrying amount of the assets
may not be fully recoverable. In performing the review, the
Company estimates undiscounted cash flows from products under
development that are covered by these patents and licenses. An
impairment loss would be recognized when estimated undiscounted
future cash flows expected to result from the use of the asset
and its eventual disposition is less than the carrying amount of
the asset. If the evaluation indicates that the carrying value
of
F-12
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
an asset is not recoverable from its undiscounted cash flows, an
impairment loss is measured by comparing the carrying value of
the asset to its fair value, based on discounted cash flows.
Australian
Goods and Services Tax (GST)
Revenues, expenses and assets are recognized net of the amount
of associated GST, unless the GST incurred is not recoverable
from the taxation authority. In this case it is recognized as
part of the cost of acquisition of the asset or as part of the
expense. Receivables and payables are stated inclusive of the
amount of GST receivable or payable. The net amount of GST
recoverable from, or payable to, the taxation authority is
included with other receivables or payables in the balance
sheet. Cash flows are presented on a gross basis.
Borrowings
In March 2009, Universal Biosensors Pty Ltd entered into an
arrangement with Pacific Premium Funding Pty Limited to fund the
Groups insurance premium. The total amount financed was
A$479,673 at inception. Interest was charged at a rate of 2% per
annum and the short-term borrowing was repayable over an eight
month period. The short-term borrowing was secured by the
insurance premium refund. The borrowing was fully repaid in
August 2009.
Revenue
Recognition
Revenue
from products and services and milestone payment
The revenue from products and the milestone payment are part of
an arrangement with multiple deliverables. On October 29,
2007 Universal Biosensors entered into a Master Services and
Supply Agreement which contains the terms pursuant to which
Universal Biosensors Pty Ltd would provide certain services in
the field of blood glucose monitoring to LifeScan and would
generally act as a non-exclusive manufacturer of an original
version of the initial blood glucose test strips we developed
for LifeScan. On May 15, 2009, the agreement was amended
and restated to incorporate certain amendments made in December
2008 and to update the commercial terms of the agreement to
reflect a change to an enhanced version of the blood glucose
test strip. The Master Services and Supply Agreement is
structured as an umbrella agreement which enables LifeScan and
us to enter into a series of additional arrangements for the
supply by us of additional services and products in the field of
blood glucose monitoring.
The Master Services and Supply Agreement may be terminated as a
result of a party defaulting on its material obligations, a
party becoming insolvent, at LifeScans option after paying
a lump sum service fee, or as a result of other factors detailed
in the Master Services and Supply Agreement.
Revenue received under the Master Services and Supply Agreement
was recognised in accordance with ASU
No. 2009-13,
which was issued by the FASB in October 2009 and is effective
prospectively for revenue arrangements entered into or
materially modified in fiscal years beginning on or after
June 15, 2010. Early adoption and retrospective application
are also permitted. The Company elected to early adopt the
provisions of ASU
No. 2009-13
in fiscal 2009 as there was a material modification to the
Master Services and Supply Agreement in May 2009. Since there
were no amounts recognized in the financial statements relating
to the deliverables under the arrangement for the previous three
quarters, there is no impact on previously filed financial
statements during the year.
F-13
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
The deliverables under the arrangement described above are as
follows:
|
|
|
|
|
milestone payment. The Company received
a milestone payment of A$17,722,641 triggered by the first grant
to LifeScan of regulatory clearance to sell the blood glucose
product;
|
|
|
|
contract manufacturing. One of two
pricing methodologies will apply depending on whether we are
manufacturing above or below a specified quantity of blood
glucose tests strips in a quarter. As we produced less than the
specified quantity of test strips per quarter, we are considered
to be in the interim costing period. In the interim
costing period, the Company is establishing its commercial scale
manufacturing and therefore is not expected to generate any
profit, but is expected to recover most of its glucose
manufacturing costs. As volumes increase beyond the specified
quantity of blood glucose test strips sold per quarter, the
interim costing period will cease to apply and a different
pricing methodology will apply, at which time we expect to be
profitable in the sale of blood glucose test strips; and
|
|
|
|
product enhancement. A service fee
based on the number of strips sold by LifeScan is payable to us
as an ongoing reward for our efforts to enhance the product.
|
Milestone payment is considered a separate unit of accounting as
it has stand alone value to LifeScan on the basis that
subsequent to receiving regulatory approval to market this
product, LifeScan can manufacture and sell the product on an
ongoing basis without involving us. There are no other
activities related to this deliverable and consideration is
contingent upon regulatory approval. The best estimate of
selling price is commensurate with the efforts expended over a
number of years plus a reasonable margin to assist LifeScan to
achieve the agreed deliverable.
Contract manufacturing of the strip by us is considered a
separate unit of accounting as it has stand alone value to
LifeScan as these will be on-sold by LifeScan to its customers.
We generally act only as a non-exclusive manufacturer of the
blood glucose test strips we developed for LifeScan. There are
no general rights of return of the delivered item. There are no
other activities related to this deliverable. Consideration is
contingent upon receiving firm purchase orders from LifeScan.
The best estimate of selling price for contract manufacturing
and ongoing efforts to enhance the product has been based on
expected costs plus a reasonable margin at normalized volumes.
The ongoing efforts to enhance the product is considered a
separate unit of accounting as it has stand alone value to
LifeScan as it increases the marketability of the product. There
are no general rights of return of the delivered item. There are
no other activities related to this deliverable. Consideration
is contingent upon the sale of the strips by LifeScan. The best
estimate of selling price for this deliverable is based on the
expected efforts required to achieve this deliverable plus a
reasonable margin.
All consideration within the contract is contingent. The
remaining undelivered items are not priced at a significant
incremental discount to the delivered items. Revenue for each
deliverable will be recognized as each contingency is met and
the consideration becomes fixed and determinable. Milestone
payment is considered to be a substantive payment and the entire
amount has been recognized as revenue when the regulatory
approval was received. The regulatory approval to market the
initial blood glucose product was received on November 4,
2009. Revenue for contract manufacturing is recognised in
accordance with generally accepted accounting principles as
outlined in ASC
605-10-S99
(formerly Staff Accounting
Bulletin No. 104 Revenue Recognition),
which requires that four basic criteria be met before revenue
can be recognized: (i) persuasive evidence of an
arrangement exists; (ii) the price is fixed or
determinable; (iii) collectability is reasonably assured;
and (iv) product delivery has occurred or services have
been rendered. Revenue for
F-14
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
ongoing efforts to enhance the product is also recognised in
accordance with ASC
605-10-S99
when the final product is sold by LifeScan.
Management has concluded that the core operations of the Company
are expected to be the research and development activities,
commercial manufacture of approved medical or testing devices
and the provision of services such as those specified under the
Master Services and Supply Agreement including contract research
work. The Companys ultimate goal is to utilize the
underlying technology and skill base for the development of a
marketable product that the Company will manufacture. The
Company considers the income received from milestone payment,
contract manufacturing and the ongoing efforts to enhance the
product indicative of its core operating activities or revenue
producing goals of the Company, and as such have accounted for
this income as Net sales and gross revenues per
Statement of Financial Accounting Concepts No. 6, Elements
of Financial Statements and SEC
Regulation S-X
Article 5-03.
We perform other services for LifeScan based on their
requirements. There are different arrangements for each service
being provided. Revenue recognition principles are assessed for
each new contractual arrangement and the appropriate accounting
is determined for each service. Revenues received in advance of
performing the services are treated as deferred income and
included in liabilities on the balance sheet as the Group has
not earned these amounts until the relevant services have been
performed. We recognize revenue from these services, other than
as already detailed above, on the following basis:
(1) as we perform the services
Under the terms of our arrangement with LifeScan, we provide
certain services relating to the blood glucose field. In
accordance with ASC 605 Revenue Recognition
(formerly Emerging Issues Task Force (EITF) Issue
99-19),
revenue has been recognized on a gross basis as the Company has
earned revenue from the provision of services. Other factors
which management considered, which support the gross basis of
revenue recognition are as follows:
|
|
|
|
|
the Company was responsible for providing the service and was
also the primary obligor with respect to purchasing goods and
services from third party suppliers which in turn were used to
provide services to LifeScan;
|
|
|
|
the Company had unmitigated general inventory risk;
|
|
|
|
the Company had credit risk; and
|
|
|
|
pricing was not fixed but determined by the level of activity.
|
The transaction with LifeScan satisfies the revenue recognition
criteria outlined in ASC 605 (formerly Staff Accounting
Bulletin 101/104). The principles of revenue recognition in
ASC 605 have all been satisfied; services were performed by us
which were supported by purchase orders issued by LifeScan on a
regular basis, collection was assured, delivery of the services
had occurred and the amount was objectively determined.
(2) on a proportional performance basis where revenues is
related to costs incurred in providing the services required
under the contract
The Company has been providing services to LifeScan to enable
LifeScan to establish its own manufacturing line for the blood
glucose sensor strips. The proportional performance method has
been used to recognize revenue. We believe this method is
appropriate as the contract amount was determined prior to the
commencement of the service, LifeScan receives value as the
services are performed and LifeScan need not
F-15
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
re-perform the services that it has already received from the
Company should the service arrangement be terminated.
Research
and development income
On April 1, 2002, the Company and LifeScan entered into a
Development and Research Agreement pursuant to which the Company
agreed to undertake contract research and development for
LifeScan in the area of diabetes management to extend and
develop the glucose sensor technology owned by LifeScan. The
research and development activities are supervised by a steering
committee comprised of representatives from both the Company and
LifeScan. In consideration of us undertaking the research and
development activities, LifeScan makes quarterly payments to the
Company. The Development and Research Agreement automatically
renews for successive one year periods on the same terms and
conditions unless either LifeScan or the Company gives written
notice of termination not less than nine months prior to the end
of the relevant one year period (in which case the agreement
terminates at the end of the relevant one year period), or the
Development and Research Agreement is otherwise terminated in
accordance with its terms. LifeScan owns all intellectual
property developed by the Group under the Development and
Research Agreement and the Group receives a license to such
intellectual property outside of the LifeScan Field.
The Development and Research Agreement provides details of the
amount to be charged to LifeScan each year for the provision of
research and development services. Income is recognized ratably
over the period to which it relates and when the amount of the
payment can be reliably measured and collectibility is
reasonably assured. For fiscal 2009, LifeScan paid the Company
A$1,337,125 under the Development and Research Agreement. For
fiscal 2010, the Development and Research Agreement sets out a
range of values that the Company or Universal Biosensors Pty Ltd
will be paid depending on the level of research and development
services required by LifeScan. In subsequent years, the steering
committee will recommend the level of funding consistent with
LifeScans requirements.
The income derived from the Development and Research Agreement
is recognized over the period in which the agreed upon research
services are completed. The Company recognizes income for
accounting purposes ratably over the annual grant period. Under
the Development and Research Agreement, the Company is not
matching the income to a specific expenditure but instead to a
specified period of research. The annual research and
development income received from LifeScan is agreed upon with
LifeScan from time to time and is subject to the Company
continuing its research and development activities in the blood
glucose area, the provision of quarterly reports and other
obligations under the Development and Research Agreement. The
Company has and continues to satisfy the requirements of the
Development and Research Agreement.
Income recognized pursuant to the Development and Research
Agreement has all been received in the financial years stated.
No upfront payments have been received from LifeScan. There are
no claw backs or repayment obligations relating to the
Development and Research Agreement.
Fee
Income
Pursuant to the agreement with LifeScan, consideration of
A$1,131,222 was paid in 2008 by LifeScan in consideration of the
grant of rights by us. The grant of rights to LifeScan included
a detailed written description of the Companys process for
the manufacture of the initial blood glucose product, including
all underlying know-how relevant to the process. Whilst the
non-refundable fee is part of an arrangement with multiple
deliverables, this fee and the deliverable associated with it
was considered a separate unit of accounting. There are no other
activities related to this deliverable and there is objective
and reliable evidence of the fair value of the undelivered
items. The fair value of the rights as determined by management
was
F-16
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
based on estimated market value of labour hours consumed in
writing up the documents relating to the rights. There are no
general rights of return of the delivered items. These rights
were internally generated and were carried at zero value within
our financial statements. The rights were transferred and the
consideration received in January 2008 at which time the service
requirements (granting of the rights) had been fully satisfied.
The grant of these rights is considered to be a discrete
earnings event as they are not linked in any way to the other
deliverables in the arrangement and there is a risk that the
other deliverables may not be achieved. The other deliverables
in the arrangement are primarily related to manufacturing and
the Companys ability to manufacture which can only occur
once regulatory approval is received to market the product.
Regulatory approval to market the product was only received in
November 2009 and up until that date there was a risk that
regulatory approval would not be obtained. Under the arrangement
we have with LifeScan, they have the option of terminating the
arrangement, which includes the rights for us to manufacture the
product. There was no such risk involved in fulfilling our
service requirements for the grant of rights as the service
requirements were completed and fully satisfied when the
consideration was received at which point the rights were
transferred to LifeScan. These rights have value to LifeScan as
they are able to use this information to build their own
manufacturing capability.
Management has concluded that the core operations of the Company
in the short term are expected to be research and development
activities and the commercial manufacture of approved medical or
testing devices and the provision of services such as those
specified under the Master Services and Supply Agreement. The
Companys ultimate goal is to utilize the underlying
technology and skill base for the development of other
marketable products that the Company will manufacture. The
Company considers the income received for the grant of rights is
not indicative of its core operating activities or revenue
producing goals of the Company, and as such have accounted for
this income as non-operating income per Statement of
Financial Accounting Concepts No. 6, Elements of Financial
Statements and SEC
Regulation S-X
Article 5-03.
Interest
revenue
Interest revenue is recognized as it accrues, taking into
account the effective yield on the financial asset.
Foreign
Currency
Functional
and reporting currency
Items included in the financial statements of each of the
Groups entities are measured using the currency of the
primary economic environment in which the entity operates
(the functional currency). The functional currency
of the Company and Universal Biosensors Pty Ltd is AUD for all
years presented.
The consolidated financial statements are presented using a
reporting currency of Australian dollars. Effective October
2008, the Company changed its reporting currency from
U.S. Dollars (USD) to AUD. Prior to October 2008, the
Company reported its consolidated balance sheet, statement of
operations and stockholders equity and cash flows in USD.
The related statements and corresponding notes for and prior to
December 31, 2007 have been revised to reflect Australian
Dollars as the reporting currency for comparison to the
financial results for the years ended December 31, 2008 and
2009. The change in reporting currency is to better reflect the
Companys performance and to improve investors
ability to compare the Companys financial results.
The functional currency of the Company for financial years up to
December 31, 2005 was determined by management to be USD.
This was based on the facts that the denomination of a
significant proportion of transactions and the major source of
finance were in USD.
F-17
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
In 2006, the Company expanded significantly its Australian based
research activities. At this time, all of the Companys
directors became residents in Australia. Currently, with the
exception of one director, all the other directors are
Australian residents. Most of the Companys expenditure on
research and development is Australian dollar denominated. It
also began planning for and successfully accomplished a capital
raising in Australian dollars and listed on the Australian Stock
Exchange. The majority of cash and other monetary assets now
held by the Company are denominated in Australian dollars.
Due to these changes in circumstance, management are of the view
that the functional currency of the Company changed in 2006 to
Australian dollars. This change was effective from
December 1, 2006. The difference in the foreign exchange
movements recognized in 2006 as a result of the change in
functional currency was A$44,430.
Transactions
and balances
Foreign currency transactions are translated into the functional
currency using the exchange rates prevailing at the dates of the
transactions. Foreign exchange gains and losses resulting from
the settlement of such transactions and from the translation at
year-end exchange rates of monetary assets and liabilities
denominated in foreign currencies are recognized in the
Statement of Operations.
The Company has recorded foreign currency transaction
gains/(losses) of (A$250,886), A$265,310, (A$210,382) and
(A$105,152) for each of the years ended December 31, 2009,
2008 and 2007 and the period from inception to December 31,
2009, respectively.
The results and financial position of all the Group entities
that have a functional currency different from the reporting
currency are translated into the reporting currency as follows:
|
|
|
|
|
assets and liabilities for each balance sheet item reported are
translated at the closing rate at the date of that balance sheet;
|
|
|
|
income and expenses for each income statement are translated at
average exchange rates (unless this is not a reasonable
approximation of the effect of the rates prevailing on the
transaction dates, in which case income and expenses are
translated at the dates of the transactions); and
|
|
|
|
all resulting exchange differences are recognized as a separate
component of equity.
|
On consolidation, exchange differences arising from the
translation of any net investment in foreign entities are taken
to the Foreign Currency Translation Reserve (FCTR).
Commitments
and Contingencies
Liabilities for loss contingencies, arising from claims,
assessments, litigation, fines, and penalties and other sources
are recorded when it is probable that a liability has been
incurred and the amount of the assessment can be reasonably
estimated.
Patent
and License Costs
Legal fees incurred for patent application costs have been
charged to expense and reported in research and development
expense.
F-18
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Clinical
Trial Expenses
Clinical trial costs are a component of research and development
expenses. These expenses include fees paid to participating
hospitals and other service providers, which conduct certain
testing activities on behalf of the Company. Depending on the
timing of payments to the service providers and the level of
service provided, the Company records prepaid or accrued
expenses relating to these costs.
These prepaid or accrued expenses are based on estimates of the
work performed under service agreements.
Leased
Assets
All of the Companys leases for the years ended
December 31, 2009, 2008 and 2007 are considered operating
leases. The costs of operating leases are charged to the
statement of operations on a straight-line basis over the lease
term.
Stock-based
Compensation
Prior to January 1, 2006, the Company applied ASC
718 Compensation Stock Compensation
(formerly Accounting Principles Board (APB) Opinion
No. 25 Accounting for Stock Issued to
Employees) and related interpretations, in accounting for its
fixed-plan stock options. For periods prior to January 1,
2006, the Company complied with the disclosure only provisions
of ASC 718 (formerly FASB Statement No. 123
Accounting for Stock-Based Compensation, or SFAS 123). No
stock-based employee compensation cost was reflected in net
income, as all options granted under those plans had an exercise
price equal to or greater than the market value of the
underlying common stock on the date of grant (or within
permitted discounted prices as it pertains to the Employee
Option Plan). Results for periods before January 1, 2006
have not been restated to reflect, and do not include the impact
of, ASC 718 (formerly FASB Statement No. 123(R)
Share Based Payment, or SFAS 123(R)).
As of January 1, 2006, the Company adopted ASC 718, using
the modified prospective method, which requires measurement of
compensation expense of all stock-based awards at fair value on
the date of grant and amortization of the fair value over the
vesting period of the award. The Company has elected to use the
straight-line method of amortization. Under the modified
prospective method, the provisions of ASC 718 apply to all
awards granted or modified after the date of adoption. In
addition, the unrecognized expense of awards not yet vested at
the date of adoption, determined under the original provisions
of ASC 718 shall be recognized in net income in the periods
after adoption. The fair value of stock options is determined
using the Trinomial Lattice model, which is consistent with
valuation techniques previously utilized for options in footnote
disclosures required under ASC 718, as amended by ASC 718
(formerly SFAS No. 148 Accounting for
Stock-Based Compensation Transition and Disclosure). Such value
is recognized as expense over the service period, net of
estimated forfeitures, using the straight-line method under ASC
718. There were no transitional adjustments on adoption of ASC
718.
Pension
Costs
The Company contributes to standard defined contribution
superannuation funds on behalf of all employees at nine percent
of each such employees salary. Superannuation is a
compulsory savings program whereby employers are required to pay
a portion of an employees remuneration to an approved
superannuation fund that the employee is typically not able to
access until they are retired. The Company permits
F-19
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
employees to choose an approved and registered superannuation
fund into which the contributions are paid. Contributions are
charged to the statement of operations as they become payable.
Net
Profit/(Loss) per Share and Anti-dilutive
Securities
Basic and diluted net profit/(loss) per share is presented in
conformity with ASC 260 Earnings per Share (formerly
Statement of Financial Accounting Standards
No. 128 Earnings Per Share). Basic and diluted
net profit/(loss) per share has been computed using the
weighted-average number of common shares outstanding during the
period. All periods presented in these financial statements have
been retroactively adjusted to give effect to the stock split in
December 2006 (note 11). Other than in a profit making
year, the potentially dilutive options issued under the
Universal Biosensors Employee Option Plan were not considered in
the computation of diluted net profit/(loss) per share because
they would be anti-dilutive given the Companys loss making
position.
Total
Comprehensive Income
The Company follows ASC 220 Comprehensive Income
(formerly SFAS No. 130 Reporting
Comprehensive Income (Loss)). Comprehensive income is defined as
the total change in shareholders equity during the period
other than from transactions with shareholders, and for the
Company, includes net income and cumulative translation
adjustments.
Recent
Accounting Pronouncements
In March 2008, the Financial Accounting Standards Board
(FASB) issued ASC 815 Derivative and
Hedging (formerly SFAS No. 161, Disclosures
about Derivative Instruments and Hedging Activities). The
new standard is intended to improve financial reporting about
derivative instruments and hedging activities by requiring
enhanced disclosures to enable investors to better understand
their effects on an entitys financial position, financial
performance, and cash flows. The Company adopted ASC 815
effective January 1, 2009 which has not had a material
impact on the Companys consolidated financial statements.
In January, 2009, the company adopted ASC 808
Collaborative Arrangements (formerly EITF Issue
07-01:
Accounting for Collaborative Arrangements Related to the
Development and Commercialization of Intellectual
Property). This issue addresses the income statement
classification of payments made between parties in a
collaborative arrangement. ASC 808 has not had a material impact
on the Companys consolidated financial statements.
On July 1, 2009, the FASB issued ASC 105 (formerly
SFAS No. 168, The FASB Accounting Standards
Codification and the Hierarchy of Generally Accepted Accounting
Principles, also known as FASB Accounting Standards
Codification (ASC) 105, Generally Accepted
Accounting Principles (ASC 105) (the
Codification)). ASC 105 establishes the exclusive
authoritative reference for U.S. GAAP for use in financial
statements, except for SEC rules and interpretive releases,
which are also authoritative GAAP for SEC registrants. The
Codification will supersede all existing non-SEC accounting and
reporting standards. For convenience, we have provided
references to the Codification throughout this report in
addition to the current GAAP source reference.
In April 2009, the FASB issued ASC 825 Financial
Instruments (formerly Staff Position
No. FAS 107-1
and APB
28-1,
Interim Disclosures about Fair Value of Financial
Instruments). ASC 825 amends FASB Statement No. 107,
Disclosures about Fair Value of Financial
Instruments to require disclosures about fair value of
financial instruments in interim reporting periods. These
disclosures were previously only required in
F-20
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
annual financial statements. The adoption of ASC 825 did not
have a material impact on our consolidated financial statements
as this only requires additional disclosures.
In May 2009, the FASB issued ASC 855 Subsequent
Events (formerly SFAS No. 165 Subsequent
Events), which is effective for interim and annual periods
ending after June 15, 2009. ASC 855 establishes general
standards of accounting for and disclosure of events that occur
after the balance sheet date but before financial statements are
issued or are available to be issued. ASC 855 did not have a
material impact on our consolidated financial statements.
In October 2009, the FASB issued Accounting Standards Update
No. 2009-13,
Multiple-Deliverable Revenue Arrangements (ASU
No. 2009-13).
ASU
No. 2009-13
amends guidance included within ASC Topic
605-25 to
require an entity to use an estimated selling price when vendor
specific objective evidence or acceptable third party evidence
does not exist for any products or services included in a
multiple element arrangement. The arrangement consideration
should be allocated among the products and services based upon
their relative selling prices, thus eliminating the use of the
residual method of allocation. ASU
No. 2009-13
also requires expanded qualitative and quantitative disclosures
regarding significant judgments made and changes in applying
this guidance. ASU
No. 2009-13
is effective prospectively for revenue arrangements entered into
or materially modified in fiscal years beginning on or after
June 15, 2010. Early adoption and retrospective application
are also permitted. The Company elected to early adopt the
provisions of ASU
No. 2009-13
in fiscal 2009.
|
|
(4)
|
Commitments
and Contingent Liabilities
|
Operating
Leases
Universal Biosensors Pty Ltd entered into a lease with respect
to premises at 1 Corporate Avenue, Rowville Victoria which
commenced on November 1, 2006 for an initial period of
seven years and five months, with two options to renew the lease
for successive five-year periods. The Companys primary
bank has issued a bank guarantee of A$250,000 in relation to a
rental bond to secure the payments under the lease. This bank
guarantee is secured by a security deposit held at the bank.
In accordance with the terms of the lease, the lessee has to
restore part of the building upon vacating the premises.
The Company has also entered into a lease with respect to
certain office equipment. The lease is for a period of
60 months which commenced in December 2007.
Future minimum lease payments under non-cancelable operating
leases (with initial or remaining lease terms in excess of one
year) as of December 31, 2009 are:
|
|
|
|
|
|
|
A$
|
|
|
2010
|
|
|
519,598
|
|
2011
|
|
|
537,526
|
|
2012
|
|
|
556,082
|
|
2013
|
|
|
567,931
|
|
2014 and thereafter
|
|
|
146,312
|
|
|
|
|
|
|
Total minimum lease payments
|
|
|
2,327,449
|
|
|
|
|
|
|
F-21
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Rent expense was A$533,749, A$514,984, A$482,805 and A$2,352,303
for the fiscal years ended December 31, 2009, 2008 and 2007
and for the period from inception to December 31, 2009,
respectively.
Government
research grants
Universal Biosensors Pty Ltd received a research grant from the
Commonwealth of Australia under the R&D START Program up to
a maximum grant amount of A$2,366,063 payable over the period
from January 1, 2005 to September 30, 2007. The grant
was previously to expire on September 30, 2007. However,
the term of the grant was extended to September 30, 2009.
The Commonwealth of Australia may terminate the grant agreement
for breach of the agreement by Universal Biosensors Pty Ltd, for
failure to undertake the required research, if there is a change
in control of Universal Biosensors Pty Ltd, or on the grounds of
insolvency. In certain limited circumstances where Universal
Biosensors Pty Ltd fails to use its best endeavors to
commercialize the project within a reasonable time of completion
or upon termination of the grant due to breach or insolvency,
the Commonwealth of Australia may require Universal Biosensors
Pty Ltd to repay some or the entire grant. The Company continues
the development of the project funded by the R&D Start
Program.
The Company believes that the likelihood of being required to
repay grant funding is remote because the Company continues to
act in good faith with respect to the grant. Research and
development start grant advances of nil (2008: A$262,119) were
received during 2009 and income of nil (2008: A$300,613, 2007:
A$872,513, and period from inception to December 31, 2009:
A$2,366,063) was recognized with A$118,305 recorded as accrued
income at December 31, 2009 (2008: A$118,305).
On October 28, 2006, Universal Biosensors Pty Ltd was
awarded a grant by the State of Victoria to support the
establishment of a medical diagnostic manufacturing facility in
Victoria, Australia for the manufacture of new technologies for
disease monitoring and to increase support of local and export
markets. These payments are subject to the achievement of
milestones which include capital expenditure by Universal
Biosensors Pty Ltd of predetermined minimum amounts. The State
of Victoria may require Universal Biosensors Pty Ltd to refund
any amounts paid under the grant together with interest should
Universal Biosensors Pty Ltd commit a breach of its obligations
under the grant agreement. The State of Victoria may also
withhold, suspend, cancel or terminate any payment or payments
upon a failure to comply with obligations or if Universal
Biosensors Pty Ltd chooses not to proceed with these initiatives
or it becomes insolvent. The total amount received under the
Victorian State Government Grant at December 31, 2009 was
A$130,000 (2008: A$130,000, 2007: A$150,000 and period from
inception to December 31, 2009: A$410,000). This grant has
been recognized against the acquisition cost of the related
plant and equipment.
Guarantees
There are cross guarantees given by Universal Biosensors, Inc.
and Universal Biosensors Pty Ltd as described in note 17.
No deficiencies of assets exist in any of these companies. No
liability was recognized by the parent entity or the
consolidated entity in relation to this guarantee, as the fair
value of the guarantees is immaterial.
The Company is subject to income tax in Australia and is
required to pay taxes on its Australian profits. As provided
under the Australian income tax laws, the Company and its wholly
owned resident subsidiary have formed a tax-consolidated group.
Universal Biosensors, Inc. is required to lodge
U.S. federal income tax returns. It currently is in a tax
loss situation.
F-22
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
A reconciliation of the (benefit)/provision for income taxes
with the amount computed by applying the Australian statutory
company tax rate of 30% to the profit/(loss) before income taxes
is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
$
|
|
|
%
|
|
|
Profit/(loss) before income taxes
|
|
|
(22,904,894
|
)
|
|
|
|
|
|
|
1,430,463
|
|
|
|
|
|
|
|
(11,996,092
|
)
|
|
|
|
|
|
|
(8,962,238
|
)
|
|
|
|
|
Computed by applying income tax rate of home jurisdiction
|
|
|
(6,871,468
|
)
|
|
|
30
|
|
|
|
429,139
|
|
|
|
30
|
|
|
|
(3,598,828
|
)
|
|
|
30
|
|
|
|
(2,688,671
|
)
|
|
|
30
|
|
Research & development incentive
|
|
|
(6,144,630
|
)
|
|
|
27
|
|
|
|
(3,524,333
|
)
|
|
|
(246
|
)
|
|
|
(702,124
|
)
|
|
|
6
|
|
|
|
(983,029
|
)
|
|
|
11
|
|
Disallowed expenses/(income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share based payment
|
|
|
923,598
|
|
|
|
(4
|
)
|
|
|
323,631
|
|
|
|
22
|
|
|
|
288,332
|
|
|
|
(3
|
)
|
|
|
185,315
|
|
|
|
(2
|
)
|
Other
|
|
|
6,416
|
|
|
|
(0
|
)
|
|
|
(226,924
|
)
|
|
|
(16
|
)
|
|
|
2,600
|
|
|
|
(0
|
)
|
|
|
20,157
|
|
|
|
(0
|
)
|
Change in valuation allowance
|
|
|
12,324,710
|
|
|
|
(54
|
)
|
|
|
2,998,487
|
|
|
|
210
|
|
|
|
4,010,020
|
|
|
|
(33
|
)
|
|
|
3,484,228
|
|
|
|
(39
|
)
|
Adjustment in respect of current income tax of prior years
|
|
|
(220,832
|
)
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
(206
|
)
|
|
|
0
|
|
|
|
(163,000
|
)
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense/(benefit)
|
|
|
17,794
|
|
|
|
(0
|
)
|
|
|
(0
|
)
|
|
|
(0
|
)
|
|
|
(206
|
)
|
|
|
0
|
|
|
|
(145,000
|
)
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant components of the Companys deferred tax assets
are shown below:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Operating loss carry forwards
|
|
|
10,903,873
|
|
|
|
9,320,465
|
|
Unamortized capital raising cost
|
|
|
352,651
|
|
|
|
650,355
|
|
Depreciation and amortization
|
|
|
(392,582
|
)
|
|
|
62,699
|
|
Asset retirement obligations
|
|
|
43,024
|
|
|
|
109,228
|
|
Employee entitlements
|
|
|
205,043
|
|
|
|
189,985
|
|
Other accruals
|
|
|
587,802
|
|
|
|
268,388
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
11,699,811
|
|
|
|
10,601,120
|
|
Valuation allowance for deferred tax assets
|
|
|
(11,699,811
|
)
|
|
|
(10,601,120
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax asset
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant components of deferred income taxes reflect the net
tax effect of temporary differences between the carrying amounts
of assets and liabilities for financial reporting and tax
purposes. A valuation allowance has been established, as
realization of such assets is not more likely than not.
At December 31, 2009 the Company has A$36,346,242
(A$31,068,217 at December 31, 2008) of accumulated tax
losses available for carry forward against future earnings,
which under Australian tax laws do not expire but may not be
available under certain circumstances.
F-23
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
|
|
(6)
|
Employee
Incentive Schemes
|
All share and option amounts from inception to December 31,
2006 have been retroactively adjusted to give effect to the
share split described in note 11. In 2004, the Company
adopted an employee option plan (Plan). Options may
be granted pursuant to the Plan to any person considered by the
board to be employed by the Group on a permanent basis (whether
full time, part time or on a long term casual basis). Each
option gives the holder the right to subscribe for one share of
common stock. The total number of options that may be issued
under the Plan is such maximum amount permitted by law and the
Listing Rules of the ASX. The exercise price and any exercise
conditions are determined by the board at the time of grant of
the options. Any exercise conditions must be satisfied before
the options vest and become capable of exercise. The options
lapse on such date determined by the board at the time of grant
or earlier in accordance with the Plan. Options granted to date
have had a ten year term and generally vest in equal tranches
over three years.
An option holder is not permitted to participate in a bonus
issue or new issue of securities in respect of an option held
prior to the issue of shares to the option holder pursuant to
the exercise of an option. If Universal Biosensors changes the
number of issued shares through or as a result of any
consolidation, subdivision, or similar reconstruction of the
issued capital of the Company, the total number of options and
the exercise price of the options (as applicable) will likewise
be adjusted. Options granted in 2007, 2008 and 2009 were
1,608,000 and 1,553,000 and 4,164,200, respectively.
In accordance with ASC 718, the fair value of the option grants
was estimated on the date of each grant using the Trinomial
Lattice model. The assumptions for these grants were:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant Date
|
|
|
Nov-09
|
|
Jun-09
|
|
Jun-09
|
|
May-09
|
|
Feb-09
|
|
Aug-08
|
|
Mar-08
|
|
Oct-07
|
|
Sep-07
|
|
Mar-07
|
|
Exercise Price (A$)
|
|
$
|
1.72
|
|
|
|
Nil
|
|
|
$
|
0.94
|
|
|
|
Nil
|
|
|
$
|
0.50
|
|
|
$
|
0.70
|
|
|
$
|
0.89
|
|
|
$
|
1.13
|
|
|
$
|
1.20
|
|
|
$
|
1.18
|
|
Share Price at Grant Date (A$)
|
|
$
|
1.73
|
|
|
$
|
0.95
|
|
|
$
|
0.95
|
|
|
$
|
1.18
|
|
|
$
|
0.43
|
|
|
$
|
0.71
|
|
|
$
|
0.91
|
|
|
$
|
1.19
|
|
|
$
|
1.21
|
|
|
$
|
1.21
|
|
Volatility
|
|
|
78
|
%
|
|
|
80
|
%
|
|
|
80
|
%
|
|
|
81
|
%
|
|
|
77
|
%
|
|
|
71
|
%
|
|
|
76
|
%
|
|
|
76
|
%
|
|
|
72
|
%
|
|
|
74
|
%
|
Expected Life
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
|
|
10 years
|
|
Risk Free Interest Rate
|
|
|
5.63
|
%
|
|
|
5.49
|
%
|
|
|
5.49
|
%
|
|
|
4.87
|
%
|
|
|
4.26
|
%
|
|
|
5.85
|
%
|
|
|
5.87
|
%
|
|
|
6.13
|
%
|
|
|
5.99
|
%
|
|
|
5.86
|
%
|
Fair Value of Option (A$)
|
|
$
|
1.13
|
|
|
$
|
0.95
|
|
|
$
|
0.62
|
|
|
$
|
1.04
|
|
|
$
|
0.28
|
|
|
$
|
0.45
|
|
|
$
|
0.59
|
|
|
$
|
0.78
|
|
|
$
|
0.78
|
|
|
$
|
0.79
|
|
Each of the inputs to the Trinomial Lattice model is discussed
below.
Share
price at valuation date
In order to value options over shares of common stock which we
granted in 2003 and 2006, by virtue of the fact that our
securities were not traded at that time on any public exchange,
we have valued our options consistent with the shares that were
issued in certain private capital raisings undertaken by the
Company around the respective valuation dates of the options, as
these prices are most indicative of the fair value of the
Companys equity in the market to a willing participant at
and around the applicable valuation date of the options.
Although we raised capital by issuing preferred shares, for the
purposes of valuing our options we regarded our ordinary and
preferred shares as being equivalent in relevant economic
aspects and therefore the capital raisings served as a suitable
valuation point with respect to the valuation of our options. In
this regard we note that the preference shares carried the right
to convert to ordinary basis on a one to one basis, and all were
converted during 2006 in conjunction with our initial public
offering.
F-24
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
We consider that value of the shares we issued in the capital
raisings undertaken by us in 2003 and 2006 (as applicable) most
accurately represent the value of our common stock for valuation
purposes at the time of those capital raisings. We summarize the
per-share subscription value of the relevant shares issued by us
below.
|
|
|
|
|
|
|
Value per Preferred Stock A$ (Post Stock Split
|
Date of Capital Raising
|
|
Described in Note 11)
|
|
December 2003
|
|
|
0.39
|
|
June 2006
|
|
|
0.45
|
|
August 2006
|
|
|
0.45
|
|
Based on these valuation points, we applied an assumed per share
price of A$0.39 with respect to the options we granted in 2003
and A$0.45 for the options we granted in 2006.
The value of the options granted post 2007 have been determined
using the closing price of our common stock trading in the form
of CDIs on ASX at the time of grant of the options. The ASX is
the only exchange upon which our securities are quoted.
On December 12, 2007 as a result of the impact of the
closing of the rights offering, the exercise prices of each
option granted by the Company prior to November 19, 2007
was reduced by a maximum of A$0.10 in accordance with the terms
of the options and a formula set out in the Listing Rules of the
ASX. The table below reflects the changes to the exercise price
and the fair value of option as a result of the rights offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre Rights Offering
|
|
Post Rights Offering
|
|
|
|
|
Fair Value of
|
|
Exercise
|
|
Fair Value of
|
Grant Date of Option
|
|
Exercise Price
|
|
Option
|
|
Price
|
|
Option
|
|
|
A$
|
|
A$
|
|
A$
|
|
A$
|
|
Dec-03
|
|
$
|
0.39
|
|
|
$
|
0.11
|
|
|
$
|
0.30
|
|
|
$
|
0.11
|
|
Jan-06
|
|
$
|
0.45
|
|
|
$
|
0.30
|
|
|
$
|
0.35
|
|
|
$
|
0.27
|
|
Mar-07
|
|
$
|
1.25
|
|
|
$
|
0.78
|
|
|
$
|
1.18
|
|
|
$
|
0.79
|
|
Sep-07
|
|
$
|
1.27
|
|
|
$
|
0.77
|
|
|
$
|
1.20
|
|
|
$
|
0.78
|
|
Oct-07
|
|
$
|
1.20
|
|
|
$
|
0.77
|
|
|
$
|
1.13
|
|
|
$
|
0.78
|
|
Volatility
With respect to the options granted in 2003 and 2006, we had
insufficient available share price data to accurately estimate
the volatility of our shares of common stock. As a result, we
examined and based our volatility for these options by reference
to the annual volatilities of a number of ASX listed companies
of a similar size and with similar operations to us, over a
range of historic estimation periods. Based on our analysis we
selected an annual volatility of 40%-45% for the options granted
in 2003 and 55% for the options granted in 2006. These figures
were within the range of observed volatilities for comparable
listed companies.
With respect to the options granted post 2007, we applied an
annual volatility determined partially by reference to the
annual volatilities of a number of ASX listed companies of a
similar size and with similar operations but also having regard
to the volatility on the trading data of our shares in the form
of CDIs available from the ASX. Our shares in the form of CDIs
were first quoted on ASX on December 13, 2006 with an
initial offering price of A$0.50.
F-25
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Consequently, the high level and varying movement on our shares
was the key driver for the volatility increasing from 55% at
December 31, 2006 to volatility in the 70% 80%
range for options issued subsequent to December 2006.
Time
to expiry
All options granted under our share option plan have a maximum
10 year term and are non-transferable.
Risk
free rate
The risk free rate which we applied is equivalent to the yield
on an Australian government bond with a time to expiry
approximately equal to the expected time to expiry on the
options being valued.
Stock option activity during the current period is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
Number of Shares
|
|
|
Exercise Price
|
|
|
|
|
|
|
A$
|
|
|
Balance at December 31, 2008
|
|
|
6,373,284
|
|
|
|
0.66
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
4,164,200
|
|
|
|
1.16
|
|
Exercised
|
|
|
(138,327
|
)
|
|
|
0.60
|
|
Lapsed
|
|
|
(359,671
|
)
|
|
|
0.95
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
10,039,486
|
|
|
|
0.85
|
|
|
|
|
|
|
|
|
|
|
At December 31, 2009, the number of options exercisable was
5,808,324 (2008: 4,324,915 and 2007: 2,851,609).
The following table represents information relating to stock
options outstanding under the plans as of December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding
|
|
|
Options
|
|
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
Exercisable
|
|
Exercise Price
|
|
|
Shares
|
|
|
Remaining Life in Years
|
|
|
Shares
|
|
A$
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
$
|
0.30
|
|
|
|
1,594,894
|
|
|
|
4.00
|
|
|
|
1,594,894
|
|
|
|
$
|
0.35
|
|
|
|
1,638,395
|
|
|
|
6.00
|
|
|
|
1,638,395
|
|
|
|
$
|
1.18
|
|
|
|
745,332
|
|
|
|
7.20
|
|
|
|
745,332
|
|
|
|
$
|
1.20
|
|
|
|
620,332
|
|
|
|
7.70
|
|
|
|
415,326
|
|
|
|
$
|
1.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
0.89
|
|
|
|
1,112,333
|
|
|
|
8.20
|
|
|
|
742,641
|
|
|
|
$
|
0.70
|
|
|
|
326,000
|
|
|
|
8.60
|
|
|
|
106,000
|
|
|
|
$
|
0.50
|
|
|
|
124,000
|
|
|
|
9.10
|
|
|
|
41,330
|
|
|
|
|
Nil
|
|
|
|
100,000
|
|
|
|
9.40
|
|
|
|
33,333
|
|
|
|
$
|
0.94
|
|
|
|
1,473,200
|
|
|
|
9.50
|
|
|
|
491,073
|
|
|
|
|
Nil
|
|
|
|
420,000
|
|
|
|
9.50
|
|
|
|
|
|
|
|
$
|
1.72
|
|
|
|
1,885,000
|
|
|
|
9.90
|
|
|
|
|
|
F-26
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
The table below sets forth the number of employee stock options
exercised and the number of shares issued in the period from
December 31, 2006. We issued these shares in reliance upon
exemptions from registration under Regulation S under the
Securities Act of 1933, as amended.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of Options Exercised
|
|
|
|
|
|
|
|
|
|
and Corresponding Number of
|
|
|
Weighted Average
|
|
|
|
|
Period Ending
|
|
Shares Issued
|
|
|
Exercise Price
|
|
|
Proceeds Received
|
|
|
|
|
|
|
A$
|
|
|
A$
|
|
|
2007
|
|
|
420,474
|
|
|
|
0.32
|
|
|
|
148,428
|
|
2008
|
|
|
18,124
|
|
|
|
0.35
|
|
|
|
5,047
|
|
2009
|
|
|
138,327
|
|
|
|
0.60
|
|
|
|
78,998
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
576,925
|
|
|
|
|
|
|
|
232,473
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(b)
|
Restricted
Share Plan
|
Our Employee Share Plan was adopted by the Board of Directors in
2009. The Employee Share Plan permits our Board to grant shares
of our common stock to our employees and directors. The number
of shares able to be granted is limited to the amount permitted
to be granted at law, the ASX Listing Rules and by the limits on
our authorized share capital in our certificate of
incorporation. All our employees are eligible for shares under
the Employee Plan. The Company currently proposes to issue
A$1,000 worth of restricted shares of common stock to all
employees of the Company on a recurring basis, but no more
frequently than annually. The restricted shares have the same
terms of issue as our existing shares of common stock but are
not able to be traded until the earlier of three years from the
date on which the shares are issued or the date the relevant
employee ceases to be an employee of the Company or any of its
associated group of companies.
The table below sets forth the restricted shares issued by the
Company:
|
|
|
|
|
|
|
|
|
|
|
Number of Restricted
|
|
Market Value of
|
|
|
Shares Issued
|
|
Restricted Shares Issued
|
|
November 10, 2009
|
|
|
40,670
|
|
|
A$
|
69,952
|
|
The Company has entered into the following agreements with
LifeScan.
LifeScan
License and Research and Development Agreement
Since April 2002 the Company has undertaken contracted research
and development activities for LifeScan pursuant to a
Development and Research Agreement. The Development and Research
Agreement has historically been an important source of revenue
for the Company. If the Development and Research Agreement was
terminated, we would lose a source of income.
The Company also currently holds a license from LifeScan to a
range of patents, patent applications and know-how, pursuant to
a License Agreement. If the Company were to breach the License
Agreement, which the Company does not intend to do, LifeScan
might validly terminate the License Agreement. This would
seriously restrict or eliminate the Companys development
and commercialization activities.
F-27
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Master
Services and Supply Agreement
On October 29, 2007 Universal Biosensors entered into a
Master Services and Supply Agreement which contains the terms
pursuant to which Universal Biosensors Pty Ltd would provide
certain services in the field of blood glucose monitoring to
LifeScan and would generally act as a non-exclusive manufacturer
of an original version of the blood glucose test strips we
developed for LifeScan. On December 11, 2008, we entered
into an additional services addendum to provide manufacturing
process support to assist LifeScan to establish LifeScans
own manufacturing line for initial blood glucose test strips at
a location of its choosing. On December 11, 2008, the
Master Services and Supply Agreement was amended to reflect
certain definitional matters in the document. On May 15,
2009, the agreement was amended and restated to incorporate the
amendments made in December 2008 and to update the commercial
terms of the agreement to reflect a change from the original
version of the blood glucose test strip to an enhanced version
of the blood glucose test strip. The Master Services and Supply
Agreement is structured as an umbrella agreement which enables
LifeScan and us to enter into a series of additional
arrangements for the supply by us of additional services and
products in the field of blood glucose monitoring.
The Master Services and Supply Agreement may be terminated as a
result of a party defaulting on its material obligations, a
party becoming insolvent, at LifeScans option after paying
a lump sum service fee, or as a result of other factors detailed
in the Master Services and Supply Agreement, Universal
Biosensors Pty Ltd will lose rights to receiving some or all
revenues from the sale of blood glucose strips and provision of
additional services, which would have a material adverse effect
on our business and financial condition.
We commenced manufacture of the blood glucose test strips in our
facility in Corporate Avenue, Rowville, Melbourne, in December
2009. Our ability to maintain profitability in the future will
be adversely affected if the blood glucose product and any of
the other products we develop with LifeScan in the future fail
to achieve or maintain market acceptance.
|
|
(8)
|
Related
Party Transactions
|
Details of related party transactions material to the operations
of the Group other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of
business, are set out below:
Johnson & Johnson Development Corporation, a wholly
owned subsidiary of Johnson and Johnson, owns approximately 12%
of the Companys shares.
LifeScan, a wholly owned subsidiary of Johnson &
Johnson, makes payments to the Company through the research and
development agreement, Master Services and Supply Agreement and
issuance of purchase orders to the Company to undertake
additional services in the field of blood glucose monitoring.
The terms of the arrangements are mentioned in note 7.
F-28
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
The following transactions occurred with LifeScan:
|
|
|
|
|
|
|
|
|
|
|
As of December, 31
|
|
|
|
2009
|
|
|
2008
|
|
|
|
A$
|
|
|
A$
|
|
|
Current Receivables
|
|
|
|
|
|
|
|
|
Reimbursement of expenses
|
|
|
|
|
|
|
31,919
|
|
Sale of goods
|
|
|
396,378
|
|
|
|
|
|
Sale of services
|
|
|
19,019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
415,397
|
|
|
|
31,919
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
Revenue from products
|
|
|
132,733
|
|
|
|
|
|
Revenue from services
|
|
|
2,850,071
|
|
|
|
3,121,754
|
|
Research and develoment income
|
|
|
1,337,125
|
|
|
|
1,170,190
|
|
Milestone payment
|
|
|
17,722,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22,042,570
|
|
|
|
4,291,944
|
|
|
|
|
|
|
|
|
|
|
Operating costs & expenses
|
|
|
|
|
|
|
|
|
Support services provided by LifeScan
|
|
|
|
|
|
|
1,064,736
|
|
|
|
|
|
|
|
|
|
|
Other transactions with LifeScan are detailed as follows:
|
|
|
|
|
the Company received an initial non-refundable fee of
A$1,131,222 in 2008 in consideration for the grant of certain
rights to LifeScan pursuant to the Master Services and Supply
Agreement
|
|
|
|
the Company was reimbursed A$477,898 in 2008 for certain
expenditure incurred on behalf of LifeScan
|
Messrs Denis Hanley, Andrew Denver and Dr. Colin Adam are
shareholders and directors of the Company and of PFM Cornerstone
Ltd which was paid a total of A$450,000 in the year ended
December 31, 2007 from Wilson HTM Corporate Finance Ltd as
sub-underwriting
fee in connection with the renounceable rights issue.
Mr. Cameron Billingsley is the company secretary and a
stockholder of PFM Cornerstone Ltd. Mr. Charles Kiefel, who
ceased to be a director of the Company in January 2010, is also
a director and shareholder of PFM Cornerstone Ltd. Our recently
appointed director, Mr. Heinberg, also holds a small
non-controlling number of shares in PFM Cornerstone Ltd.
Dr. Elizabeth (Jane) Wilson is the spouse of
Mr. Steven Wilson who is a substantial stockholder and
officer of the parent company of Wilson HTM Corporate Finance
Pty Ltd, the underwriter of the renounceable rights issue in
2007. Wilson HTM Corporate Finance Pty Ltd was paid A$1,626,687
in connection with the Companys renounceable rights issue.
F-29
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
|
|
(9)
|
Property,
Plant and Equipment
|
|
|
|
|
|
|
|
|
|
|
|
As of December, 31
|
|
|
|
2009
|
|
|
2008
|
|
|
|
A$
|
|
|
A$
|
|
|
Plant and equipment
|
|
|
13,271,715
|
|
|
|
13,003,248
|
|
Leasehold improvements
|
|
|
8,328,270
|
|
|
|
8,123,925
|
|
Capital work in process
|
|
|
6,298,114
|
|
|
|
2,395,533
|
|
|
|
|
|
|
|
|
|
|
|
|
|
27,898,099
|
|
|
|
23,522,706
|
|
Accumulated depreciation
|
|
|
(6,597,956
|
)
|
|
|
(3,767,457
|
)
|
|
|
|
|
|
|
|
|
|
Property, plant & equipment, net
|
|
|
21,300,143
|
|
|
|
19,755,249
|
|
|
|
|
|
|
|
|
|
|
Capital work in process relates to assets under construction and
comprises primarily of specialized manufacturing equipment.
Legal right to the assets under construction rests with the
Company. The amounts capitalized for capital work in process
represents the percentage of expenditure that has been
completed, and once the assets are placed into service the
Company begins depreciating the respective assets. The
accumulated amortisation of capitalised leasehold improvements
for the fiscal years ended December 31, 2009, 2008 and 2007
was A$2,770,434, A$1,501,516 and A$300,213, respectively.
The Company receives Victorian government grants under certain
research agreements to purchase plant and equipment. Plant and
equipment is presented net of the government grant of A$410,000
for the year ended December 31, 2009 (2008: A$280,000). The
grants are recognized against the acquisition costs of the
related plant and equipment as and when the related assets are
purchased. Grants received in advance of the relevant
expenditure are treated as deferred income and included in
Current Liabilities on the balance sheet as the Company does not
control the monies until the relevant expenditure has been
incurred. Grants due to the Company under research agreements
are recorded as Currents Assets on the balance sheet.
Depreciation expense was A$2,851,285, A$2,266,847, A$708,699 and
A$7,132,568 for the fiscal years ended December 31, 2009,
2008 and 2007 and for the period from inception to
December 31, 2009, respectively.
The movement in accumulated depreciation for the 2009 and 2008
financial year is agreed to depreciation expense as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December, 31
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
A$
|
|
|
A$
|
|
|
|
|
|
Movement in accumulated depreciation
|
|
|
2,830,499
|
|
|
|
2,195,236
|
|
|
|
|
|
Accumulated depreciation of fixed assets disposed
|
|
|
20,786
|
|
|
|
71,611
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense for the financial year
|
|
|
2,851,285
|
|
|
|
2,266,847
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-30
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December, 31
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
A$
|
|
|
A$
|
|
|
|
|
|
Legal, tax and accounting fees
|
|
|
176,000
|
|
|
|
346,000
|
|
|
|
|
|
Salary and related on-costs
|
|
|
327,665
|
|
|
|
460,761
|
|
|
|
|
|
Research and development materials
|
|
|
698,228
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
31,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,201,893
|
|
|
|
838,697
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(11)
|
Stockholders
Equity Common Stock
|
In fiscal year 2006, in connection with an initial public
offering in Australia in the form of an offer of new shares of
common stock in the capital of the Company (Public
Offer) and a concurrent separate offer of shares of common
stock in the US to certain US Persons (as that term is defined
in Regulation S promulgated under the US Securities Act of
1933) (US Private Placement), shareholders approved:
a) the conversion of all series A convertible
preferred stock into common stock; b) the adoption of a new
certificate of incorporation which was filed with the State of
Delaware on December 5, 2006; c) a subdivision of
existing common stock by 3,624.7518771; and d) an issue and
allotment of common stock to subscribers under the Public Offer
and US Private Placement.
As noted in note 12, during fiscal year 2006 the Company
also issued 30,176,036 series A convertible preferred stock
in two separate private placements to institutional and
sophisticated investors in both the US and Australia. This
series A convertible preferred stock was subsequently
converted into common stock on December 6, 2006. Before the
stock split by 3,624.7518771, the Company had on issue
12,032 shares of common stock and 11,142 series A
convertible preferred stock. After the conversion of all
series A convertible preferred stock into shares of common
stock, there were 23,174 shares of common stock on issue.
Immediately following the subdivision on December 6, 2006,
there were 83,999,976 shares on issue. All share and per
share amounts from the period from inception to
December 31, 2006 presented in the accompanying financial
statements have been retroactively adjusted to give effect to
the stock split.
The Company completed its Public Offer of 36,000,000 shares
of common stock and concurrent US Private Placement of
8,000,000 shares in the US to institutional and accredited
investors, raising A$22 million in aggregate before costs.
The Company listed on ASX on December 13, 2006.
In December 2007, we closed the renounceable rights issue of new
ordinary shares by issuing 28,538,362 shares of common
stock in which we raised A$34,246,043.
Holders of common stock are generally entitled to one vote per
share held on all matters submitted to a vote of the holders of
common stock. At any meeting of the shareholders, the presence,
in person or by proxy, of the majority of the outstanding stock
entitled to vote shall constitute a quorum. Except where a
greater percentage is required by the Companys Amended and
Restated Certificate of Incorporation or By-laws, the
affirmative vote of the holders of a majority of the shares of
common stock then represented at the meeting and entitled to
vote at the meeting shall be sufficient to pass a resolution.
Holders of common stock are not entitled to cumulative voting
rights with respect to the election of directors, and the common
stock does not have pre-emptive rights.
F-31
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
Trading in our shares of common stock on ASX is undertaken using
CHESS Depositary Interests (CDIs). Each CDI
represents beneficial ownership in one underlying share. Legal
title to the shares underlying CDIs is held by CHESS Depositary
Nominees Pty Ltd (CDN), a wholly owned subsidiary of
ASX.
Holders of CDIs have the same economic benefits of holding the
shares, such as dividends (if any), bonus issues or rights
issues as though they were holders of the legal title. Holders
of CDIs are not permitted to vote but are entitled to direct CDN
how to vote. Subject to Delaware General Corporation Law,
dividends may be declared by the Board and holders of common
stock may be entitled to participate in such dividends from time
to time.
|
|
(12)
|
Convertible
preferred stock
|
Up until the time of the Companys Australian initial
public offering, the Company had on issue 40,386,962
Series A convertible preferred stock. The Company issued
3,758,844, series A convertible preferred stock on
June 15, 2006 and 26,417,192 series A convertible
preferred stock on August 30, 2006, raising a total of
A$12,624,795 before costs associated with the issues.
Immediately prior to the issue of shares in connection with the
Public Offer and the U.S. Private Placement, all the
Companys convertible preference shares were converted into
common stock (refer note 11).
The rights and obligations attaching to the series A
convertible preferred stock were derived by a combination of an
Investor Rights Agreement (which was terminated in connection
with the close of the Public Offer), the By-laws and Amended and
Restated Certificate of Incorporation of the Company. Without
limitation, the terms of issue of the series A convertible
preferred stock were as follows:
|
|
|
|
|
the right to receive notices of general meetings and to attend
and vote at general meetings of the Company;
|
|
|
|
each preferred share entitled the stockholder to such number of
votes at a general meeting equal to the number of shares of
common stock that the preferred stock would have converted into
(whether or not it had been converted);
|
|
|
|
rights of conversion into common stock;
|
|
|
|
may participate in dividends declared in respect of that class
of share at the discretion of the Board, the rights to which may
not be similar to the rights of the holders of common stock;
|
|
|
|
anti-dilution protection in certain circumstances; and
|
|
|
|
a liquidation preference over common stockholders in the event
of liquidation or a capital reduction of the Company.
|
The series A convertible preferred stock were convertible
by the holders into shares of common stock at any time or could
be compulsorily converted at the time of an initial public
offering, subject to certain conditions. The conversion ratio
was one share of common stock per convertible preference share,
subject to variation for capital reconstructions and share
dilutions.
In the event of a return of assets on liquidation or capital
reduction or otherwise, the assets of the Company remaining
after payment of its liabilities were applied first in paying
the preferred stockholders an amount equal to the issue price of
such preferred stock adjusted as necessary for capital
reconstructions and secondly, to the common stockholders an
amount equal to the relevant issue price. Thirdly an amount per
preferred share equal to the amount of interest that would have
accrued on the amount subscribed for by the
F-32
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
preference stockholder if interest had accrued daily at a rate
of 10% per annum from the date of issue. Finally, the balance of
assets remaining (if any) was to have been distributed among the
holders of preferred and common stock pari passu as if they
constituted one class of shares.
Universal Biosensors Pty Ltd contributes to standard defined
contributions superannuation funds on behalf of all employees at
an amount up to nine percent of employee salary. The Company
permits employees to choose the superannuation fund into which
the contributions are paid, provided the fund is appropriately
registered.
Universal Biosensors Pty Ltd contributed A$698,919, A$587,885,
A$507,270 and A$2,473,101 for the fiscal years ended
December 31, 2009, 2008 and 2007, and the period from
inception to December 31, 2009, respectively.
|
|
(14)
|
Net
Profit/(Loss) per Share
|
Basic net profit/(loss) per ordinary share was computed by
dividing the net profit/(loss) applicable to common stock by the
weighted-average number of common stock outstanding during the
period. All periods presented in the financial statements have
been retroactively adjusted to give effect to the share split
described in note 11. Options granted to employees under
the Universal Biosensors Employee Option Plan are considered to
be potential ordinary shares for the purpose of calculating
diluted net profit/(loss) per share. However, all these were not
included in the calculation of diluted net profit/(loss) per
share in the year when the Group made a net loss as the effect
of including them is anti-dilutive.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Period from
|
|
|
|
|
|
|
|
|
|
|
|
|
Inception to
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Weighted average number of ordinary shares used as denominator
in calculating:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
157,013,578
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net profit/(loss) per share
|
|
|
80,967,756
|
|
|
|
161,354,802
|
|
|
|
156,970,679
|
|
|
|
129,637,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(15)
|
Guarantees
and Indemnifications
|
The certificate of incorporation and amended and restated
by-laws of the Company provide that the Company will indemnify
officers and directors and former officers and directors in
certain circumstances, including for expenses, judgments, fines
and settlement amounts incurred by them in connection with their
services as an officer or director of the Company or its
subsidiaries, provided that such person acted in good faith and
in a manner such person reasonably believed to be in the best
interests of the Company.
In addition to the indemnities provided in the certificate of
incorporation and amended and restated by-laws, the Company has
entered into indemnification agreements with certain of its
officers and each of its
F-33
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
directors. Subject to the relevant limitations imposed by
applicable law, the indemnification agreements, among other
things:
|
|
|
|
|
indemnify the relevant officers and directors for certain
expenses, judgments, fines and settlement amounts incurred by
them in connection with their services as an officer or director
of the Company or its subsidiaries; and
|
|
|
|
require the Company to make a good faith determination whether
or not it is practicable to maintain liability insurance for
officers and directors or to ensure the Companys
performance of its indemnification obligations under the
agreements.
|
No liability has arisen under these indemnities as at
December 31, 2009.
The Company operates in one segment. The principal activities of
the Company are the research and development activities,
commercial manufacture of approved medical or testing devices
and the provision of services such as those specified under the
Master Services and Supply Agreement including contract research
work.
The Company operates predominantly in one geographical area,
being Australia.
|
|
(17)
|
Deed of
Cross Guarantee
|
Universal Biosensors, Inc. and its wholly owned subsidiary,
Universal Biosensors Pty Ltd, are parties to a deed of cross
guarantee under which each company guarantees the debts of the
other. By entering into the deed, the wholly-owned entity has
been relieved from the requirements to prepare a financial
report and directors report under Class Order 98/1418
(as amended) issued by the Australian Securities and Investments
Commission.
The above companies represent a Closed Group for the
purposes of the Class Order, and as there are no other
parties to the Deed of Cross Guarantee that are controlled by
Universal Biosensors, Inc., they also represent the
Extended Closed Group.
The consolidated financial statements presented within this
report comprise that of Universal Biosensors, Inc. and its
wholly owned subsidiary, Universal Biosensors Pty Ltd. These two
entities also represent the Closed Group and the
Extended Closed Group.
On January 11, 2010, there was a change in the
Companys board of directors with the appointment of
Marshall Heinberg and the retirement of Charles Keifel.
On January 28, 2010, the Company announced that
LifeScans new product incorporating technology developed
by the Company has been made available for sale in Netherlands
under the One Touch Verio brand.
The following options were exercised by employees under the
Companys Employee Option Plan
F-34
UNIVERSAL
BIOSENSORS, INC.
(A Development Stage Enterprise)
Notes to Consolidated Financial
Statements (Continued)
(for the years ended December 31, 2007, 2008 and 2009 and
for the period from inception
(September 14, 2001) to December 31, 2009)
|
|
|
|
|
|
|
Exercise Date
|
|
Options Exercised
|
|
|
Type of Options
|
|
February 1, 2010
|
|
|
40,000
|
|
|
Market price employee options
|
February 10, 2010
|
|
|
33,333
|
|
|
Zero exercise price options
|
February 15, 2010
|
|
|
4,000
|
|
|
Market price employee options
|
February 22, 2010
|
|
|
34,789
|
|
|
Market price employee options
|
February 25, 2010
|
|
|
18,124
|
|
|
Market price employee options
|
March 1, 2010
|
|
|
6,666
|
|
|
Market price employee options
|
With the exception of the above, there has not arisen in the
interval between the end of the financial year to the date of
this report any item, transaction or event of a material and
unusual nature likely, in the opinion of the directors of the
Company, to affect significantly the operations of the Company,
the results of those operations, or the state of affairs of the
Company in future financial years.
F-35
(for the years ended December 31, 2007, 2008 and
2009 and for the period from inception
(September 14, 2001) to December 31, 2009)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additions
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
Charged to
|
|
|
Charged to
|
|
|
|
|
|
|
|
|
|
Beginning of
|
|
|
Costs and
|
|
|
Other
|
|
|
|
|
|
Balance at
|
|
|
|
Period
|
|
|
Expenses
|
|
|
Accounts
|
|
|
Deductions
|
|
|
End of Period
|
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
A$
|
|
|
Year ended December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax valuation allowance
|
|
|
2,092,417
|
|
|
|
3,484,228
|
|
|
|
503,884
|
|
|
|
|
|
|
|
6,080,529
|
|
Year ended December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax valuation allowance
|
|
|
6,080,529
|
|
|
|
4,010,020
|
|
|
|
510,571
|
|
|
|
|
|
|
|
10,601,120
|
|
Year ended December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax valuation allowance
|
|
|
10,601,120
|
|
|
|
2,998,487
|
|
|
|
(1,899,796
|
)
|
|
|
|
|
|
|
11,699,811
|
|
Period from inception to December 31, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred income tax valuation allowance
|
|
|
|
|
|
|
12,324,710
|
|
|
|
(624,899
|
)
|
|
|
|
|
|
|
11,699,811
|
|
F-36
INDEX TO
EXHIBITS
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description
|
|
Location
|
|
|
1
|
.0
|
|
Underwriting Agreement, by and between Universal Biosensors,
Inc. and Wilson HTM Corporate Finance Limited dated
November 9, 2007.
|
|
Incorporated by reference to our Current Report on Form 8-K
filed on November 16, 2007 as Exhibit 1.1.
|
|
3
|
.1
|
|
Amended and restated articles of incorporation dated
December 5, 2006.
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 3.1.
|
|
3
|
.2
|
|
Amended and restated by-laws dated December 5, 2006.
|
|
Incorporated by reference to our Amendment No. 5 to Form 10
filed on April 29, 2008 as Exhibit 3.2.
|
|
10
|
.1
|
|
License Agreement between LifeScan and Universal Biosensors, Inc
effective April 1, 2002, as amended on October 29,
2007, December 5, 2005)
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit
10.1. October 2007 amendment incorporated by reference to our
Form 10-Q filed on November 14, 2007 as Exhibit 10.2.
|
|
10
|
.2
|
|
Development and Research Agreement by and between Universal
Biosensors, Inc and LifeScan, Inc dated April 1, 2002 (as
amended on October 29, 2007, June 1, 2007,
December 7, 2005, December 21, 2004 and March 31,
2004
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit
10.2. June 2007 amendment incorporated by reference to our
Amendment No. 2 to Form 10 filed on June 12, 2007 as Exhibit
10.2. October 2007 amendment incorporated by reference to our
Form 10-Q filed on November 14, 2007 as Exhibit 10.3.
|
|
10
|
.3
|
|
Form of indemnity agreement entered into with directors of us,
our chief financial officer and company secretary
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.3.
|
|
10
|
.4
|
|
Lease of premises 1 Corporate Avenue, Rowville Victoria
Australia by and between Universal Biosensors Pty Ltd and Heyram
Properties Pty Ltd.
|
|
Incorporated by reference to our Amendment No. 4 to Form 10
filed on September 19, 2007 as Exhibit 10.5.
|
|
10
|
.5
|
|
AusIndustry, R&D Start Program Agreement, effective
February 25, 2005 (particular and general conditions)
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.6.
|
|
10
|
.6
|
|
Employee Option Plan
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.7
|
|
10
|
.7
|
|
Employment agreement between Universal Biosensors Pty Ltd and
Mr. Salesh Balak effective November 27, 2006
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.8
|
|
10
|
.8
|
|
Employment agreement between Universal Biosensors Pty Ltd and
Mr. Garry Chambers effective April 1, 2006
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.9
|
|
10
|
.9
|
|
Employment agreement between Universal Biosensors Pty Ltd and Dr
Ronald Chatelier dated April 1, 2006
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit
10.10
|
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description
|
|
Location
|
|
|
10
|
.10
|
|
Employment agreement between Universal Biosensors Pty Ltd and Dr
Alastair Hodges effective April 1, 2006
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.11
|
|
10
|
.11
|
|
Employment agreement between Universal Biosensors Pty Ltd and
Mr. Mark Morrisson dated July 1, 2006
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 10.12
|
|
10
|
.12
|
|
Employment agreement between Universal Biosensors Pty Ltd and
Mr. Adrian Oates dated August 15, 2007
|
|
Filed herewith
|
|
10
|
.13
|
|
Master Services and Supply Agreement by and between Universal
Biosensors Pty Ltd, Universal Biosensors, Inc. and LifeScan,
Inc. dated October 29, 2007
|
|
Incorporated by reference to our Quarterly Report on Form 10-Q
filed on November 14, 2007 as Exhibit 10.1. Confidentiality
treatment has been granted for portions of this exhibit. These
confidential portions have been omitted and were filed
separately with the SEC.
|
|
10
|
.14
|
|
First Amendment to the Master services and Supply Agreement
dated December 11, 2008 (which amends the Master Services
and Supply Agreement by and between Universal Biosensors Pty
Ltd, Universal Biosensors, Inc. and LifeScan, Inc. dated
October 29, 2007 and filed on November 14, 2007 as
Exhibit 10.1 to our Quarterly Report on
Form 10-Q)
|
|
Incorporated by reference to our Annual Report on Form 10-K
filed on March 30, 2009 as Exhibit 10.14
|
|
10
|
.15
|
|
Second Services Addendum manufacturing Process
Support (which amends the Master Services and Supply Agreement
by and between Universal Biosensors Pty Ltd, Universal
Biosensors, Inc. and LifeScan, Inc. dated October 29, 2007
incorporated by reference to our Quarterly Report on
Form 10-Q
filed on November 14, 2007 as Exhibit 10.1.)
|
|
Incorporated by reference to our Annual Report on Form 10-K
filed on March 30, 2009 as Exhibit 10.15
|
|
10
|
.16
|
|
Advanced Care Enhanced Product Agreement (which is an addendum
to the Amended and Restated Master Services and Supply Agreement
filed on August 7, 2009 as Exhibit 10.3 to our
Quarterly Report on
Form 10-Q)
|
|
Incorporated by reference to our Quarterly Report on Form 10-Q
filed on August 7, 2009 as Exhibit 10.1. Confidentiality
treatment has been granted for portions of this exhibit. These
confidential portions have been omitted and were filed
separately with the SEC.
|
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description
|
|
Location
|
|
|
10
|
.17
|
|
Amendment to Development and Research Agreement (which amends
the Development and Research Agreement by and between Universal
Biosensors, Inc. and LifeScan, Inc. dated April 1, 2002 and
filed on April 30, 2007 as Exhibit 10.2 to our
Form 10, the Amendment to the Development and Research
Agreement filed on June 12 as Exhibit 10.2 to Amendment
No. 2 to our Form 10 and the Amendment to Development
and Research Agreement filed on November 14, 2007 as
Exhibit 10.3 to our Quarterly Report on
Form 10-Q.
|
|
Incorporated by reference to our Quarterly Report on Form 10-Q
filed on August 7, 2009 as Exhibit 10.2.
|
|
10
|
.18
|
|
Amended and Restated Master Services and Supply Agreement (which
amends and restates the Master Services and Supply Agreement by
and between Universal Biosensors Pty. Ltd., Universal
Biosensors, Inc., and LifeScan, Inc. dated October 29, 2007
filed on November 14, 2007 as Exhibit 10.1 to our
Quarterly Report on
Form 10-Q
and the First Amendment to the Master Services and Supply
Agreement filed on March 30, 2009 as Exhibit 10.14 to
our Annual Report on
Form 10-K)
|
|
Incorporated by reference to our Quarterly Report on Form 10-Q
filed on August 7, 2009 as Exhibit 10.3. Confidentiality
treatment has been granted for portions of this exhibit. These
confidential portions have been omitted and were filed
separately with the SEC.
|
|
10
|
.19
|
|
Manufacturing Initiation Payment Addendum to Master Services and
Supply Agreement (which is an addendum to the Amended and
Restated Master Services and Supply Agreement filed on
August 7, 2009 as Exhibit 10.3 to our Quarterly Report
on
Form 10-Q)
|
|
Incorporated by reference to our Quarterly Report on Form 10-Q
filed on August 7, 2009 as Exhibit 10.4. Confidentiality
treatment has been granted for portions of this exhibit. These
confidential portions have been omitted and were filed
separately with the SEC.
|
|
14
|
.0
|
|
Code of Ethics
|
|
Incorporated by reference to our Annual Report on Form 10-K
filed on March 28, 2008 as Exhibit 14.0
|
|
21
|
.0
|
|
List of Subsidiaries
|
|
Incorporated by reference to our General Form for Registration
of Securities on Form 10 filed on April 30, 2007 as Exhibit 21.00
|
|
24
|
.0
|
|
Power of Attorney
|
|
Included on signature page
|
|
31
|
.1
|
|
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act
|
|
Filed herewith
|
|
|
|
|
|
|
|
Exhibit
|
|
|
|
|
Number
|
|
Description
|
|
Location
|
|
|
31
|
.2
|
|
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act
|
|
Filed herewith
|
|
32
|
.0
|
|
Certification of Chief Executive Officer and Chief Financial
Officer pursuant to Section 906 of the Sarbanes-Oxley Act
|
|
Filed herewith
|